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ABSTRACT
Literature and other background information on prevention of mother-to-child transmission
of HIV (PMTCT) and maternal syphilis screening programmes in Tanzania reveal that little has
been documented on accessibility and utilization of these services. This thesis presents the
results from a research conducted in Mwanza city, Tanzania to assess the operational
performance of PMTCT and maternal syphilis screening and treatment during pregnancy, at
delivery and in the postnatal period.
From different sub-studies conducted at the antenatal clinics (ANC) and in the maternity ward
for this research, a number of missed implementation opportunities were identified. A review
of records found that 24% of pregnant women who delivered in hospital left the maternity
ward with unknown HIV status and 50% of HIV-positive women tested at ANC did not receive
Antiretroviral therapy (ART) for PMTCT.
A cross-sectional study at the maternity ward found that 12% of pregnant women who were
not screened for syphilis, 27% of RPR-positive women who were not treated at ANC, and all
infants of RPR-positive women did not receive any intervention to prevent congenital syphilis.
Forty-one percent of HIV-positive women recruited in the cohort study successfully completed
all PMTCT interventions. Only 18% of HIV-positive women identified through PMTCT were
successfully referred to, and attended an adult care and treatment clinic (CTC). Of 403 HIV-
positive women in the cohort study, 50% did not intend to get pregnant and by four months
postpartum, 20% of them reported to have not received any counselling on family planning.
HIV-positive women who did not receive counselling on FP use were at a higher risk of not
using contraception compared to those who were counselled (adj. OR=6, 95% Cl; 2.8-12.9).
About 27% of HIV-positive mothers were not counselled regarding infant feeding and 40.2% of
women who were not counselled on infant feeding were undecided on how to feed their
infants before they left the hospital compared to only 2.5% of women who were counselled
(P<O.OOl)
It was found that pregnant women attending ANC for the first time during pregnancy spent
between three and 5.5 hours at the clinic, on average, 78% of this time was spent waiting for
services.
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Fewer ANC visits, attending private or rural ANC facilities, failure to attend a CTCprenatally,
and lack of knowledge among users and provider of health services were factors found to
hamper the performance of the programmes.
Integration of these programmes at all levels and training of health workers in basic
components of the programmes are fundamental to the successful implementation of the
programmes.
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CHAPTER 1: INTRODUCTION
1.1 Background
In Africa more than 70% of pregnant women attend the antenatal care (ANC) services at least
once during pregnancy [1]. Antenatal care (ANC) clinics are known as an excellent entry point
for reaching pregnant women with various health interventions particularly prevention of
mother-ta-child transmission (PMTCT) of human immunodeficiency virus ,(HIV) and maternal
syphilis screening and treatment.
While PMTCThas become a priority in many developing countries and research has reported a
decrease in proportion of HIV-exposed infants (HEI) who acquire HIV through mother- to-child
transmission (MTCT) of HIV [2], in Tanzania it is not known how many HIV-positive women
who have access to these services, successful complete the program. In addition, it is not clear
what the factors are that influence the failure to complete the program. In reality a high
proportion of HIV-positive pregnant women who attend the ANC during pregnancy are being
identified through PMTCT, but many get lost along the way before the completion of PMTCT
interventions.
Previously, HIV testing in ANC during pregnancy mainly focused on preventing the infection
from HIV-positive mothers to their infants with less focus on keeping the mothers healthy.
However, recently WHO following the global effort to combat HIV in children called for best
eVidence-based interventions to reduce the risk of transmission from HIV-positive mothers to
their infants as well as promoting the health of the mothers [3]. Health benefits as a result of
initiating HAART during pregnancy, such as stronger immune system and decreased risk of
HIV-related morbidity for the mothers and lower risk of acquiring HIV for their infants, have
been documented [4]. However, studies in other parts of Africa estimated that only 40% of
HIV-positive pregnant women in need of HAART receive it [5]. In Tanzania, it is not known how
many HIV-positive pregnant women identified through PMTCT HIV screening get referral to a
care and treatment clinic (CTC) and attend a CTC during pregnancy or during the postnatal
period. In addition, it is not known how many women are assessed at a CTCfor the eligibility
to initiate on HAARTand how many initiate HAARTbefore or after delivery.
Research has reported an increasing number of babies with congenital syphilis (CS) despite
getting PMTCT [6-7], This indicates a failure in the basic system of sexually transmitted
diseases (STD) control and prenatal care and raises concerns that other ANC health
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interventions are being given less or no attention as a result of the focus on PMTCT
intervention. The reality is that in developing countries, infants who receive antiretroviral
prophylaxis and successfully complete PMTCT programme may still die from CSdue to lack of
syphilis screening interventions during ANC [7). This scenario and the opposite of it may as
well apply in Tanzania where syphilis screening is frequently not being implemented in clinics
that offer PMTCT services or where PMTCT services are not offered in ANC facilities that offer
syphilis screening and treatment during pregnancy.
The epidemiology and transmission of HIV and syphilis are closely correlated. Screening for
both HIV and syphilis during pregnancy is possible and would lead to better maternal health
and pregnancy outcomes. In addition, when compared to PMTCT, prevention of congenital
syphilis (CS)has been reported to be inexpensive, simple and highly cost effective [8-9) .
Innovative ways are therefore needed to address these potentially preventable and treatable
maternal conditions in resource-limited countries. Understanding the reality and key barriers
to successful implementation of these two key maternal programmes, PMTCT and maternal
syphilis screening and treatment is needed in order to provide recommendation that may help
strengthen the integration of PMTCT and maternal syphilis screening and treatment services.
1.2 Outline 0/ the work to be presented
This thesis consists of twelve chapters. A brief introduction of the subject is given in Chapter 1.
Published literature relating to MTCT and PMTCT of HIV and maternal syphilis screening and
treatment are reviewed in Chapter 2. The study conceptual framework, objectives and
rationale are documented in Chapter 3. Six sub-studies were conducted to address the
objectives of the research; the descriptions of the methodology for these sub-studies are
presented in chapter 4. Chapters 5, 6, 7, 8, 9 and 10 review the studies in details and discuss
the results. Chapter 11 presents the overall discussion of the key findings and the conclusion
and recommendations are presented in chapter 12.
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CHAPTER 2: LITERATURE REVIEW
The review of global literature on mother-to-child transmission (MTCT) and prevention of
mother-to-child (PMTCT) of both HIV and syphilis is presented in this chapter. The literature
review was done on the work conducted worldwide but mainly focused on studies conducted
in Africa and specifically sub-Saharan Africa and, where available, studies conducted in
Tanzania were reviewed.
2.1 HIV/AIDS global overview
The HIV pandemic is one of the most serious health problems the world faces today. The Joint
United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organisation (WHO)
estimates that over 6,800 persons become infected with HIV and over 5,700 person die from
Acquired Immunodeficiency Syndrome (AIDS) every day [10]. An estimated 33.4 million
people are living with HIV, 2.7 million people have been infected with HIV and 2.0 million
deaths due to AIDS occurred globally in 2008 alone. Women account for 50.2% of all adults
living with HIV globally. The number of children living with HIV increased from 1.5 million in
2001 to 2.1 million globally in 2008. However, estimated new infections among children
declined from 460,000 in 2001 to 430,000 in 2008 [11].
Sub-Saharan Africa continues to be the region most affected by HIV. More than 68% of HIV-
positive adults are living in sub-Saharan Africa. Sixty-eight percent of all new infections and
76% of all death due to AIDS in 2007 occurred in sub-Saharan Africa. An unequal burden has
been placed on women and children, who, in many settings, continue to experience high rates
of new HIV infections and HIV related illness and death. Women account for 61% of all adults
living with HIV in sub-Saharan Africa and almost 90% of all HIV infected children are currently
living in sub-Saharan Africa [10].
AIDS is a leading cause of death among adults in Tanzania. It was estimated that 160,000
adults and children died of HIV/ AIDS in 2006 [12]. In Tanzania, which has a population of 34.5
million, WHO estimates an HIV prevalence of 7% in the general population [10, 12]. The main
modes of HIV transmission in Tanzania are heterosexual and MTCT.
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2.2 Mother-to-child transmission of HIV
MTCT of HIV occurs when an HIV-positive woman passes the virus to her baby. MTCT of HIV
accounts for 90% of all HIV infections in children [13]. MTCT of HIV can occur during
pregnancy, especially in the last trimester, during labour and delivery, and post-natal, during
breastfeeding [14].
In the absence of treatment, around 15-30% of babies born to HIV-positive women will
become infected with HIV during pregnancy and delivery and a further 5-20% will become
infected through breastfeeding [14].
Another previous study estimated that 30% of the infants get infected vertically and that the
relative frequency of timing of transmission is as follows: 2% early in gestation, 3% late in
gestation, 15% during labour and delivery, 5% in the early postpartum period and 5% in the
late postpartum period [15].
At the end of 2008, 2.1 million children were living with HIV globally. In 2008 alone, an
estimated 430,000 children became infected with HIV, mainly through MTCT and of the two
million people who died of AIDS in 2008, more than 10% were children [11]. HIV-exposed
infants (HEI) face two significant challenges in their early life; if they escape the risk of MTCT
of HIV during the perinatal and breast-feeding periods, they remain at high risk of becoming
orphans by losing one or both parents to the HIV disease.
AIDS is an important cause of mortality and morbidity in infants after the first month of life in
many African countries. A study conducted using data collected from seven sub-Saharan
countries to assess mortality rates in children of HIV-positive mothers found that when
compared to HIV-uninfected children, HIV infected children were at a higher risk of death
from HIV-related complications. Overall, in the absence of ARV to the infants, 30% of
newborns infected with HIV die before the age of one year, more than 50% die before
reaching their second birthday and most are dead before they are five years old [16].
In high income countries MTCT has been virtually eliminated as a result of effective voluntary
testing and counselling (VCT), availability and access to antiretroviral therapy (ART), safe
delivery practices and availability and affordability of safe infant feeding replacement [13,17]
24
2.2.1 Risk factors for mother-to-chlld transmission of HIV
Potential risk factors for MTCT of HIV can be divided into three categories, namely, maternal,
obstetric and paediatric factors [18].
2.2.1.1 Maternal risk/actors
Studies documented AIDS disease (the stage of illness where AIDS defining illnesses are
present) and maternal viral load as the strongest independent predictor of MTCT of HIV [19-
20]. An unborn child can get infected in utero through maternal blood, transplacental
haemorrhage and infection via the umbilical cord or via the gastrointestinal mucosa while
swallowing infected amniotic fluid [15]. Untreated reproductive tract infections, especially
bacterial vaginosis (BV), were also documented to have an association with MTCT of HIV. The
findings by Taha and colleagues reported that BV may be associated with an increased risk
MTCT of HIV aswell as maternal HIV infection in pregnancy and premature delivery [21].
2.2.1.2 Obstetric risk/actors
Obstetric factors that increase the risk of MTCT of HIV include longer duration of ruptured
membranes [22]. Contact with the mother's blood and/or secretions during labour and
delivery also increased the risk of HIV transmission to the infant [15]. Vaginal delivery was also
documented as a risk factor for MTCT of HIV, which may occur via direct contact of the infant
with the virus present in the genital tract during delivery. The risk associated with vaginal
delivery is higher for pregnant women with high viral load and low CD4 counts who are not on
ARTduring delivery [23].
2.2.1.3 Paediatric risk/actors
Paediatric risk factors for MTCT of HIV include premature delivery, breastfeeding and breast
health [18]. Premature infants of HIV-positive mothers were reported to be more likely
infected than full-term infants and the risk was more significant with prolonged duration of
ruptured membranes [24].
Studies have proved that HIV is present in breast milk, although the viral concentrations in
breast milk are significantly lower than those found in blood [25]. High maternal viral load
measured during pregnancy or after delivery and low maternal CD4 count are reported to be
associated with increased rate of MTCT of HIV through breast milk [26]. The risk of MTCT of
HIV through breastfeeding is greatest in early infancy and carries on as long as breastfeeding
continues [27]; the efficiency of transmission through breast milk ranges between 16%-29%
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[15). Breastfeeding for a long duration was associated with increased risk of MTCT of HIV [28-
30). Findings from a randomised clinical trial of breastfeeding versus formula feeding in
infants of HIV-1 infected mothers in Nairobi, Kenya, suggested that the volume of milk
ingested is also an important factor in breast milk transmission of HIV [31). An individual
patient meta-analysis from Tanzania, Kenya, Uganda, South Africa, Burkina Faso and Cote
d'ivoire estimated that 42% of the cases of HIV infection in children werE7attributable to
breastfeeding [32).
Other factors that increase the risk of transmitting HIV during breastfeeding include mastitis,
cracked or bleeding nipples, breast abscesses, candidal infection of the breast, and oral ulcers
or sores in the infants' mouth, which usually occur with recent HIV infection or an advanced
HIV disease (AIDS) [32-34). A study conducted in South Africa to assessthe HIV-1 transmission
risks and survival associated with exclusive breastfeeding and other types of infant feeding
found that babies who were exclusively breastfed had a lower risk of becoming infected with
HIV compared to those who had mixed feeding [35).
2.2.2 Core interventions for PMTCT of HIV
Core PMTCT interventions are those which directly prevent MTCT of HIV during pregnancy,
labour and delivery as well as during the postpartum period for women who are already HIV-
infected. These includes: comprehensive Reproductive and Child Health (RCH) services
(antenatal; postnatal and child health); HIV voluntary counselling and testing; antiretroviral
therapy; optimal obstetric care; caesarean delivery; and safer infant feeding practices [18).
2.2.2.1 Comprehensive RCHservices (antenatal, postnatal and child health)
For pregnant women to access any or all core interventions for PMTCT, they must be
identified as being HIV-infected and have access to health services during antenatal period. A
full antenatal service package needs to include: provider-initiated HIV counselling and testing;
maternal tetanus toxoid immunization; sexually transmitted diseases (STD) screening and
treatment (at least for syphilis); iron and folate supplementation, malaria preventive
intermittent treatment; basic obstetric care; and information on HIV prevention, infant
feeding and family planning [36). The comprehensive strategy approach aims to respond to
the wide range of health needs of women and their children including family. It is an excellent
entry point for delivering HIV/AIDS education and prevention to pregnant women who should
be encouraged to use existing services more frequently and earlier in pregnancy.
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2.2.2.2 Provider initiated HIV testing and counselling (PITC)
Provider initiated testing and counselling (PITC) refers to HIV testing and counselling which is
recommended by health care providers to persons attending health care facilities as a
standard component of medical care [37]. The key purpose of such testing is to enable specific
medical services to be offered that will not be possible without knowledge of the person's HIV
status and to give an opportunity to offer risk reduction counselling.
PITC services are necessary for PMTCT in order to identify women who may benefit from
PMTCT interventions. In the absence of PITCservices, most women have no definitive way to
know their HIV status. Asa result, they have no access to PMTCT interventions. For example,
in Tanzania, according to the national PMTCT guidelines, ARV prophylaxis for PMTCT is only
given to women with confirmed HIV infection [37]. Also counselling on infant feeding is the
most effective measure when it can take into account the actual mother's HIV status.
Therefore, a routine provider initiated offer of HIV testing and counselling for all pregnant
women, preferably as early in pregnancy as possible, should be considered an integral
component of essential care to women during pregnancy.
Research in developing countries have shown that voluntary counselling and testing (VCT) is a
cost effective intervention for reducing HIV-related risk behaviour, particularly when it targets
couples at high risk [2, 38]. Experience from Thailand in early years of the epidemic confirmed
the value of VCT in contributing to reduction of HIV transmission [39]. In areas highly affected
with HIV, PITC or VCT is increasingly being viewed as an integral part of access to
comprehensive, essential, quality health care.
For pregnant women who fail to access the PMTCT services in the antenatal period, PITCfor
women in labour or shortly after child birth can also facilitate their entry into PMTCT services
aswell as other HIV prevention, treatment and care services [37].
2.2.2.3 Antiretroviral therapy (ART)
Antiretroviral therapies are drugs that inhibit the ability of HIV to multiply in the body. ART
decreases HIV viral load in the infected mother, which reduces an infant's exposure to HIV.
ART given to the mother during pregnancy or to the infant soon after delivery also provides
prophylaxis or protection for the infant during and after exposure to HIV. While ART drugs do
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not cure HIV or eliminate the virus from the body, they are effective for both treating HIV
infection in the pregnant woman and reducing MTCT of HIV.
Providing HIV treatment, care and support is vital for enabling HIV-infected women to address
their health needs. According to the WHO guidelines, all pregnant women eligible for highly
active antiretroviral therapy (HAART) must be started on treatment, and pregnant women
who do not yet need HAARTmust be given a highly effective ART as HIV prophylaxis for MTCT
[40].
Various ARV drugs, either alone or in combination with two or more drugs, reduce the risk of
MTCT of HIV [41-46]. The first major breakthrough in the prevention of MTCT of HIV came in
1994, with the three part Paediatric AIDS Clinical Trials Group (PATG) 076 trial, which
confirmed that long course Azidothymidine (AZT) prophylaxis given early in pregnancy and
intravenously during delivery to the mother and for six weeks to the infant orally, significantly
reduces the risk of MTCT from 25% to 8% [42]. The regime was quickly introduced in Europe
and North America, but it seemed costly and complex for resource poor countries.
The simplest of all PMTCTdrug regimens was tested in the HIVNET012 trial, which took place
in Uganda between 1997 and 1999. This study found that a single dose of Nevirapine (sdNVP)
200mg orally given to the mother at the onset of labour and a 2mg/kg body weight dose given
to the baby within 72 hours of delivery roughly halved the rate of HIV transmission (42,46]. As
it is given once to the mother and the baby, sdNVP was recommended as one of the few
deliverable and suitable strategies for the prevention of peri-natal HIV-1 in resource poor
countries [46].
Other short course ARV prophylaxis includes AZT alone, AZT with Lamivudine (3TC), and
combinations of AZT and sdNVP or AZT, Lamivudine (3TC) and sdNVP (43]. Other studies
documented that combined and longer regimes starting earlier in pregnancy are more
efficacious than single drug and/or shorter regimes (47-48]. Therefore, in order to increase
the effectiveness of PMTCT programmes, many countries with a heavy burden of HIV, have
adopted more effective ARV regimes, beginning in the third trimester of pregnancy, which can
reduce the risk of transmission during pregnancy and childbirth to 2-4% (49-50].
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Recently, following the confirmation that ARV prophylaxis for mothers or their infants could
significantly reduce the risk of postnatal HIV transmission [51-53], WHO developed new
treatment guidelines for pregnant women who do not need HAART for their own health and
for their infants. The new treatment guidelines provide two options. First, for the mother, AZT
twice a day should be started at 14 weeks gestation or any time thereafter during pregnancy.
At onset of labour and delivery, the mother should be given sdNVP plus A~T and 3TC twice
daily until delivery. AZT and 3TC should be continued for 7 days postpartum. For the
breastfeeding infants, daily NVP prophylaxis should be given from birth until 1 week after the
end of the breastfeeding. For HEI receiving replacement-feeding sdNVP at birth is
recommended plus twlce-dailv AZT from birth until4 to 6 weeks after birth.
The second option is a three drug regimen for the mother, taken during pregnancy, starting at
14 weeks gestation until delivery and if breastfeeding, throughout the breastfeeding period
while their infants use the prophylaxis for six weeks after birth [3].
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Table 2-1 ARV prophylaxis options recommended for HIV-infected pregnant women
who do not need treatment for their own health [3)
Option A Option B
Triple ARV prophylaxis starting
Ante partum twice-daily AZT starting from
from as early as 14 weeks of
as early as 14 weeks of gestation and
gestation and continued until
continued during pregnancy. At onset of
delivery, or, if breastfeeding,
labour, sd-NVP and initiation of twice
continued until1 week after all
daily AZT+ 3TCfor 7 days postpartum.
infant exposure to breast milk has
Mother (Note: Ifmaternal AZTwas provided for
ended.
more than 4 weeks antenatally, omission
Recommended regimens include:
of the sd-NVP and AZT+ 3TCtail can be
AZT + 3TC+ LPV/r or
considered; in this case, continue
AZT + 3TC+ ABCor
maternal AZT during labour and stop at
AZT + 3TC+ EFVor
delivery).
TDF + 3TC (or FTC)+ EFV
Daily NVPfrom birth for a minimum of 4
Daily NVP or twice daily AZT fromBreastfeeding
infants
to 6 weeks, and until1 week after all
birth until 4 to 6 weeks of age
exposure to breast milk has ended.
Infants receiving Daily NVP or sd-NVP + twice-daily AZT Daily NVP or twice daily AZT from
replacement
from birth until4 to 6 weeks of age. birth until 4 to 6 weeks of age.feeding only
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2.2.2.4 Optimal obstetric practises during labour and delivery.
MTCT of HIV during the intrapartum period is believed to be due to the infant exposure to
infected blood and other fluids from the mother. Thus, great care during delivery is needed to
avoid practices that may facilitate this exposure, such as artificial rupture of membranes and
episiotomy in cases where there is no obstetric indication. These safer practices should be a
routine part of the management of labour for all women in high HIV sero-prevalence areas
[54].
A caesarean section is an operation to deliver a baby through its mother's abdominal wall. For
HIV-positive mothers, the caesarean section may be done to protect the baby from direct
contact with the mother's blood and other body fluids. Studies conducted in developed
countries demonstrated a strong association between mode of delivery and the risk of MTCT
of HIV [55]. HIV infected women who delivered by caesarean section performed before labour
and ruptured membranes had significantly decreased risk of transmission compared with
women who delivered by other modes [56-57]. Such intervention is recommended for
mothers not taking any antiretroviral drugs [57]. However, the caesarean section was also
reported to have an increased risk of illness after delivery among HIV-positive and HIV
negative women [58], and therefore, there is a need to weigh the risk of HIV transmission
against the risk of harm due to the intervention. In many resource poor settings, the
procedure is rarely recommended.
2.2.2.5 Counselling for safer infant feeding practices
The problem of MTCT of HIV through breastfeeding has made safe infant feeding one of the
most difficult and distressing aspects of PMTCT. Breastfeeding for a long time has been
advocated as one of the most important child survival and early childhood development
interventions [59] and it has many health, nutritional, birth spacing, emotional and
psychosocial benefits.
Research has shown that the protective benefits of antiretroviral drugs are reduced when
babies continue to be exposed to HIV through breastfeeding. A randomised controlled trial
whereby mother-infant pairs were randomized to breastfeeding against formula feeding arms
in order to determine the frequency of HIV transmission through breastfeeding and
comparison mortality rates among breastfed and formula fed infants of antiretroviral na'ive
mothers in Kenya found that the frequency of breast milk transmission of HIV-1 was 16.2%,
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and that the majority of infections occurred early during breastfeeding. The same study found
out that the use of breast milk substitutes prevented 44% of infant infections and was
associated with significantly improved HIV-1-free survival [60].
However, a study among infants of mothers who received AZT 300mg orally tw.ice a day from
34 weeks gestation and during labour in Botswana documented no improved HIV free survival
with breast milk substitutes. The Mashi study that compared the efficacy and safety of two
infant feeding strategies for prevention of postnatal MTCT found that breastfeeding combined
with maternal AZT prophylaxis was not as effective as formula feeding in preventing postnatal
HIV transmission, but was associated with a lower infant mortality rate at 7 months. Both
strategies were reported to have comparable HIV-free survival at 18 months [61]. Therefore,
the effects of breastfeeding to children born to HIV-positive mothers regarding the infant
morbidity or mortality are still contradictory.
Complete avoidance of breastfeeding is often not feasible in resource poor settings due to
several reasons including the cost of formula or replacement feeding, stigma associated with
not-breastfeeding, and the potential morbidity as well as and mortality associated with
replacement feeding [30]. In situations where breastfeeding is the chosen method of infant
feeding, exclusive breastfeeding (EBF) is the best option since EBF is associated with a lower
risk of MTCT of HIV than mixed feeding [62-63].
Despite the inconclusive evidence on the benefits of formula feeding in women taking ART,
HIV-positive mothers are advised not to breastfeed whenever the use of breast milk
substitutes is acceptable, feasible, affordable, sustainable and safe [37, 64]. In poor
developing Countries where safe water is often not available, then the risk of life-threatening
conditions from formula feeding may be higher than the risk from breastfeeding [65]. The
WHO infant feeding guidance also states that HIV-positive mothers should receive counselling
including general information about the risks and benefits of various infant feeding options
and specific guidance in selecting the option most likely to suite their circumstances [66]. They
should also have access to follow-up, care and support, including family planning and
nutritional support and the mothers' choice should always be respected.
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2.2.2.6 Family planning counselling and services
The broader approach to prevent MTCT of HIV defined by the United Nations includes
preventing unintended pregnancies to HIV-positive women and recommends the linkage of
family planning (FP) and PMTCT [67].
Several studies have demonstrated the important role of family planning in PMTCT of HIV. A
study conducted in eight African countries found that a moderate decrease in the number of
pregnancies to HIV-positive women resulted in an equivalent number of HIV-positive births
averted as the current PMTCT effort of using sdNVP for HIV-positive women and their
newborns [68]. Another study that examined the benefits of adding family planning to PMTCT
programs in fourteen countries found that in addition to the other positive benefits, family
planning added onto PMTCT services averted 71,000 child HIV infections compared with the
39,000 HIV-positive births averted with PMTCT only [69]. Furthermore, Reynolds and
colleagues estimated that current levels of contraceptives use in sub-Saharan Africa are
already preventing 22% of HIV-positive births [70], and that increasing contraceptive use
among women who do not want to become pregnant and who may not necessarily know
their HIV status is at least as cost effective as reducing HIV transmission by sdNVP for PMTCT
[71].
Many countries still experience high levels of unintended childbearing particularly countries
with high HIV prevalence [72]. Women who find out that they are HIV-positive may perhaps
have a strong desire to avoid bearing children who might be born HIV-positive and/or may
become orphaned at an early age. Furthermore, HIV-positive mothers who opt not to
breastfeed miss the birth spacing effect of lactational amenorrhea and have their own special
needs for contraception to space or limit future births. Women's understanding of the fact
that the risk of MTCT increases as the mother's own infection progresses and that the risk of
MTCTof HIV may increase with following pregnancies is important.
Therefore, HIV-positive births could be prevented by preventing HIV infection among women
of reproductive age and by preventing unintended pregnancies in HIV-positive women.
Correct and consistent use of condoms has long been promoted to protect against STD
including HIV among sera-discordant couples [2]. Condoms are the only contraceptive method
that protect against acquisition of HIV and other STDs. Therefore, family planning services
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should strongly encourage and facilitate HIV-positive women to use condoms consistently and
correctly.
PMTCT services provide an excellent opportunity to offer family planning counselling and
referral while informing HIV-positive women and couples about MTCT of HIV risks inherent in
current and future pregnancies.
2.3 Challenges to the implementation of PMTCT programmes
Progress in implementing PMTCT in resource limited countries has been slow, with overall
PMTCT coverage in low and middle income countries at about 11% in 2005 [73]. PMTCT
programmes have been shown to be feasible, acceptable and cost effective. Nevertheless,
despite significant progress in developed countries, they have not been implemented widely
in resource-constrained settings including Tanzania.
A functioning PMTCT program must provide counselling and testing services to pregnant
women. Clinical trials have proved the effectiveness of PMTCT programs in preventing MTCT
of HIV. However, results from the trial may be different to programmatic results in the real
world. Even where PMTCT services are available, not all women receive the full benefit of the
services. Reasons for pregnant women not accessing PMTCT interventions include:
1. Not being offered the service;
2. Lack of trained staff;
3. Lack of integration of PMTCTservices into maternal and child health;
4. Lackof intensive education;
5. Refusing to take a test;
6. Unavailability of treatment;
7. Not returning for treatment or follow up visits;
8. Lack of adherence support;
9. Not adhering to self-administered ART.
Although some clinics offer counselling and testing to every pregnant woman, the reality is
that not all women accept the services. Others are tested but fail to return to receive their
results. Data from pilot PMTCT programmes supported by UNICEF, reported that among more
than 500,000 women attending ANC clinics in eleven countries including: Botswana, Burundi,
Cote d'ivoire, Honduras, India, Kenya, Rwanda, Tanzania, Uganda, Zambia, and Zimbabwe,
only 71% received counselling [74]. Of those who were counselled, only 70% took an HIV test
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and among HIV-positive women, only 49% received ARV for PMTCT. Assuming equal HIV
prevalence among tested and non-tested women, fewer than 1 in 4 HIV infected women who
attended the clinic went on to receive the intervention that they needed [75). Many other
studies in developing countries have shown that such high dropout rates are common [76-79).
A review of the national programme data for 2004-2005 from low and middle-income
countries, to track progress in PMTCT reported that less than 50% of pregnant women testing
positive for HIV at PMTCTsites in 2005 actually received ARV for PMTCT. In addition, only 11%
of infants in need of HIV treatment were actually treated, revealing the fact that even when
pregnant women with HIV are identified and initiated into health care system, many are being
lost along the way aswell as their infants [73).
2.4 Situation of PMTCT activities in Tanzania
In Tanzania, the Ministry of Health in collaboration with UNICEFinitiated a PMTCT programme
in 2000. This commenced after two years of initial planning and needs assessment, which
started in 1998. Facilities that were involved in study included Muhimbili National Hospital
(MNH) in Dar es Salaam, Bugando Medical Centre (BMC) in Mwanza city, Mbeya Referral
Hospital in Mbeya city, Kilimanjaro Christian Medical Centre (KCMC) in Moshi and Kagera
Regional Hospital in Bukoba [80).
Coverage and performance of PMTCT programmes in Tanzania have been poor. The
proportion of HIV-positive pregnant women receiving antiretroviral prophylaxis for PMTCT in
2005 in Tanzania were less than 10% [81].
A few studies conducted in Tanzania, mainly, in Dar es Salaam and Kilimanjaro Regions, on the
acceptance of HIV testing for PMTCT uptake have found that low HIV risk perception, stigma,
lack of male partner involvement, frequency of antenatal care visits, lack of knowledge about
MTCT, and individual counsellor effects were often associated with women's reluctance to be
tested for HIV [82-84]. Other reasons included procedural failures within the RCHclinics and
difficulty accessing services before and after delivery [78]. Most of these studies were
conducted either in settings that offered VCT through client initiated HIV counselling and
testing rather than through routine provider initiated services and/or where clients were
required to go back on a different day for the HIV results.
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Knowledge about MTCT and quality of counselling was also found have an influence on
PMTCT uptake among pregnant women attending antenatal care (ANe) services [82, 84].
However, knowledge about MTCT among the general population in Tanzania is low. During
the Tanzania HIV indicator survey in 2003/2004, it was found that more than 60% of males
and females knew that HIV could be transmitted from the mother to the child. However, less
than 20% knew about the preventive effect of ARV therapy on MTCT and only 15% knew that
HIV can be transmitted from the mother to the infant by breastfeeding [85].
2.5 Recommended PMTCTimplementation strategy in Tanzania
2.5.1 laboratory diagnosis in PMTCT
According to the PMTCT National guidelines in Tanzania [37], all pregnant women attending
reproductive and child health (RCH) facilities at their first antenatal visit receive HIV pre-test
counselling as a routine provider initiated (opt-out) service at the clinic. Nationally, diagnosis
of HIV is established by detecting HIV antibodies using three simple rapid tests, namely
Bioline™ (Standard Diagnostic Inc. Kyunggi-do, Korea), Determine" (Abbott laboratories, II,
USA) and Uni-Gold™ HIV (Trinity Biotech PLC., Bray, Ireland), by following the National HIV
rapid testing algorithm illustrated in Figure2-1. All pregnant women who are tested for HIV
should receive post-test counselling regardless of their HIV status and the HIV results should
be given in person on the same day.
2.5.2 Antenatal Services for HIV-Positive women
Antenatal care for HIV-positive women includes the same basic services like all other pregnant
women. However, obstetric and medical care for HIV-positive pregnant women is
theoretically expanded to address the specific needs of infected women such as assessment
and prompt treatment of HIV-related infections, provision of ARV prophylaxis, counselling on
safer infant feeding and referral of the mother to CTC for assessment of eligibility for HIV
treatment [37]. This is done through clinical staging or CD4 counts. However, the latter is not
usually available through most PMTCTcentres in Tanzania.
HIV-positive women should be given referrals for ongoing follow up, HIV care and assessment
of treatment for themselves, their partners, their HIV-exposed infants and other family
members. Under the National guidelines, ARV treatment is recommended for HIV-infected
pregnant women in the following situations; WHO stage IV disease, regardless of CD4 count,
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WHO stage III disease and CD4 count less than 350cells/mm3 or if she has a CD4 count of less
than ~OOcells/mm" [37].
2.5.3 Intrapartum and postnatal services to HIV-positive women
Although it is difficult to offer counselling or obtain informed consent for HIV testing during
labour, it is of great importance in areas where PMTCT is at an initial scaling up stage since
most pregnant women miss this opportunity during the ANC period. Therefore, in Tanzania it
is recommended that all pregnant women admitted for delivery in early labour with unknown
HIV status receive routine pre-test education and, if consented, a rapid HIV test is performed
so that ARV prophylaxis for PMTCTcan be administered before delivery if the woman is found
to be HIV-positive.
Women with known HIV-positive status who are already on a HAART regimen considered safe
in pregnancy continue taking their medication during labour and delivery. All medication
administered during delivery should be documented in the PMTCT register books accordingly.
HIV-positive women who fail to deliver in a health care facility are advised to bring the
newborn infants to the health facility within 72 hours after delivery to receive ARV prophylaxis
for PMTCT.
Postnatal care for HIV-positive mothers include on-going care at maternal and child health
(MCH) clinics for postpartum follow up and close coordination with the HIV care and
treatment centres (CTC) staff to address HIV related emotional and clinical issues. The
postnatal examination is specifically directed towards eliciting signs and symptoms suggestive
of physical illness and emotional stress in the mother.
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Figure 2-1 The National HIV-Rapid Testing Algorithm for PMTCT.
• Report positive
• Counsel HIV-positive
Non-reactive result
• Report negative
• Counsel HIV-Negative
• Advise mother to return after 3
months for testing
Reactive result
Non-reactive resultReactive results
• Report negative
• Counsel HIV-negative
• Ask mother to return
after 3 month for
testing
• Report positive
.Counsel HIV-positive
Source: Tanzania National PMTCT guidelines: May 2007 [37]
2.5.4 ARV prophylaxis for PMTCT for mothers and infants
According to the Tanzanian PMTCTguidelines of 2007, HIV-positive pregnant women who are
not eligible for ARV treatment for their own health should receive ARV prophylaxis for PMTCT
[37]. Recommended approaches to ARV prophylaxis are described below.
2.5.4.1 ARV prophylaxis if the pregnant woman tested HIV-positive during pregnancy at
ANC
It is recommended that if the HIV-positive pregnant woman presents at an ANC that has the
capacity to initiate ARV treatment and the ARVmedication is available, and she does not need
ARV treatment for her own stage of disease, she should be given AZT 300mg BD from 28
weeks or anytime thereafter during ANC. At the onset of labour, she should receive sdNVP
200 mg, AZT 300mg and 3TC 150mg. She is asked to continue with AZT 300mg every 3hrs and
3TC 150mg every 12 hrs until delivery. During the postpartum period, she should continue on
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AZT 300mg BD and 3TC 150 mg BD for 7 days. For the infant, sdNVP 2mg/kg should be given
as soon as possible after delivery and AZT syrup 4mg/kg BD for 4 weeks or 4mg/kg BD for 1
week if a mother received at least 4 weeks of AZT during ANC. This is illustrated in Table 2-1.
If the woman attends an ANC facility that has no capacity to initiate ARV drugs, she should be
given a sdNVP 200 mg tablet at the 28th week visit or anytime thereafter to keep and she
should be educated that the tablet should be taken at onset of true labour. If the woman
delivers at the facility that has the capacity to initiate ARV treatment then during the
postpartum period, she should receive AZT 300mg BD and 3TC 150 mg BD for 7 days. The
infant should receive sdNVP as soon as possible after delivery or within 72 hrs. Similarly, if the
woman deliver at the hospital that as the capacity to initiate ARV treatment, the infant should
also receive AZTsyrup 4mg/kg BD for 4 weeks {Table 2-1}.
2.5.4.2 ARV prophylaxis i/ the pregnant woman tested HIV-positive during labour at the
maternity ward-be/ore delivery
According to the guidelines, if the woman tests HIV-positive at the maternity ward before
delivery and has not been tested at ANC, she should receive a sdNVP 200 mg, AZT 300mg and
3TC 150m at the onset of labour then should continue with AZT 300mg every 3hrs and 3TC
150mg every 12 hrs until delivery. During the postpartum period, she should continue with
AZT 300mg BD and 3TC 150 mg BD for 7 days. For the infant, sdNVP 2mg/kg should be given
as soon as possible after delivery and AZTsyrup 4mg/kg BD for 4 weeks {Table2-1}.
2.5.4.3 ARV prophylaxis i/ the pregnant woman tested HIV-positive during labour at the
maternity ward-after delivery
Infants of mothers who test HIV-positive after delivery are given sdNVP 2mg/kg as soon as
possible after delivery and AZT syrup 4mg/kg BD for 4 weeks. ARV prophylaxis for the infants
should be given as soon as the infant can tolerate oral feedings and within 12 hrs after
delivery [37].
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2.5.5 HIV-exposed infant's assessment of HIV status
The National guidelines recommended that HIV-exposed infants born in a health facility
receive an MCH card in which the ARV prophylaxis for PMTCT is indicated [37]. Infants should
be seen in the health care facility or at home within one week of delivery or sooner to monitor
feeding progress. Follow up visits for HIV-exposed infants are scheduled to coincide with the
recommended immunisation schedule at the first, second and third months post-delivery and
thereafter during routine growth monitoring scheduled visits as indicated on the MCH card
(that is, monthly up to one year and then 3 monthly up to 5 years). A full clinical re-
assessment including growth and development is done at each follow up visit [37,86].
Figure 2-2 Blood sample (OBS)collection for the peR test at STRH
Source: field data
The guidelines recommend that HIV-exposed infants be given cotrimoxazole preventive
therapy (CPT)starting from four weeks onwards at 5mg/kg dosage. CPTis continued until the
child is proven to be HIV antibody negative. Infants exposed to HIV may test HIV-positive on
HIV tib d .an ioouv testing for up to 18 months due to persistence of maternal antibodies
transferred across the placenta. Therefore, antibody testing for HIV infection with using
conventional ELISAis performed at 18 months if the child is no longer breastfeeding. If a child
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is still breastfeeding at 18 months, the test is done six weeks after stopping breastfeeding.
Earlier diagnosis is possible using HIV PCR,which detects HIV DNA. The test can be done at
four weeks after birth. If the initial PCR is positive, a repeat test is recommended before
disclosure of the result [86]. Currently in Tanzania HIV PCRtesting is available at the Muhimbili
National Hospital in Dar-es Salaam and two referral hospitals, namely, Bugando Medical
Centre (BMC) in Mwanza and at the Kilimanjaro Christian Medical Centre (KCMC) in Moshi.
2.6 Maternal syphilis global overview
Syphilis is a bacterial infection caused by Treponema pallidum and is usually sexually
transmitted. It is a curable infection, which if left untreated, can eventually lead to irreversible
damage to the heart and nervous system.
Syphilis is classified into several stages: primary, secondary, latent and tertiary stages [87].
During the primary stage, the infected person develops a painless ulcer (chancre), which lasts
for 2-6 weeks. The second stage is characterised by skin rashes, fever and muscle pain
including other symptoms as well as signs. The latent phase is the dormant stage with no
symptoms. The tertiary stage usually occurs many years after initial infection and presents as
neurosyphilis (affecting the brain or spinal cord), cardiovascular syphilis (in which the aorta
and heart are infected) or late benign syphilis (affecting the skin). An infected mother can
transmit the syphilis infection to the foetus at all stage but the risk is higher in earlier stages of
syphilis [88]. The infection can also be transmitted by blood transfusion. Syphilis has been
identified as a principal cofactorfacilitating the transmission of HIV in adults [89].
Syphilis sero-prevalence during pregnancy is in general low in developed countries, ranging
between 0.02% in Europe to 4.5% in parts of the United States. Among pregnant women
attending antenatal clinics in Africa, syphilis prevalence rate between 3% and 18% have
consistently been reported at antenatal clinics [90-91]
2.6.1 Impact of maternal syphilis on pregnancy outcome
Syphilis infection in pregnant women has long been recognized as a major factor for adverse
perinatal and maternal outcomes [92-93]. Common documented adverse pregnancy
outcomes of women infected with syphilis includes stillbirth, spontaneous abortion [94],
neonatal death, perinatal death and neonatal syphilis infection or congenital syphilis [92].
Others are low birth weight, prematurity and intrauterine growth retardation [95]. A
retrospective cohort study conducted among pregnant women admitted for delivery in
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Mwanza region, Tanzania, found that 49% of women with untreated high titre syphilis
experienced an adverse pregnancy outcome compared to 11% of uninfected women [96).
2.6.2 Congenital syphilis
Congenital syphilis occurs when the pregnant woman passes Treponema pal/idum, the
causative agent of syphilis, to her unborn baby. There is a 70% probability of an untreated
pregnant woman transmitting the infection to her foetus within four years after acquiring
syphilis [97). More than 50% of live born infants with congenital syphilis develop serious
problems such as blindness and/or deafness and developmental disability later in life.
Currently, WHO estimates that up to 1.4 million cases of congenital syphilis occur worldwide
each year [6) this is more than twice the UNAIDS' estimates of the 530,000 children under 15
years who are annually infected with HIV [13]. Congenital syphilis following untreated
maternal infection is preventable when infected women are identified and treated
appropriately as early in pregnancy as possible.
2.6.3 Interventions to prevent congenital syphilis
The basis of the prevention of congenital syphilis and other sequalae of untreated maternal
syphilis has been syphilis screening and treatment during pregnancy. Vertical transmission of
congenital syphilis most commonly occurs after 4 months of gestation. Thus, an approach to
early antenatal screening and appropriate treatment is important in order to prevent most
casesof foetal infections.
2.6.3.1 Syphilis diagnosis in pregnant women
Due to asymptomatic infection, screening for syphilis needs laboratory tests. Syphilis tests fall
into four groups [98]:
1. Direct microscopic examination- used when lesion(s) are present;
2. Non treponemal tests- used for screening;
3. Treponemal tests-used as confirmatory tests; and
4. Direct antigen detection tests - gold standards for test evaluation.
Syphilis screening is traditionally performed using non-treponemal tests such as the rapid
plasma reagin (RPR)or Venereal Disease Research Laboratory (VDRL) assays [99]. RPRand
VDRL are helpful indicators of syphilis infection and are cheaper to perform than treponemal
tests. However, their sensitivity varies according to the stage of the disease while their
specificity is low in certain settings and false positive results are encountered [93], especially
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in pregnant women due to factors such as malaria, tuberculosis and viral fever. Thus, it leads
to over treatment. Furthermore, it takes 10-45 days for the infection to be detected by a non-
treponemal blood test and therefore, a single initial negative test does not prove absence of
the infection. Pregnant women who are negative on the first test should ideally be screened
again later in pregnancy or at delivery but in practice, that rarely happens.
Ideally, non-treponemal tests (RPRand VORL)should be confirmed by treponemal tests. These
include the Treponemal Pallidum Haemagglutination Assay (TPHA) or Treponemal Pallidum
Particle Agglutination (TPPA) assay. Treponemal tests have higher sensitivity and specificity
but are expensive, they require a laboratory with trained personnel, refrigeration for the
storage of reagents, electricity to run equipments and they cannot distinguish between
current and past infections [100].
Treponemal rapid, simple and effective screening tests are now becoming available. Such
point-of-care (POe) tests can use both whole blood from finger prick or serum or plasma. They
do not require access to a laboratory or refrigeration. They offer a practical alternative to
traditional techniques and have the potential to change the whole approach to syphilis testing
even in primary health care settings [101-102]. Because the results can be available
immediately (within 20-30 minutes), women can be tested and receive treatment on the same
visit. Rapid tests cost between US$ 0.93-1.44 per screened woman [9]. Although this is more
than the cost of the previously standard tests, rapid tests are in fact more cost-effective, since
women can be tested and treated in a timely manner such that more cases of congenital
syphilis prevented. However, like non-rapid treponemal tests, these POC test cannot
distinguish between past and current infections.
2.6.3.2 Syphilis treatment in pregnant women
According to the CDCrecommendations of 2006 [103], when syphilis is diagnosed in pregnant
women, the treatment should consist of the penicillin regimen appropriate for her stage of
syphilis. For primary, secondary and early latent syphilis, the recommended treatment is
benzathine penicillin G, 2.4 million units (m.u) 1M in a single dose. For late latent syphilis or
syphilis of unknown duration, benzathine penicillin G, 7.2 million unit (m.u) total is
recommended, administered in three doses of 2.4 m.u 1Meach at one-week intervals.
For pregnant women allergic to penicillin, the recommendations are to desensitize and treat
them with penicillin if this is possible. HIV-positive pregnant women with early syphilis
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infection may be at high risk of neurologic complications, which may increase the treatment
failure with benzathine penicillin, and therefore, careful follow up after therapy is
recommended.
A study conducted in Mwanza, Tanzania, to estimate the cost effectiveness of onsite antenatal
syphilis screening and treatment found that the economic cost was $1.44 per women
screened and the cost effectiveness was $10.56 per disability adjusted lost years (DALY) saved
[9]. When compared to preventing mother-ta-child transmission of HIV, prevention of
congenital syphilis (CS)found to be inexpensive, simple and highly cost effective [8-9]. Thus,
prevention of syphilis in pregnant women by screening with new, simple rapid tests and
treating using benzathine penicillin is likely to be cost effective and affordable for countries
with limited resources.
2.7 Challenges to the implementation 0/maternal syphilis screening
Even though syphilis has long been known as an important cause of morbidity and mortality
among pregnant women, and maternal syphilis screening and treatment are relatively feasible
and effective. Such an intervention has not been fully available to the majority of the pregnant
women in developing countries. Even in countries with maternal syphilis screening as a
national policy and wide utilization of antenatal care services, syphilis screening among
pregnant women appears to be low [104]. Reasons for low maternal syphilis screening among
pregnant women include:
1. Not attending the ANC clinic in pregnancy;
2. Lackof services at ANC clinics, that is,
a. Syphilis screening services not offered,
b. Run out of test kits and/or treatment,
c. Unavailability of trained staff;
3. Not returning for test results to facilities which implement offsite syphilis testing;
4. Lack of screening and treatment of partners;
5. Late attendance for antenatal care during pregnancy;
6. Refusing to take a test.
Similarly, maternal syphilis screening and treatment in Tanzania faces many of these
challenges. A study conducted in Tanzania in 2000/2001 to examine maternal syphilis
screening and its operational implementation in antenatal clinics documented a failure in
effective implementation of syphilis screening programmes in the country. About 57% of
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pregnant women who attended the ANC services were not screened for syphilis due to a lack
of trained health workers to perform the RPRtest, lack of supplies and poor supervision as
well as quality control. Of those who were screened and found RPR-positive, only 61% were
treated and only 37% had partners who came for treatment [96].
In Zambia, although 90% of pregnant women attended prenatal services and syphilis
screening was mandatory according the government policy, there were many barriers to its
effective implementation. They included late attendance to ANC, not being offered a test,
failure to give treatment to male partners, which resulted in re-infection, and failure to
recognise infection acquired late in pregnancy [88].
Case studies in Bolivia, Kenya and South Africa found that in many antenatal care facilities
there were no syphilis screening and treatment guidelines and women attended the antenatal
services late in pregnancy and thus, made it difficult for timely detection and treatment of
syphilis. Furthermore, knowledge about syphilis was limited among pregnant women and
health education talks and counselling was not put into practice [lOS].
2.8 Maternal Syphilis screening in Tanzania
Maternal syphilis screening is a national policy in Tanzania [106]. It is recommended that all
pregnant women attending ANC clinic for their first visit during that pregnancy should be
screened with the rapid plasma reagin (RPR)test. It is recommended that syphilis screening
should be done on site and results and treatment made available to the pregnant women on
the same day before they leave the clinic. Furthermore, it is recommended that women, at
each antenatal Visit, should be asked about STIsymptoms in themselves and in their partners.
When syphilis is diagnosed, the recommended treatment is benzathine penicillin 2.4-m.u 1M
single dose given as two injections at separate anatomical sites.
Theoretically, at the time of delivery, syphilis test results should be reviewed, and the infant
evaluated for signs of CS. It is recommended that women who missed an RPR test during
antenatal care should be tested during delivery and the test results should be obtained as
soon as possible so that early treatment can be given to the infants of women who test
positive and to the mothers.
All infants born to RPR positive mothers with signs of congenital syphilis such as vesicular
eruptions on palms or soles, hepatosplenomegaly, pseudoparalysis, oedema/ascites, fever (in
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the first week of life), prolonged or conjugated hyperbilirubinaemia, petechiae, bleeding and
syphilitic facies, should be treated with single dose benzathine penicillin 50,000 iu/kg
regardless of whether the mothers were treated during pregnancy or not. Infants who have
signs of congenital syphilis and who are born to mothers with unknown syphilis status should
be started on treatment and their mothers should be tested.
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CHAPTER 3: AIMS OF THE STUDY
3.1 Rationale for research studies presented in this thesis
Literature on prevention of mother-to-child transmission (PMTCT) of HIV and maternal
syphilis screening and treatment programmes in Tanzania reveal that little has been
documented on accessibility and utilization of these services. To date, no study has
documented the proportion of women who successfully completed the programmes and the
reasons for non-completion of these interventions are not known.
Although there are clear guidelines for PMTCT and syphilis screening and treatment during
pregnancy in Tanzania, it is not known how effective and practical they are at ANC clinics and
during delivery. Therefore, there is a need to document what works and what does not.
Maternal viral load is an important risk factor for mother-to-child (MTCT) of HIV, and it has
been confirmed that ARV medication decreases HIV viral load, which reduces an infant's
exposure to HIV. In Tanzania, no studies have documented whether HIV-positive pregnant
women, identified through PMTCT, receive proper referrals for their own care and treatment
before delivery, and whether they attend their referrals. Reasons for non-attendance are not
known. In this study, we examine the referral procedures for HIV women identified through
PMTCTto a CTC,determine the attendance rates at the care and treatment clinic (CTC), and
explore reasons for non-attendance.
Breastfeeding is an important risk factor for MTCT of HIV, especially in resource poor
countries like Tanzania, where replacement feeding is often not acceptable, feasible,
affordable, sustainable or safe. While counselling on infant feeding is of great importance to
all HIV-positive mothers, little is known about the impact of counselling on infant feeding
among HIV-positive women and whether women adhere to their planned infant feeding
methods.
Despite having maternal syphilis screening and treatment as a national policy, the rollout of
PMTCT since 2004 and the wide use of antenatal services in Tanzania, the majority of the
pregnant women still present to the hospital for delivery without being screened for syphilis
and with unknown HIV status. In this study, we determine the factors that contributed to the
failure of the implementation of these two important maternal and reproductive health
programs at the individual and health facility levels in Mwanza Region.
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A study conducted in 2000/2001 in nine districts in Tanzania to examine maternal syphilis
screening and treatment and its operational implementation in ANC revealed a failure in the
implementation of the programmes [96]. The introduction of PMTCT in Tanzania is an
excellent opportunity to offer other maternal health related interventions such as syphilis
screening and treatment. In this research, we assess and document the extent of integration
of PMTCT and maternal syphilis screening and treatment services at the facility level in
Mwanza- Tanzania.
Different sub-studies conducted for this research and presented in this thesis we evaluates
general knowledge about MTCT of HIV and syphilis among health workers and pregnant
women and assessthe quality of the information given to pregnant women during counselling
sessions at public ANC clinics in Mwanza-Tanzania.
3.2 Conceptualframework
Figure 3-1 demonstrates the conceptual framework that was used to select the research
methods and to prepare the data collection tools. From the literature review, various factors
have been documented to influence pregnant women's accessibility to PMTCT and maternal
syphilis screening and treatment. Access to PMTCT and maternal syphilis screening and
treatment is determined to some extent by the individual situation, the health systems and
policy factors as well as the community factors. The roles of these factors in hindering the
successful implementation of the programmes for pregnant women must be addressed.
The yellow box represents the community level factors these factors indirectly affect the
women's decisions regarding access to services. While community factors such as levels of
HIV-related stigma can influence health systems e.g. through health workers' behaviour
towards HIV-positive women, individual-level factors such as lack of knowledge, financial
barrier or influence of family members, health seeking behaviour can directly affect an
individual's decision to access PMTCTand maternal syphilis screening and treatment services.
The blue box represents health systems factors. These factors are also influenced by policy as
well as some community factors. Health systems factors can have both a direct and an indirect
effect on decisions to access services.
The green box represents the individual factors affecting pregnant women's health-seeking
behaviour. These factors are likely to be different for each individual within the study, while
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the community and health systems factors are likely to be quite similar for all individuals
attending the same study facility.
Figure 3-1
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treatment programmes in Tanzania
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3.3 Study aims
The broad aim of the studies described in this thesis was to assess the operational
performance of PMTCT and antenatal syphilis screening ~nd treatment during pregnancy,
delivery and in the postnatal period within public health facilities in Mwanza City; northwest
Tanzania
3.4 Specific objectives
The specific objectives were to:
1. Determine the proportion of pregnant women who successfully complete the PMTCT
and maternal syphilis screening programmes.
2. Identify potential individual and health facility factors that are likely to influence
women's successful completion of PMTCTand maternal syphilis screening and treatment
programmes.
3. Determine whether HIV-positive women identified through PMTCT receive appropriate
referral and care for their own health concerning HIV.
4. Assess the effect of antenatal HIV education and counselling on pregnant women's
knowledge about MTCT and PMTCT.
5. Determine whether HIV-positive women are offered and take up family planning (FP) as
an option after delivery.
6. Assess the integration of PMTCT and syphilis screening and treatment within public
ANC/RCHclinics.
The actual transmission of HIV to the infants were not specifically examined as part of this
thesis because mothers were only followed to 4 months after delivery and there was no
budget to test infants for HIV or to follow mothers for longer. HIV testing of infants by PCRat
4 weeks is recommended as part of the National PMTCT programme [37], but from the data
collected during this study we found that many infants are not tested and some are tested but
not on time (Le. 4 weeks after birth). Those who are tested some do not have their results by
4 months post-delivery, especially those who test eight or twelve months after birth.
Therefore, at the end of the 4 months follow up period only few had their HIV test results.
Early HIV infection is associated with increased HIV-l viraemia[107], therefore, HIV
seroconversion during pregnancy or breastfeeding could increase the risk of MTCT of HIV.
Studies conducted in Tanzania and South Africa report that about 3% and 5% of pregnant
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women who initially test HIV negative at ANC sero-convert prior to delivery and/or during
breastfeeding, respectively[108-109] . This study observed what was done in the actual
programmes. In Tanzanian the PMTCT programme do not retest women at delivery if they
tested HIV negative at the ANC and as a result, we had no way of measuring incident HIV
infection in mothers during pregnancy or breastfeeding as part of the cohort study.
Infants born to women who test RPR-positive during pregnancy were not followed up to
determine if they developed signs and symptoms of congenital syphilis, because, according
to the National guidelines for management of sexually transmitted and reproductive tract
infections, these infants should be treated at birth regardless of whether the mother was
treated during pregnancy or the infant is having any signs of congenital syphilis.
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CHAPTER 4: RESEARCH METHODOLOGY
4.1 Introduction
This Chapter presents research methodology under the following sections: study area, data
collection methods and sample size calculation. Other sections include data management and
ethical considerations.
4.2 Study area
The study was conducted in Mwanza city, an administrative capital for Mwanza region. The
region is located northwest in the United Republic of Tanzania. Tanzania is the largest country
in East Africa covering 940,000 square kilometres, 60,000 of which are inland water. Tanzania
lies south of the equator and shares borders with eight other countries namely: Kenya and
Uganda to the north; Rwanda, Burundi, Democratic Republic of Congo, and Zambia to the
west; and Malawi and Mozambique to the south. In 2002 the total population was about 34.4
million (51% women, 46% under age 15 years and 8% aged over 54 years) [12].
HIV prevalence in the general population in Tanzania is estimated to be 7% and the main
mode oftransmission is through heterosexual transmission and MTCT [10]. The surveillance of
HIV and syphilis infections among ANC clinic attendees in Tanzania in 2003/2004 reported an
overall HIV and syphilis prevalence of 8.4% and 7.3% respectively [110].
Mwanza region covers an area of 35,872 square kilometres. According to the last National
census in 2002, the region has a population of about 3 million [111]. The main ethnic groups
in Mwanza region are the Sukuma, Zinza, Haya, Sumbwa, Nyamwezi, luo, Kurya, Jita and
Kerewe. The Sukuma tribe constitutes over 90% of the population in this region. The rest of
the groups constitute various smaller proportions. The population of Mwanza Region has
been estimated to consist of approximately one-third of Muslims, one-third of Christians and
one-third followers of traditional religion [111]. The local language in Mwanza region is
Sukuma; however Swahili is the official national language and is used in all public sectors and
in conversation between different tribes. Mwanza Region is administratively divided into eight
districts. Mwanza city is composed of two districts, Nyamagana and lIemera. Mwanza city is
the second largest city in Tanzania and had an estimated population of 474,679 in 2002 [111].
Three antenatal care (ANe) clinics (Makongoro, Igoma Nyamagana(previously known as
Butimba) in Mwanza city and two delivery sites, Bugando Medical Centre (BMC) a large
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tertiary referral hospital, and Sekou-Toure Regional Hospital (STRH),participated in the study.
The two hospitals are the largest in the city and they provide delivery services for most of the
women attending public and private ANC clinics in Mwanza city. Since most of the private ANC
clinics in Mwanza city operate independently, (i.e. they are not situated in hospitals), the
majority of pregnant women attending these facilities during pregnancy deliver at BMC or
STRH. At BMC, there is also an ANC clinic for pregnant women who have complications during
pregnancy and who receive referral to BMC from their local ANC clinics.
Both BMC and STRHhave care and treatment clinics (CTC)that offer services to HIV-positive
individuals including pregnant women who are identified as HIV-positive through PMTCT and
who receive referral from ANC to attend a CTCat one of these hospitals. Pregnant women
referred to these hospitals, follow the same HIV assessment protocol as any other HIV
individuals attending the clinic.
Figure4-1 Map of Tanzania
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Figure4-2 Map of Mwanza Region
Bugando Medical Centre (BMC)
NVAMAGANA
IlEMElA
Sekou-Toure Regional Hospital (STRH)
4.3 Overview and aims of the data collection methods
To achieve the objectives of the overall study several observational studies were conducted.
Table 4-2, below is a summary description of the different study methodologies used in the
study and the specific aims that were addressed by each study.
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4.4 Situational analysis at the antenatal clinics and maternity wards in
Mwanza
A situational analysis comprising of retrospective data collection and observation of the clinic
activities was conducted at the three participating ANCclinics. These included Makongoro, a large
regional reproductive and child health clinic situated in the centre of Mwanza city, Nyamagana
clinic located at Nyamagana district hospital in the southern part of the city and Igoma health
Centre located on the road leading Eastout of the city.
4.4.1 Review of the health facility record books
In order to assessthe utilization of PMTCTand syphilis screening and treatment services, review
of the ANC clinic record books at Makongoro, NDH and Igoma ANC clinics were conducted by the
principal investigator. This review provided information regarding service utilization between 1st
September 2007 and 31st August 2008, 12 months prior to the commencement of this PMTCTand
Syphilis study in September 2008.
Record books that were reviewed at the ANC facilities included ANC register book, syphilis
screening and treatment register book and a PMTCTregister book. However, some of these books
were not available; in such a case instead of the books, the monthly reports were used. Table 4-2
shows the information that was collected from each book.
A structured form was used to collect data for this review and included:
1. The total numbers of pregnant women attending the facility for the first ANC visit in that
pregnancy;
2. The total number of pregnant women tested for syphilis at that visit;
3. The total number of pregnant women with positive RPRresults;
4. The total number of syphilis positive pregnant women treated;
5. The total number of pregnant women offered, accepted and tested for HIV for PMTCT;
6. The total number of pregnant women who tested positive for HIV;
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7. The total number of HIV-positive pregnant women who were referred to a care and
treatment centre (CTC)for assessment of HIV infection before delivery;
8. The total number of HIV-positive pregnant women who were given ARVprophylaxis.
Table 4-2 ANC register books
Name of the register book Information recorded in the register book
ANC register book ./ Document details of all pregnant women attending
ANCfor the first time during the current pregnancy
o Date of attendance
o Name
o Age/date of birth
o Address
o LMPdate
o Clinic number
o Gravidity
Syphilis screening and
treatment
./ Document details of women who are screened for
syphilis during pregnancy
o Date
o Name
o Clinic number
o RPRresults
• For RPRpositive
• whether treated
• Date of treatment (Makongoro
& Igoma ANC)
PMTCTANCcounselling
daily register book
./ Document details of women tested for HIV at ANC
o Registration number
o Name
o Age
o Date of HIV test
o HIV results
o ARVgiven
o Date ARVgiven
o Other information not in register (separate log
book and on summary forms
• Referral to CTC
• Date partner tested
• Partner's HIV test results
Similarly, a review of the maternity ward record books was conducted at BMC and STRH.At the
maternity wards two types of record books were reviewed and these were the delivery register
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books and the PMTCTmaternity register books. Details of each register book are shown in Table 4-
3. Examination of these records provided information on whether PMTCT services had been
offered, either at the ANC or delivery suite to women admitted for delivery at the two maternity
wards over the past 12 months.
Table 4-3 Maternity ward register books
Name of the register book Information recorded in the register book
Delivery register ./ Date of delivery
book
PMTCT
maternity
register book
./ Registration number
./ Mother's name
./ Mother's age
./ Gravidity
./ Birth outcome
./ Sexof infant
./ Weight of the infant
./ Date
./ Registration number
./ Information on mothers
0 Age
HIV status from ANC (Positive, Negative or Unknown)
For the case of unknown HIV status
• HIV test results at/after delivery (Positive, negative or
unknown)
• For HIV-positive mothers
• If the woman took NVPor other ARV (AZT)
• If woman use ARVduring labour
• For HIV-exposed infants
• If the infant received NVP
• Infant feeding option
./ On a different log book they recorded women who were referred to CTC
o
o
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A structure form was used to collect information on:
1. The total number of women admitted for delivery;
2. The total number of women admitted for delivery who had tested for HIV at ANC;
3. The total number of women admitted for delivery who had a known HIV-positive status
from ANC;
4. The total number of women admitted for delivery with unknown HIV status from ANCand
who were tested for HIV at the maternity ward;
5. The total number of women tested at the maternity wards who were HIV-positive;
6. The total number of HIV-positive women admitted for delivery who were referred to a CTC
prior to delivery;
7. The total number of HIV-positive women admitted for delivery who attended a CTCand
received HAARTbefore delivery;
8. The total number of HIV-positive women admitted for delivery who received ARV for
PMTCT;
9. The total number of HIV-positive women admitted for delivery whose infants received
ARVfor PMTCTprior discharge from the hospital;
10. The total number of HIV-positive women admitted for delivery who intended to
breastfeed their infants;
11. The total number of HIV-positive women admitted for delivery who intended to use
replacement feeding for their infants;
4.4.2 Participant observation
Two types of observations were conducted at the ANC facility in order to understand the flow of
the activities at the facility and the content of the health education talk offered to the pregnant
women at their first visit to the ANC during pregnancy. The purposes of these observations were
clearly explained to the health facility workers during the introductory meetings.
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4.4.2.1 Observation of health education
On three different occasions between a" September 200g and zs" June 2009, participant
observation were conducted to observe the health education talk (group pre-HIV test counselling)
at each study ANC facility. A modified tool adapted from the 2007 UNAIDStools for evaluating
quality and contents of counselling for HIV testing uptake [112] (Annex 1) was used to document
all key points covered during the health education talks and to assess the quality including
content of the information that was given to the pregnant women. All questions raised by
pregnant women attending such sessions were documented by the observer, along with
responses from the health care personnel delivering the counselling and health education talks.
Figure 4-3 Health education sessions at NOH ANC clinic
Source: Field data
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4.4.2.2 Observation of the client flow within the antenatal clinics
A research assistant (nurse midwifery) followed the movement of a pregnant woman attending
the ANC for the first time during the current pregnancy in order to determine the services that
were offered to her, the time she spent at each station in the ANCaccessingdifferent services and
how long she was in the ANC facility for that visit. Two observations were conducted at each of
the ANC facilities at Makongoro RCHclinic, Nyamagana district hospital (NDH) and Igoma health
centre.
Women were selected randomly among women attending ANC for the first time during the
current pregnancy and who arrived at the clinic before or soon after the official opening hours of
the clinic. Women were given a unique number at arrival at the ANC starting with 1 (collecting
numbers on arrival is a normal procedure at all the clinics so that those who come first should be
attended first). Women were then asked to wait until enough have arrived before the clinic
services commence. The research assistant examined the highest number (N) that was given to
the last woman who arrived at the clinic before or soon after the commencement of the services.
Then the research assistant communicated the highest number to the principal investigator via
phone who randomly selected one number between 1 and N using a random number generator
(http://www.random.org/integers/). The selected number was then communicated back to the
research assistance via phone. A research assistant then approached women with the selected
numbers; they were given information about the observation study and asked for oral informed
consent. The research assistant recorded the time of arrival and she then watched the
participant's movement through all the different procedures and different stations at the clinic.
During these observations, a research assistant did not enter the rooms while the woman was
being attended to instead she recorded the time at entry and the time at exit so as to be able to
calculate the time spent at each station. In addition, the time that the woman spent waiting for
the services was also recorded. A map of how the women moved around the clinic to accessthe
services and the total time spent at the clinic was obtained.
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4.5 Health workers interviews
A structured questionnaire with open and closed questions was administered to 90 health worker
staff at all the participating ANC clinics and the two maternity wards, Bugando Medical Centre
(BMC) and Sekou-Toure Regional Hospital (STRH).Data gathered included key work activities,
training received on PMTCT and syphilis diagnosis. Others included challenges that they have
faced in implementing these services, knowledge about MTCT of HIV and syphilis and their
perspective on utilization of PMTCTand syphilis screening services. These interviews took place
during the entire period of the study (September 2008 to May 2009).
4.6 Cross-sectional study at the maternity wards
A cross-sectional study at BMC and STRHdelivery suites was conducted in order to measure the
proportion of pregnant women who were offered PMTCT services during pregnancy and who
were screened and treated for syphilis at the ANC. This took place at the maternity wards on
Monday to Friday over a period of one month between a" September 2008 and iz" October
2008. Pregnant women admitted for delivery during Monday to Friday over the period specified
above, were asked for written informed consent to participate in the study and a structured
questionnaire was administered to all consenting women
During the cross-sectional study, data collected included socio-demographic characteristics,
parity, gravidity, outcomes of previous pregnancies and past contraceptive use. In addition, data
were collected about ANC services received for the current pregnancy including where
participants attended for their antenatal care, whether they were screened for syphilis, if they
had access to PMTCTservices at the ANC/RCHand whether they were tested for HIV. For those
not screened for either syphilis or HIV during pregnancy, information was collected on potential
reasons they were not screened at that time. Other information collected included knowledge
about syphilis, MTCT of HIV and syphilis, ways of preventing MTCT of HIV and syphilis and
awareness of PMTCTand syphilis screening and treatment services during pregnancy.
4.7 Cohort study
A prospective cohort of 403 HIV-positive women was recruited at the two maternity wards (BMC
and STRH)in Mwanza city over five months between 8
th
September 2008 and zo" February 2009.
The main aim of this study was to determine the proportion of HIV-positive women who
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successfully completed the PMTCTinterventions in addition to other secondary aims as indicated
in Table 4-1.
4.7.1 Inclusioncriteria
Inclusion criteria included being admitted to the labour ward for delivery, known positive HIV
status (either from the ANCor tested at admission for delivery), willingness to participate, able to
give informed written or fingerprint consent and being resident in Mwanza City for at least four
months post delivery. Birth outcome was not considered as an inclusion or exclusion factor
because mothers whose infants had a poor birth outcome, such as stillbirth, may be, for example,
vulnerable to falling out of HIV care and treatment programmes.
4.7.2 Cohort recruitment
The cross-sectional study took place during the first months of the cohort recruitment. During this
period, all women admitted for delivery were given the information about the study in the
maternity ward while at their beds, and thereafter they were called one by one in a private room
where they were given written information about the study and asked to sign a consent form.
During this first month, all HIV-positive women were first seen by the counsellor who informed
them about the study and if they agreed to participate, the counsellor then introduced them to a
research assistant. A woman was then given verbal and written information about the cohort
study and was asked to participate. Those who agreed were asked to sign or fingerprint a consent
form. Women who did not fulfil the inclusion criteria were asked to participate in the cross-
sectional study. After the cross-sectional study, HIV-positive women were seen by the counsellor
who introduced them to a research assistant after informing them about the study. The
information about the study was given to individual women in a private room, and the procedure
explained was followed.
After informed consent, a research assistant (trained clinical officer/nurse midwife) based at each
delivery site administered a structured questionnaire to the women so as to gather information
on socio-demographic characteristics, parity, gravidity, outcomes of previous pregnancies and
past contraceptive use. Data were also collected about the current pregnancy including where
they attended the antenatal care, whether they were screened for syphilis, whether they had
access to PMTCT services at the ANC/RCH, and were tested. For those not screened during
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pregnancy at ANC/RCHclinic, data were collected on potential reasons they were not screened at
that time.
For women who were tested during pregnancy and found to be HIV infected, data were collected
on which PMTCTdrug(s) were given, whether the mother took her ARVprophylaxis appropriately,
whether she had an HIV assessment at a CTCduring that pregnancy, details on her CD4 counts if
available and whether she was started on HAART. Other information collected included
knowledge about syphilis, MTCTand PMTCT,where the women intended to attend for under-five
services and tracing information for women who agreed to have home visits.
According to the Tanzania national guidelines on management of sexually transmitted and
reproductive tract infections [106], pregnant women not screened for syphilis during pregnancy
at ANC should be screened at the maternity ward. The research team observed that this was not
happening at the two study maternity wards, and for ethical reasons, we organised for a blood
sample to be collected for syphilis screening from women in the cohort who had not been
screened and treated for syphilis during pregnancy. These samples were sent to Makongoro clinic
for a rapid plasma reagin (RPR)test. Women who found to be RPRpositive on this test were
traced at home by the research team and were taken to Makongoro clinic with their infants for
syphilis treatment as soon as possible. At Makongoro clinic mothers were treated with benzathine
penicillin 2.4 mu 1M single dose and their infants were treated with single dose of benzathine
penicillin 50,000 iu/kg according to the Tanzanian guidelines [106]. Efforts were also made to
treat their husbands/partners.
After delivery and before the mother was discharged from the hospital, data were collected on
the delivery mode, outcome of the pregnancy, sex of the infant and whether the infant received
ARV prophylaxis after births and which drug(s) were given, what counselling was given about
infant feeding, what method of feeding the mother had chosen and whether the mother was
counselled on family planning. The Study Identification Card was provided to all enrolled women
to bring to the under-five RCHclinics during the follow up.
For mothers who had opted for replacement feeding, no data were collected to evaluate the
AFASScriteria. Traditionally, in the maternity wards in Tanzania, soon after delivery, women are
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encouraged to put the baby to the breast to stimulate the breast-milk and they do not give any
oral solution (e.g. glucose) to the infants in the maternity ward. During this study we observed
that apart from the medicine syrup (mainly ARV syrup that was administered to HIV exposed
infants (HE!)), there was no oral glucose or any liquid given to infants in the maternity ward with
the exceptional of few HIV exposed infants whose mothers had opted for replacement feeding
and who started feeding their infants before discharge from the hospital.
4.7.3 Cohort follow-up
All women recruited into the prospective cohort were followed up post-delivery at their monthly
under-five RCH clinic visits for four months. At each visit standardized questionnaires was
administered by research assistants (clinical officers and nurse midwife) to collect data on infant
feeding, uptake of infant HIV testing post-delivery, progress of the mother at the CTCclinic, family
planning (FP) counselling and uptake, disclosure of HIV status to partner and other relatives and
information on sexual behaviour.
Women who failed to attend the under-five RCH clinic visits were followed up at home to
administer the same questionnaire and to record reasons for non-attendance to the under-five
RCHclinic.
During these follow up visits, HIV-positive mothers who had not attended a CTCwere asked
several extra questions to explore reasons for non-attendance to a CTC. They were then re-
referred to the counsellor at the RCHclinics to explain why assessment of their own health was
important and to encourage them to attend the nearest CTC.
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Figure4-4 Homevisit
Source: Field data
4.8 Sample size available, estimated power and probable precision for the
major study outcomes
4.8.1 Cross-sectional study at BMC and STRHmaternity wards
A structured questionnaire was administered to women admitted for delivery at BMC and STRH
for a period of one month. The average number of deliveries per day was estimated to be 30 and
15 at STRHand BMC respectively. To calculate the number of women who were expected to be
interviewed at the maternity wards, the following assumptions were made:
1. Interviews were to be conducted from Monday to Friday (i.e. 22 days)
2. Refusal rate was estimated to be 10%
With these assumptions, it was envisaged that 990 women were to be admitted for delivery at
both maternity wards during the study period of one month (22 working days) of which 900
women would be interviewed. Table 4-4 shows the estimated power and probable precision that
would be obtained for different estimates of the three main outcomes from a sample size of 900
women. The three outcomes are:
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1. Percentage of pregnant women delivering at BMC & STRHwho were tested for HIV during
ANC
2. Percentage of pregnant women delivering at BMC & STRHwho were screened and treated
for syphilis during ANC
3. Percentage of pregnant women delivering at BMC & STRHwho were tested for HIV &
syphilis during ANC
Table4-4 Estimated power and probable precision for the main outcomes, with a given
sample size of 900 women
Outcome
Pregnant women admitted
for delivery who were tested
for HIV during ANC
Pregnant women admitted
for delivery who were
screened and treated for
syphilis during ANC
% Precision Power
20% ±3.9% 80%
30% ±4.2% 80%
40% ±4.5% 80%
50% ±4.7% 80%
60% ±4.6% 80%
70% ±4.4% 80%
20% ±3.9% 80%
30% ±4.2% 80%
40% ±4.5% 80%
Pregnant women screened
for both HIV and syphilis
during ANC
4.8.2 Prospective cohort at BMC and STRHmaternity wards.
The prospective cohort at BMC and STRHwas recruited over a period of five months .. To estimate
the number of HIV-positive women who could be recruited over the five months, the following
assumptions were made
1. HIV prevalence on admission to delivery (includes women tested at ANC/RCH and those
tested during admission for delivery):-
a. 10% at STRHmaternity ward from an average of 30 women per day
b. 7% at BMCmaternity ward from an average of 15 women per day
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From these estimates, an average of 4 HIV-positive women were estimated to deliver at the
two sites each day giving a total of 440 HIV-positive women admitted for delivery over a five
months period.
2. Approximately 10% of HIV-positive women were expected not to meet the inclusion
criteria
3. The refusal rate at cohort recruitment was estimated to be 10%.
4. loss to follow-up during the 4 months study period would be about 20%.
Therefore, 264 women were expected to complete the 4 months follow up after delivery. Table
4-5 shows the estimated power and probable precision that would be obtained for different
estimates of the 3 main outcomes from a sample size of 264 women who were expected to be
seen 4 months after delivery. These outcomes include:
1. The percentage of HIV-positive women who were referred to CTCand attend;
2. The percentage of HIV-positive women counselled on infant feeding options before
discharge from the hospital;
3. The percentage of HIV-positive women following their planned feeding regimen.
Table 4-5 Estimated precision for the main outcomes, with a given sample size of 264
women
Outcome % Precision Power
40% ±8.1% 80%
50% ±8.5% 80%
60% ±8.6% 80%
70% ±8.3% 80%
60% ±8.6% 80%
70% ±8.3% 80%
80% ±7.5% 80%
90% ±6.0% 80%
40% ± 8.1% 80%
50% ±8.5% 80%
60% ± 8.6% 80%
HIV-positive women referred and attend CTC
HIV-positive women counselled on infant
feeding option before discharge from the
hospital
HIV-positive women adhering to their planned
feeding regimen
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4.9 Data management
Research assistants, crosschecked all questionnaires for completeness on a daily basis.
Questionnaires were then submitted to the data entry section and double-entered into Epidata
Entry 3.1 (The Epidata Association" Odense, Denmark) and cleaned and analysed using Stata 9.0
and Stata 11.0 (STATACorporation, Texas, USA)software respectively.
Data from the cross-sectional and cohort studies were used to determine the proportion of
women who successfully completed the PMTCT and maternal syphilis interventions. A Piot-
Fransen Model was used that describes the percentage of women that complete the different
steps they have to pass through as part of the specific intervention activities in order to prevent
the transmission of HIV and congenital syphilis to their infants [113). By analyzing this model it
was possible to identify the gaps in the delivery of services focusing on prevention of HIV and
syphilis to the infants during and after pregnancy. The fall-off at each step of the different PMTCT
and maternal syphilis interventions was calculated using the denominator of women who
successfully completed the previous step. Finally, the overall fall off from beginning to end of the
intervention steps was calculated.
To identify potential client and provider factors that are likely to influence women's successfully
completion of PMTCT and maternal syphilis screening and treatment programmes, crude odds
ratios with 95% Cl were estimated using logistic regression analysis of the facility level factors.
Factors whose univariable association with the outcome (e.g. acceptance of HIV testing or syphilis
screening or completion of PMTCT interventions) reaches statistical significance at p<O.l were
included in an initial multivariate model and retained if significant at p<O.1. Individual level factors
were added to the module (adjusted for the core set of facility level factors). Factors with the
likelihood ratio test (LRT)p<O.l in the final model were retained.
4.10 Ethical considerations
4.10.1 Ethicalapproval
Ethical approval was given by the LSHTM ethics Committee and the Medical Research
Coordinating Committee (MRCC) in Dar es Salaam, Tanzania on 8th July 2008 and t" July 2008
respectively (Annex 2 and Annex 3).
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4.10.2 Informed consent
Written informed consent (Annex 4) was sought from each pregnant woman participating into the
cross-sectional study and the cohort study at the maternity wards. All participants were informed
that participation in the study was voluntary and that they could withdraw from the study at
anytime. They were also informed that participants who did not wish to participate would
continue to be offered the routine antenatal and delivery services. For HIV-positive women who
participated in the cohort study, a special request for home visit was made so that follow up could
continue if the women failed to be seen at the under-five clinics and only those who agreed for
home visits were visited and interviewed at home. This agreement was part of the written
consent (Annex 4) and it was documented on the tracing forms (Annex 8).
4.10.3 Confidentiality
Codes rather than names were used in all forms with sensitive information. Personal names were
used only for tracing information and this was linked to other information by the principal
researcher when required. Privacy was rnalntalned all the time during the interviews with HIV-
positive women, interview rooms were locked during the interview and no person was allowed to
enter into these room during the interviews.
4.10.4 Dissemination
Dissemination meetings will be held with the Municipal Health Management team and PMTCT
stakeholders to inform them of the results of the study in late 2010 or early 2011.
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CHAPTER 5: COMPLETION OF PMTCT AND MATERNAL SYPHILIS SCREENING AND
TREATMENT PROGRAMMES AMONG PREGNANT WOMEN
5.1 Introduction
This chapter examines the proportion of pregnant women who successfully complete different
steps of prevention of mother-to-child transmission of HIV (PMTCT) interventions and maternal
syphilis screening and treatment. Data to address this aim were collected from several studies
that were conducted at three antenatal care (ANC) facilities and two maternity wards and among
pregnant women attending those health facilities in Mwanza City between 2008 and 2009. These
studies are briefly explained below.
5.1.1 Recordreview
A review of the record books at Makongoro, Nyamagana and Igoma Reproductive and Child
Health (RCH)cllnlcs'. and at Sekou-Toure Regional Hospital (STRH)and Bugando Medical Centre
(BMC) maternity wards was conducted in order to assess the utilization of PMTCT and syphilis
screening and treatment services. The records contained information on service utilization at the
health facilities and the review focused on the period between 1st September 2007 and 31st
August 2008.
5.1.2 Cross-sectional study
A cross-sectional study at STRHand BMC maternity wards in Mwanza city was conducted to
coliect data on PMTCT and syphilis screening services offered during the current pregnancy
amongst women being admitted for delivery. This study provided data on i) the proportion of
pregnant women who were tested for HIV and syphilis either at the ANC or at the labour ward
when they were admitted for delivery, ii) the proportion of women who were RPRpositive and
who were treated for syphilis before delivery, and iii) the proportion of infants born to RPR
positive women who received treatment after birth but prior to discharge from the hospital.
1At the RCHclinics we reviewed the ANC record books that document information on women attending the facilities for
antenatal care
2 On a register book there was a column that indicated the treatment date
3 For the cross-sectional study tracing information were not collected therefore it was not possible to trace ,~
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5.1.3 Cohort study
Data from a prospective cohort of 403 HIV-positive women enrolled on admission for delivery at
STRHand BMCmaternity wards in Mwanza city who were tested for HIV either before pregnancy,
during pregnancy at the ANC or at the maternity ward when they were admitted for delivery
before or after delivery was used to estimate the proportion of HIV-positive women completing
different steps of PMTCTinterventions regardless of when they were tested and found to be HIV-
positive.
5.1.4 Piot-Fransenmodels
Using the cross-sectional data and the cohort data described above, a Plot- Fransen model was
built up to show the fall-off at each step of the PMTCT using the denominator of women who
successful completed the previous step and then the overall fall out at each step was calculated
using the denominator of all women eligible for that particular service. Similarly, using the cross-
sectional data, a Piot-Fransen model was built to show the fall off at each step in syphilis screening
and treatment services during pregnancy.
5.2 Record review
Reviews were conducted at the ANC facilities and the maternity ward. Data on service utilization
over a period of one year between 1st September 2007 and 31st August 2008 were collected
5.2.1 Recordreview at the ANCfacilities
A total of 8141 pregnant women attended ANC for the first time during the current pregnancy Le.
3546 women were seen at Makongoro, 2658 women at Nyamagana and 1937 women at Igoma
RCHclinics between i" September 2007 and 31st August 2008.
5.2.1.1 PMTCT service utilization at ANC
Table 5-1 shows the number and proportion of women attending at each of the three facilities
and the proportion that received different PMTCTinterventions. The record review indicated that
10,044 pregnant women were offered PMTCTHIV pre-test counselling over a period of one year
while the number attended the ANC for the first time during the current pregnancy was 8141.
This was due to the fact that women attending ANC facilities that do not offer PMTCTservices in
Mwanza city are referred to the nearest ANC that offers PMTCT services. These women were
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included in the PMTCT record books along with women who attended the ANC for the first time
at the facility. The records however, did not indicate which women were referred to three
facilities from clinics, which do not offer PMTCTservices. For this reason, using the record review
data it was not possible to estimate the proportion of women attending ANC for the first time
during the current pregnancy who were not offered PMTCTinterventions.
Overall, 9793 (97.5%) of pregnant women who received HIV pre-test counselling accepted the
PMTCTHIV testing and of these, 809 (8.3%) were HIV-positive. Among the HIV-positive women,
405 (50.1%) were given ARV for PMTCTat the ANC clinic. The proportion of HIV-positive women
receiving ARVfor PMTCTat ANCdiffered significantly between the three ANC facilities.
In addition review of data on HIV testing among partners of pregnant women who were tested for
HIV during the current pregnancy was done. It was found that only 83 (0.8%) of the partners were
tested for HIV at these ANC facilities and 19 (22.9%) of the partners were found to be HIV-
positive.
Table 5-1 PMTCT service utilization at ANC between 1st September 2007 and 31st August
2008
Makongoro Nyamagana Igoma Total
Number of women attending ANC
for the 1st time during current
pregnancy
3546 2658 1937 8141
Number of pregnant women
offered PMTCTHIV pre test
4918 4143 983 10044
Number and proportion of pregnant
women accept PMTCTHIV test'
4916 (99.9%) 3894 (94.0%) 983 (100%) 9793 (97.5%)
Number and proportion of pregnant
women test HIV-positive2
368 (7.5%) 346 (8.9%) 95 (9.6%) 809 (8.3%)
Number of HIV-positive women
given ARVfor PMTCTin ANC3
138 (37.5%) 264 (76.3%) 3 (3.2%) 405 (50.1%)
Number and proportion of partners
tested for Hlv"
45 (0.9%) 32 (0.8%) 6 (0.6%) 83 (0.8%)
Number and proportion of partners
who tested Htv-posttive"
7 (15.6%) 11 (34.4%) 1 (16.7%) 19 (22.9%)
positive
4Denominator is the number of women who were tested for
HIV
5 Denominator is the number of partners who were tested for
HIV
I Denominator is all women offered PMTCT HIV counselling
, Denominator is the number of women who were tested
3 Denominator is the number of women who tested HIV
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5.2.1.2 Syphilis screening and treatment at ANC
Table 5-2 shows the number of women who attended each facility and the number and
proportion of those who were screened for syphilis during pregnancy and, if RPRpositive, those
who were treated for syphilis. As for HIV counselling and testing also for syphilis screening,
women are referred from other facilities that do not offer syphilis screening and therefore it was
not possible to determine what proportion of women attending ANC for the first time during the
current pregnancy were not screened for syphilis. From the record review, it was found that
majority of the women who were RPRpositive were not given treatment on the same day though
results were given on the same da/. Reasonsfor this included the fact that most of the time the
medicine is not available at the ANC clinic. In such cases, women were given a prescription and
they were asked to buy the medicine (injectable penicillin) from their local pharmacies and bring
it to the clinic to be administered by qualified health personnel. In most cases, according to the
STDnurse at Igoma health centre, this takes on average 3 to 7 days, with few of them bringing the
medicine during the next ANC visit. It was also learnt at Nyamagana Clinic that RPRpositive
women were asked to bring their partners so that both could be treated.
In total, 8169 pregnant women were screened for syphilis, of these 538 (6.6%) were RPRpositive.
Of the RPR positive women, 191 (35.3%) were treated and only 79 (14.7%) partners of the
pregnant women who were RPRpositive were treated.
Table 5-2 Syphilis screening and treatment at ANC between 1st September 2007 and 31
st
August 2008
Makongoro Nyamagana Igoma Total
Number of women attending ANC
for the 1st time during current 3546 2658 1937 8141
pregnancy
Number of women screened for 3338 3006 1825 8169
syphilis
RPRpositive 186 (5.6%) 210 (7.0%) 142 (7.8%) 538 (6.6%)
RPRpositive and treated 76 (40.9%) 67(31.9%) 48 (33.8%) 191 (35.5%)
RPRpositive and partner treated 41 (22.0%) 33 (15.7%) 5 (3.5%) 79(14.7%)
2 On a register book there was a column that indicated the treatment date
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5.2.2 Record review at the maternity ward
In total 14923 women delivered at BMC and STRHmaternity wards between 1st September 2007
and sr' August 2008. Of these 7212 (48.3%) had tested for HIV at the ANC, 4067 (27.2%) were
tested for HIV at the maternity ward before or after delivery and 3644 (24.4%) left the maternity
ward with unknown HIV status. Table 5-3 shows the number and proportion of women admitted
for delivery at BMC and STRH and their HIV status at admission and at discharge from the
maternity ward after delivery.
There was no difference between the proportions of women tested for HIV at the maternity
wards at BMC and STRH(28.8% vs. 26.1%). However, there was a higher proportion of women
who delivered at BMC with known HIV status from the ANC compared to those who delivered at
STRH(58.6% vs. 40.7%). Following the findings above, it was found that a higher proportion of
women delivering at STRHleft the maternity ward with unknown HIV status compared to those
who delivered at BMC (33.1% vs. 12.6%). HIV prevalence in the maternity wards was slightly lower
at both maternity wards when compared to the HIV prevalence at ANC. This might be due to the
fact that some of the women who deliver at both STRHand BMC maternity wards originate from
rural areas where HIV prevalence might be lower compared to the HIV prevalence in Mwanza city.
Table 5-3 HIV prevalence and timing of HIV testing among women delivering at BMC and
STRHbetween 1st September 2007 and 31st August 2008
BMC STRH Total
Total delivered 6332 8591 14923
Tested at ANC 3713 (58.6%) 3499 (40.7%) 7212 (48.3%)
Tested at the maternity ward 1822 (28.8%) 2245 (26.1%) 4067 (27.2%)
Left the maternity ward with 797 (12.6%) 2847 (33.1%) 3644 (24.4%)
unknown HIV status
HIV-positive
Tested HIV-positive at ANC 276 (7.4%) 256 (7.3%) 532 (7.4%)
Tested HIV-positive at the 82 (4.5%) 135 (6.0%) 217 (5.3%)
maternity ward
Total known HIV-positive before 358 (6.5%) 391 (6.8%) 749 (6.6%)
discharge from the maternity ward
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5.3 Cross-sectional study at the maternity ward
A cross-sectional study was conducted among pregnant women admitted for delivery at BMC and
STRHto collect data on PMTCTand maternal syphilis screening services offered during the current
pregnancy.
Of the 1435 women admitted for delivery at BMC and STRH maternity wards between s"
September and iz" October 2008, 1157 (80.6%) women were interviewed. Two hundred and
seventy eight (19.4%) pregnant women admitted for delivery during the study period left the
hospital without being interviewed, mainly because the researchers worked during routine hours
and were not able to see women discharged early in the morning. Twenty women who were
interviewed did not have their ANC cards and therefore were excluded from the analysis for this
section.
5.3.1 Proportion of pregnant women tested for HIV
In total, 1137 women who had their ANC card at delivery were included in this analysis. Table 5-4
shows the number and proportion of women with documented HIV results and their reported
PMTCTinterventions at ANC. Overall, 915 (80.1%) women reported receiving PMTCTHIV pre-test
counselling at the ANC, of whom 826 (80.5%) had a documented HIV test result on their ANC
cards. In total 903 (79.4%) had a documented HIV result including 77 (8.5%) who reported not
receiving PMTCT HIV pre-test counselling. Of the 903 women who were tested, 877 (97.1%)
reported receiving individual HIV post-test counselling of whom 71 (8.1%) had a positive HIV test
result. There was no difference in proportion of women receiving various PMTCT interventions
between women admitted for delivery at BMCand those admitted at STRH.
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Table 5-4 PMTCT HIV testing among pregnant women admitted for delivery at STRHand
BMC between September and October 2008
HIV counselling and testing at ANC or at the maternity ward
STRH BMC
Variable n (%) n (%) Total
Number of women interviewed (ANC 711 (99.4) 426 (96.4) 1137 (98.3)
cards presented on maternity ward)
PMTCTHIV pre-test counselling received 564 (79.3) 351 (82.4) 915 (80.5)
Documented HIV test results in ANC card 573 (80.6) 330 (77.5) 903 (79.4)
Documented HIV results in ANC card and 311 (88.6) 515 (91.3) 826 (72.6)
received HIV pre-test counselling
Documented HIV results in ANCcard and 325 (86.0) 552 (91.1) 877 (89.1)
received PMTCT HIV post-test counselling
HIV-positive result in ANCcard 43 (7.8) 28 (8.6) 71 (8.1)
5.3.2 Proportion of pregnant women screened and treated for syphilis at ANC
Of 1137 women who had their ANC card at delivery, 1002 (88.1%) had a documented syphilis
screening result. Of these, 59 (5.9%) women were RPRpositive of whom 43 (78.9%) had been
treated for syphilis at the ANC facility with a single dose benzathine penicillin 2.4 m.u 1M. All 59
RPRpositive women had live births, but none of the infants born to RPRpositive women were
treated before their discharge from the hospltal" despite treatment being a recommendation in
national guidelines [106].
Table 5-5 shows the number and proportion of women admitted for delivery at BMC and STRH
between s" September and iz" October 2008 who were screened for syphilis during pregnancy,
those who were RPRpositive, and the number and proportion of those who were treated. There
was no difference in the proportion of women who were screened for syphilis during pregnancy
between the two maternity wards (87.8% vs. 88.7% at STRHand BMC respectively). However,
there was a difference in the proportion of women who were treated for syphilis (65.8% vs.
85.7%) respectively. This could be explained by the nature of the two hospitals. A proportion of
women admitted at BMC for delivery are those who have various complication that needed care
3 For the cross-sectional study tracing information were not collected therefore it was not possible to trace the
mother/infants after discharge from the hospital for syphilis treatment at the RCHclinic.
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at a referral hospital and hence more likely to have had multiple visits to the health facilities
during pregnancy and therefore a higher chance of being treated.
Table 5-5 Maternal syphilis screening and treatment among pregnant women admitted for
delivery at STRHand BMC between September and October 2008
Variable
STRH BMC
n (%) n (%)
Total
n (%)
Number of women interviewed (ANCcards
711 {99.4} 426 {96.4} 1137 (98.3)
presented on maternity ward)
Tested for syphilis at ANC 624 {87.8} 378 {88.7} 1002 {88.1}
RPR positive 38 (4.3) 21 (4.9) 59 (5.9)
RPRpositive and given treatment during
25 (65.8) 18 (85.7) 43 (72.9)
pregnancy
5.4 Cohort study
Overall, 442 HIV-positive women were admitted for delivery at the two study maternity wards for
a five month period from a" September 2008 to zo" February 2009. One hundred and ninety
three women (43.7%) were admitted at BMC and 249 (56.3%) were admitted at STRH.Of the 442
HIV-positive pregnant women delivering at the two sites, 403 (91.2%) were recruited into the
cohort study. Table 5-6 shows the number of HIV-positive women who delivered at BMC and
STRHbetween September 2008 and February 2009 and the number and proportion recruited in
the study, with the reasons for not being included in the cohort.
Equal proportions of HIV-positive women who delivered at both BMC and STRHwere recruited in
the cohort. Twenty-seven women out of 39 (69.2%) who were not recruited in the study were
living outside Mwanza city and majority of these were admitted for delivery at STRH.Only 2
women were not able to sign the consent form
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Table 5-6 HIV-positive pregnant women delivering at BMC and STRH during the cohort
recruitment
Site
BMC STRH Total
n {%} n {%} n{%}
193 {43.7} 249 {56.3} 442 {100.0}
176 {91.2} 227 {91.2} 403 {91.2}
17 22 39
Total number delivered
Recruited in the study
Total not recruited
Reason for not being recruited
Refused 4 {23.7} 2 {9.1} 6 {15.4}
9 {52.9} 18 {81.8} 27 {69.2}
1 {5.9} 1 {4.5} 2 {5.1}
3 {17.7} 1 {4.5} 4 {10.3}
living outside Mwanza City
Not able to sign the consent form
Not seen by the team
5.4.1 Timing for the HIV test among the HIV-positive women participated in the cohort study
Of the 403 women in the cohort, 93 {23.1%} women were tested for HIV before the current
pregnancy, 240 {59.5%} were tested at ANC facility during the current pregnancy, 23 {5.7%} were
tested at the maternity ward before delivery and 47 (11.7%) were tested at the maternity ward
after delivery. Of the 93 women testing HIV-positive before the current pregnancy, 24 {25.8%} did
not have a repeat HIV test when they attended the ANC facility for the current pregnancy. All
stated that this was because they had tested before and they knew their HIV status, though this is
contrary to the National PMTCT guidelines[37J. Table 5-7 shows the timing of HIV test among
HIV-positive women who participated in the cohort study
Table 5-7 Timing for HIV testing among HIV-positive women in the cohort
BMC STRH Total
Timing of the HIV test n {%} n {%} n {%}
Total 178 {44.2} 225 {55.8} 403 {100.0}
Before the current pregnancy 54 {30.3} 39 {17.3} 93 {23.1}
At ANC during the current pregnancy 96 {53.9} 144 {64.0} 240 {59.5}
Before delivery 11 {6.2} 12 {5.3} 23 {5.7}
At the maternity ward
After delivery 17 {9.6} 30 {13.4} 47 {11.7}
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A slightly higher proportion of women who tested for HIV before the current pregnancy were
admitted for delivery at BMC compared to STRH. Thirty women out of forty-seven women (63.8%)
who were tested for HIV after delivery were admitted and delivered at STRH.
5.4.2 PMTCT ARV prophylaxis use among HIV-positive women participated in the cohort
study.
To estimate the proportion of HIV-positive women who were given ARV for PMTCT, women were
divided into two categories. The first group included women who had attended an adult care and
treatment clinic (CTC) and brought their CTC cards on admission to delivery at the maternity
ward. The second group included those who reported receiving any ARV for PMTCT.
5.4.2.1 PMTCT ARV prophylaxis as indicated on eTe cards
Of the 403 women in the cohort, 84 (20.8%) attended a CTC before delivery and had brought their
CTC cards on admission for delivery. This card (Annex 5) records their HIV treatment. Of these 84
women, 38 (45.2%) women were on HAART, 11 (13.1%) had been given AZT 300 mg twice a day
(BD) starting at 28 weeks gestation or soon after being tested if the test was done after 28 weeks
gestation. Thirty-one women (36.9%) were given sdNVP. For four women (4.8%), there was no
documented ARV medication or prophylaxis that was indicated on the CTC cards. However, two of
these four women reported to have used some medication for PMTCT and two said that they
were not given any medication for PMTCT. Two women attending a CTC before delivery did not
get any ARV for PMTCT either from the CTC clinic or the ANC facility or from the maternity ward
when they were admitted for delivery.
5.4.2.2 PMTCT ARV prophylaxis as reported by the pregnant women
For the remaining 319 women who did not have a CTC card at the maternity suite, 85 (21.1%) of
403 women in the cohort reported attending the CTC but did not bring the CTC card, 164 (40.7%)
out of 403 stated that they did not attend a CTC before delivery and 70 (17.4%) had tested for HIV
at the maternity ward, therefore it was not possible for them to have attended a CTC before
delivery.
When asked if they were given medication for PMTCT to use during pregnancy 188 (58.9%)
reported receiving some ARV to use for PMTCT, 81 (25.4%) reported they were not provided with
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PMTCT ARV medication, three (0.9%) women reported that they did not know whether or not
they were given any ARVfor PMTCTand 47 (14.7%) women were tested for HIV after delivery and
therefore they were not eligible for any ARV medication for PMTCT according to the PMTCT
guidelines [37), explained in Table 2-1.
5.4.2.3 PMTCTARV prophylaxis documented and reported
In total 270 (75.8%) women who were eligible (Le. those women who were tested before
delivery) for ARV for PMTCT were actually given ARV for PMTCT. Table 5-8 shows the overall
number and proportion of HIV-positive women given any ARV for PMTCTstratified by different
timing of HIV test and the delivery suites. Eight-one out of 93 (87.1%) of women who tested for
HIV before the current pregnancy received PMTCTARV prophylaxis compared to 177 out of 240
(73.7%) who were tested for HIV during the current pregnancy at ANC facility and 12 out of 23
(52.2%) who were tested at the maternity ward. Overall, there were a low proportion of women
who were tested for HIV at delivery who received ARVfor PMTCTand this proportion was slightly
different between the two maternity wards (45.5% vs. 58.3% at BMC and STRHrespectively).
Table 5-8 HIV-posltive women given ARV medication for PMTCTby timing of the HIV test
Given any ARVfor PMTCT
Timing for HIV test BMCn (%) STRHn (%) Total n (%)
Total 127(78.9) 143 (73.3) 270 (75.8)
Before the current pregnancy 48 (88.9) 33 (84.6) 81 (87.1)
At ANCduring current pregnancy 74 (77.1) 103 (71.5) 177 (73.7)
At the maternity ward before delivery 5 (45.5) 7 (58.3) 12 (52.2)
5.4.2.4 Use0/PMTCTARV prophylaxis among HIV-positive women
All 270 women who had been given ARV during pregnancy were asked if they actually used the
medication when it was supposed to be used. Ten (3.7%) women (four at BMC and six at STRH),
who were all given sdNVP to be used at the onset of labour, reported that they did not use the
medication. When asked why, five (50%) reported that they had left the medication at home, two
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(20%) reported that they had swallowed the tablet when they felt unwell but before true labour,
two (20%) reported that they had the medication but they did not remember to take the
medication during real onset labour and one woman reported that she was told by a doctor at
BMC not to swallow the tablets since she was going to have a caesarean section.
5.4.3 PMTCTARV prophylaxis use among HIV-exposed Infants (HEI) in the study
All 403 cohort participants were interviewed after delivery, the majority (81.1%) within two to ten
hours after delivery. Women who delivered by caesarean section or who had other complications
were interviewed as soon as they were able to sit on a chair for at least one hour. Seventeen
(4.2%) women had stillbirths and were therefore excluded from the analysis of ARTprophylaxis to
the infant. All HIV-exposed infants, according to the National PMTCTguidelines [37] are supposed
to be given ARV for PMTCTas soon as the infant could tolerate oral feedings and within 12 hrs
after delivery
5.4.3.1 Reported PMTCTARV prophylaxis use among HEtat cohort recruitment
Of the 386 women who had live births, 250 (64.8%) reported that their infants were given ARVfor
PMTCTand 136 (35.2%) reported that their infants had not been given ARVfor PMTCTat the time
of the interview, two to ten hours after delivery for the majority (women who had no
complications during or after delivery).
When asked why the infant had not received ARV, 115 (84.6%) of the 136 women indicated that
were still admitted and had not been seen by the PMTCTcounsellor responsible for prescribing
ARV medication for HIV-exposed infants (HEI). Three (2.2%) had infants who died before they
could be given ARV for PMTCT (two were premature), four (2.9%) infants were reported to have
been ill, one woman refused her infant to be given ARVmedication, three (2.2%) women left the
hospital before they were seen by the PMTCTcounsellor, one woman at STRHreported that she
was told that infant ARV for PMTCTwas out of stock and nine (6.6%) women said that they did
not know why the infants were not given ARV.
5.4.3.2 Reported PMTCTARV prophylaxis use among HEt at month one fol/ow up visit
Women were followed monthly for four months post delivery. At the first month follow up, 360
(89.3%) women were seen and were asked if their infants were given any ARV medication for
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PMTCT after birth but before discharge from the hospital. This was basically to correct
information from those whose infants were not yet given ARV for PMTCT during the cohort
recruitment. Overall, 295 (81.9%) of women who were seen reported that their infant were given
ARV for PMTCT before discharge from the hospital after delivery. Of the 115 women whose
infants did not receive ARVfor PMTCTduring the cohort recruitment interview, 102 (88.7%) were
seen at the first month post delivery follow up.
Of 102 women who were seen, 65 (63.7%) women reported that their infants were given ARV for
PMTCT including two women who previously reported that their infants were sick and therefore
did not get ARV. One of nine women who had previously reported that they did not know why
their infants were not given ARV for PMTCT, at the first month follow up visit post delivery
reported that the infant was actually given ARVfor PMTCTbefore discharge from the hospital.
5.4.3.3 Use of PMTCTARV prophylaxis among HEt
Combining the information obtained from the women at the first month follow up visit with the
information collected at the time of the cohort recruitment it was found that, in total, 318
(83.0%) women reported that their infants were given ARV for PMTCTbefore discharge from the
hospital. Table 5-9 shows the overall number of HEIwho received ARVfor PMTCTat each delivery
site and the type of ARV regimen that were received.
Table 5-9 HIV-exposed Infants who received ARV prophylaxis for PMTCT at birth and type
of ARV given
BMC STRH Total
n (%) n (%) n(%}
Total HEI received any type of ARV for PMTCT 152 (89.4) 166 (77.9) 318 (83.0)
sdNVP 2mg/kg only 33 (21.7) 56 (33.7) 89 (28.0)
sdNVP 2mg/kg + All 4mg/kg BDfor 1 week 22 (14.5) 15 (9.1) 37 (11.6)
sdNVP 2 mg/kg + AZT4mg/kg BDfor 4 weeks 97 (63.8) 95 (57.2) 192 (60.4)
One hundred and ninety two (60.4%) of HEIwho received PMTCTARV prophylaxis were given a
longer combined regimen. sdNVPwas prescribed to a higher proportion of HEIat STRHcompared
to those at BMC (33.7% vs. 21.7%).
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5.4.4 Infant feeding counselling
Data were collected at the maternity ward on infant feeding counselling and planned infant
feeding choice and, at the post delivery follow up visits; information on the actual infant feeding
choice was collected. Among the 403 cohort members, 20 women were not eligible for the infant
feeding counselling either because they had stillbirths (n=17) or their infants died before
discharge from hospital (n=3). Of the 383 remaining women, 281 (73.4%) reported receiving
counselling on infant feeding methods at the maternity ward from the PMTCTcounsellor.
5.4.4.1 In/ant /eedlng choices at delivery
At cohort recruitment, women were asked which infant feeding method they were intending to
follow regardless of whether they were counselled or not at the maternity ward. Of the 383
women, 306 (79.9%) reported that they were intending to exclusively breastfeed (EBF)for at least
four months, 29 (7.6%) reported that they had decided to use replacement feeding (RFL and 49
(12.5%) reported that they had not yet decided on the infant feeding method. Table 5-10 shows
the infant feeding choices among the women who participated in the cohort study stratified by
whether women were counselled or not.
Table 5-10 Infant feeding methods selected by HIV-positive women who were either
counselled or not counselled on infant feeding at delivery
BMC STRH Total
Counselled Counselled Counselled
Yes No Yes No Yes No
n(%) n (%) n (%) n (%) n(%) n (%)
Total 135(79.4) 35 (20.6) 146(68.5) 67 (31.5) 281 (73.4) 102{26.6)
Exclusive breast
feeding for at least 119(88.2) 25 (71.5) 133(91.1) 29 (43.3) 252 (89.7) 54 (52.9)
Method 4 months
selected Replacement
7 (6.9)15 (11.1) 4 (11.4) 7 (4.8) 3 (4.5) 22 (7.8)
feeding
Not yet selected 1 (0.7) 6 (17.1) 6 (4.1) 35 (52.2) 7 (2.5) 41 (40.2)
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Overall, 281 (73.4%) of 383 women received counselling on infant feeding options and 102{26.6%)
of 383 women did not receive counselling on infant feeding option. Of the 281 women who were
counselled on infant feeding option 252 (89.7%) women opted for EBF,22 (7.8%) women opted
for RF and 7 (2.5%) had not decided on the infant feeding option at cohort recruitment. A
significantly higher proportion of women who received counselling on infant feeding option opted
for EBFcompared to those who did not receive counselling on infant feeding options (89.7% vs.
52.9%, p<O.OOl). Similarly, a significantly higher proportion of women who did not receive
counselling on infant feeding option had not decided on the infant feeding method at cohort
recruitment compared to women who were counselled on infant feeding options (40.2% vs. 2.5%;
p<O.OOl) . There was some difference in the proportion of women counselled on infant feeding
between the two hospitals. A higher proportion of women who delivered at STRHdid not receive
infant feeding counselling compared to women who delivered at BMC (31.5% vs.20.6%, p=0.017).
5.4.4.2 Reported In/ant feeding practices one month after delivery
During the first month follow up visit, 361 of 403 (89.6%) women were seen. Of these, one
woman was very sick and therefore she was not interviewed. Of the 360 women who were
interviewed, 15 (4.2%) included women who had stillbirths and whose infants died before
discharge from hospital. A further six (1.7%) women had lost their babies within the first month
after birth. These 21 women were excluded from the analysis of infant feeding choice at month 1
follow up visit. Of the 339 remaining women, 302 (89.1%) reported EBF,23 (6.8%) reported using
RF(mainly cow's milk and porridge) and 14 (4.1) reported to have used mixed feeding (MF).
When they were asked about anything else that they were giving to their infants, four of 302
women who reported EBF also reported giving the infant water and traditional medicine, 20
reported giving traditional medicine and 19 reported giving water in addition to breast milk. If the
definitions of the infant feeding methods according to the PMTCT guidelines (see Box 5-1) are
applied, then the number of women who were EBF at the first month follow up visit was
therefore 259 (76.4%) and the number of women who were practising mixed feeding was 57
(16.&%).
86
RB2010
Box 5-1: Definition of the infant feeding methods
Exclusive breastfeeding (EBF): Feeding infant ONLY
breast milk and no other liquids or solids, with the
exception of drops or syrups consisting of vitamins,
mineral supplements or medicines prescribed by a
healthcare worker.
Replacement feeding (RF): Feeding infant something
OTHER THAN breast milk.
Mixed feeding (MF): Feeding infant both breast milk
and other liquids (such as water, tea, formula, animal
milk) or foods (such as porridge or rice).
Source: Tanzania National PMTCTguidelines: May 2007 [37]
5.4.4.3 Reported in/ant feeding practices two months after delivery
Overall, 330 (81.9%) women were seen at the second month follow up visit of whom 21 had lost
their babies. Information on infant feeding was collected from 309 of whom 239 (77.4%) reported
to practice EBF,44 (14.2%) reported to have used replacement feeding and 26 (8.4%) reported to
have used mixed feeding
Nine of 239 EBFwomen reported giving the infants both water and traditional medicine, 15
reported giving traditional medicine and 14 reported giving water in addition to breast milk.
Therefore, the number of women practising EBFat the second month follow up visit was 201
(65.1%) and the number of women who were mixed feeding was 64 (20.7%).
5.4.4.4 Reported In/ant feeding practices three months after delivery
Similarly, at the third month follow up visit, 316 (78.4%) women were seen of whom 22 had lost
their babies. Information on infant feeding was collected from 294 of whom 195 (66.3%) reported
to have been EBF.However, 1 reported giving both water and traditional medicine, 15 reported
giving traditional medicine and 11 reported giving water in addition to breast milk. Thus 168
(57.1%) were practising EBF, 57 (19.4%) reported to have used replacement feeding and 69
(23.5%) were practising mixed feeding.
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5.4.4.5 Reported Infant feeding practices four months after del/very
Overall, 328 (81.4%) women were seen at the fourth month follow up visit of whom 27 had lost
their babies. Information on infant feeding was collected from 301 women of whom 155 (51.5%)
reported to have been EBF (Table 5-11) but 3 of the 155 reported giving both water and
traditional medicine, 17 reported giving traditional medicine and 8 reported giving water in
addition to breast milk. Thus 127 (42.2%) were practising EBF,89 (29.6%) reported to have used
replacement feeding and 85 (28.2%) were practising mixed feeding (Table 5-12).
Table 5-11 Infant feeding method at follow up visits as reported by mothers
Month 1 Month 2 Month 3 Month 4
n{%) n{%) n (%) n (%)
Total
339 309 294 301
Exclusive breast feeding 302 (89.1) 239 (77.4) 195 (66.3) 155 (51.5)
Replacement feeding 23 (6.8) 44 (14.2) 57 (19.4) 89 (29.6)
Mixed feeding 14 (4.1) 26 (8.4) 42 (14.3) 57 (18.9)
Table 5-11 shows the infant feeding methods that were reported by the women during the follow
up visits. As expected the majority started by practising EBF but the proportion in this group
declined at every follow up visit and by the fourth month follow up visit, only 51.5% of women
seen at this visit were still practising EBF.
When definition of EBFwas reclassified as indicated in Box 5-1 from the PMTCTguidelines [37]
we found that by the four month follow up visit 28.2% of the women were practising mixed
feeding and only 42.2% were practising EBF(Table 5-12)
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Table 5-12 Infant feeding method at follow up visits after reclassification to include water
and traditional medicine as mixed feeding
Month 1 Month 2 Month 3 Month 4
n {%} n {%} n {%} n{%}
Total 339 309 294 301
Exclusive breast feeding 259 {76.4} 201 {65.1} 168 {57.1} 127 {42.2}
Replacement feeding 23 {6.8} 44 {14.2} 57{19.4) 89 {29.6}
Mixed feeding 57 {16.8} 64 {20.7} 69 (23.5) 85 {28.2}
5.5 Piot-Fransen models
From the previous sections, the proportion of women accessing different PMTCT and maternal
syphilis screening and treatment steps were estimated. To build the Piot-Fransen model for
completion of PMTCT steps, two data sources were used; the cross-sectional study data were
used to provide the proportion of women who received PMTCT HIV pre-test counselling, the
proportion of women who accepted and tested for HIV and the proportion who received their HIV
results. The cohort study data were used to estimate the proportion of HIV-positive women who
were given ARV for PMTCT,who used the medication as required, the proportion of infants who
received ARV for PMTCT, the proportion of women who were counselled on infant feeding
options and the proportion of infant not mixed fed by the end of fourth month follow up visit.
To build the Piot-Fransen model for maternal syphilis screening and treatment, cross-sectional
study data were used to estimate the proportion of women who were screened for syphilis, and if
RPRpositive, the proportion that were treated and the proportion of infants who were treated at
birth.
5.5.1 Piot-Fransen model for completion of PMTCTinterventions
Table 5-13 shows the proportion of pregnant women accessing different PMTCTinterventions in
Mwanza city and the proportion that successfully completed each step as indicated in the PMTCT
guidelines. These proportions have been explained in the previous sections of this chapter.
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The information shown in Table 5-13 and Table 5-14, uses 3 different denominators i.e. women
attending an ANC during pregnancy, HIV-positive women who required ARV for PMTCT and
whose infants required ARVfor PMTCTand women who had live birth and whose infant remained
alive at each follow up visit (these also changes at each follow up visit). From these three
denominators three Piot-Fransen models were built (Figure 5-1 to Figure 5-3). Proportions that
are indicated in these three models were combined to produce a hypothetical model assuming
1000 HIV-positive women admitted for delivery at BMC and STRHin Mwanza city.
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Figure 5-1 Proportion of pregnant women offered and accepting HIV testing pre-delivery -
cross-sectional study data
I 1137 pregnant women attended ANC I
I 903 (79.4%) pregnant women accept and test for HIV I
71 (8.1) HIV + pregnant women
Assuming an equal HIV prevalence among women tested and those who were not tested, 21 HIV-
positive women out of 234 women who attended ANC during pregnancy and who delivered in
hospital during the study period, did not get the interventions that they required.
Overall
proportion
Proportion of HIV-positive women tested before delivery who received ARV
prophylaxis for PMTCT
Figure 5-2
356 HIV + pregnant women tested before delivery
75.8% 270 (75.8%) HIV + pregnant women given ARV medication for PMTCT before
or at delivery
260 (96.3%) HIV + pregnant women used ARV medication for PMTCT
73.0%
before and/or at delivery
! 1
248 (95.4%) 12{4.6%) Women
Women with with still births
live births /baby died
Of the 356 women tested before delivery, 270 (75.8%) received ARV for PMTCTand 260 (73.0%)
used ARV medication for PMTCT.Among the 260 women who used ARV for PMTCT, 12 women
had a stillbirth, thus 248 HEIwhose mothers used ARVfor PMTCTare being taken to the next step
of the Piot Fransen model.
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Proportion of HIV-positive women tested before delivery who received ART
during pregnancy and/or in labour and whose infants received ARV and were
not mixed fedll
Overall proportion
65.1%
52.1%
44.0%
43.7%
43.2%
41.4%
248 Women with live births
220 (88.7%) HIV-positive women whose infants received ARV
prophylaxis for PMTCT
176 (80.0%) women whose infant received ARV
and were counselled on infant feeding before
discharge from the hospital
133 (83.1%) Women whose infants were :-1-60i176 -
not mixed fed @ month 1 ~ seen at 1
st
1 follow up
1-------
122 (83.0%) Women whose infants -------: 147/176
were not mixed fed @ month 2 ..___, seen at 2"
1
!..f..9Uo_w_u o_
115 (80.40%) Women whose 1------
1 143/176
infants were not mixed fed @ _j rd
1seen at 3
month 3 : follow up
-------
114 (78.1%) Women whose infants -------
were not mixed fed @ month 4 : 146/176seen at 4th
Lf.Dllo_w_'Ln_
women were
month
visit
women were
d month
vlsu: _
women were:
month :
visit------_.
-------,
women were 1
1
month 1
vl~jj :
11 Denominators used to calculate the overall proportions are the number of women who were eligible for that
particular intervention e.g.
1. For the overall proportion of women whose infants took ARVfor PMTCTand who were counselled on infant
feeding, the denominator wasall women who had live birth (n=338).
2. Forthe overall proportion of women were tested before delivery andwhose infantswere not mixed fed 4 months
after birth, the denominator waswomenwho were seenat eachmonth follow up visit, whose infants were alive at
the time of the follow up andwho were tested before delivery (n=275)
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Figure 5-4 HIV-positive women who successfully complete PMTCTintervention in Mwanza
city assuming a hypothetical population of 1000 HIV-positive women tested
before delivery.
1000 HIV + pregnant women tested before delivery
758 (75.8%) HIV + pregnant women given ARV medication for PMTCT before or at
delivery
730 (73.0%) HIV+ pregnant women used ARV medication for PMTCT before and
lor at delivery
651 (65.1%) HIV+ pregnant women used ARV medication and infants
were given ARV medication for PMTCT
521 (52.1%) HIV+ pregnant women used ARV, infant given ARV
and were counselled on infant feeding before discharge from
the hospital
I
440 (44.0%) HIV+ women whose infants were not mixed I
fed at 1stmonth follow up
437 (43.7%) HIV+ women whose infants were not
mixed fed at 2ndmonth follow up
432 (43.2%) HIV+ women whose infants were not
mixed fed at 3'd month follow up
I
414 (41.4%) HIV+ women whose infants were I
not mixed fed at 4th month follow up
5.5.2 Piot-Fransen model for completing maternal syphilis screening and treatment
interventions
Table 5-14 shows the number and proportion of pregnant women admitted for delivery at STRH
and BMC who were screened for syphilis and, for those who were found to be RPRpositive, the
number and proportion of those who were treated and the number, and proportion of infants
who received treatment before discharge from the hospital after birth. The proportions given in
this table were used to build the Piot Fransen model.
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Table 5-15 Proportion of pregnant women successful completed maternal syphilis
screening and treatment during pregnancy - cross-sectional data.
Total women interviewed who had brought their
ANC cards
1137
Women screened for syphilis at ANC
1002
1137 (88.1%)
RPRpositive
59
(5.9%)
Treated for syphilis
43
(72.9%)
Infant treated after birth o
Figure 5-5 RPR-positive women who received treatment in Mwanza city assuming a
hypothetical population of 1000 RPR-positive women screened at ANC
I
1000 pregnant women screened for syphilis at ANC facility during the current pregnancy were I
found to be RPRpositive
729 (72.9%) RPR+ pregnant women were treated for syphilis at ANC
facility during the current pregnancy
5.6 Discussion
5.6.1 PMTCT implementation
5.6.1.1 HIV testing at ANC - findings from the review of PMTCTrecords at the ANC
From a review of the ANC clinic records, it was not possible to estimate the proportion of women
who attended ANC for the first time during the current pregnancy and who were not offered HIV
test or who were screened for syphilis. This was due to the fact that there was no separate record
for women being referred from outside the study ANCfacilities and those who were attending the
facilities for the first time. This finding prompts for an urgent need of a system that will allow
separate records of the two types of clients who attend ANC. The current system leads to over-
estimating of the service utilization.
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A high proportion (97.5%) of pregnant women who received PMTCT HIV pre-test counselling
accepted the HIV test and 8.3%were HIV-positive, However, half of the HIV-positive women were
not given any ARV for PMTCTfollowing an HIV-positive test at the ANC. This might be partially
explained by fact that some women who were referred from other facilities and who tested HIV-
positive might have not returned to collect their medication.
Lessthan 1% of the male partners of both HIV negative and HIV-positive women were tested at
the ANC.The overall HIV prevalence among partners who were tested at ANC facilities was 22.9%.
This was very high when compared to the HIV prevalence in women (8.3%). Nevertheless it was
learnt that sometimes in order to ease the HIV status disclosure among couples, HIV-positive
women were advised to bring their partners so that they can have couple HIV counselling and
testing, this might have resulted into having more partners of HIV-positive women coming for the
HIV test at the ANC.
5.6.1.2 PMTCTservices at the maternity wards-findings from review of records
Between 1st September 2007 and 31st August 2008, 48.3% of all women admitted for delivery at
BMC and STRHhad a known HIV status on admission for delivery and a further 27.2%were tested
at the maternity ward. Overall, 24.5% of pregnant women admitted for delivery at these two
large hospitals in Mwanza city did not test HIV for PMTCT.A similar proportion of women were
tested for HIV at the two maternity wards.
During the record review, there were incomplete data on other PMTCT interventions that are
offered at the maternity ward such as ARV use for both mothers and infants, therefore this
information was not presented in this chapter.
5.6.1.3 HIV testing for PMTCT-findings from the cross-sectional study at BMC and STRH
Nine hundred and three women among 1137 (79.4%) who were admitted for delivery at the two
maternity wards had tested for HIV and had a documented HIV test result on their ANC cards. Of
these women who were tested, 77 (8.5%) had not received PMTCT pre-test counselling. It was
learnt at the ANC that some women missed the PMTCT HIV pre-test counselling because they
arrived at the ANCfacility late. However, since a blood sample is normally taken for other routine
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test and the remaining blood samples and the ANC cards are then handed to the PMTCT
counsellor for the HIV test it happens that even those who did not attend the education sessions
are tested although this is contrary to the National PMTCTguidelines [37].
It was also found that 2.9% of women who were tested for HIV did not receive individual post-test
counselling. This means that these women did not get an explanation of what the results meant.
For HIV-positive pregnant woman this constitutes a missed opportunity of getting information on
available PMTCTinterventions.
5.6.1.4 Use of ARV for PMTCTfindings from the cohort study
Overall, 270 (75.8%) of HIV-positive pregnant women who were tested before delivery received
ARV medication either for their own health (HAART) or for PMTCT (ARV prophylaxis). Eleven
women (47.8%) of pregnant women who were tested at the maternity wards before delivery did
not receive any ARV prophylaxis for PMTCT.Similarly, 26% of women who tested HIV-positive at
ANC facilities and 13% of women who tested HIV-positive before pregnancy did not receive any
ARV medication to protect their unborn babies. This indicates a failure in the implementation of
PMTCT considering that these women had an opportunity to delivery in hospitals that provide
PMTCTservices.
At least 318 (83.0%) HIV-exposed infants (HEI)who were alive at discharge from hospital received
ARV prophylaxis prior discharge from the hospital. This might be an underestimate due to the fact
that some of the HEI were not yet discharged from the hospital during the cohort recruitment.
About 13 HIV-positive women whose infants were not yet discharged from the hospital during the
cohort recruitment interviews were not seen during the first month follow up visit. Nevertheless,
these findings indicate that 17% of HEIborn in hospitals that offer PMTCTservices did not receive
any ARV prophylaxis for PMTCT.
It is interesting to learn that the majority (60.4%) of the HEIwho received ARV for PMTCTwere
given an effective combined and longer therapy that is currently recommended for HEI born to
ART natve mothers, mothers who use combined therapy for less than 4 weeks or mothers who
use sdNVP for PMTCTduring true labour.
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5.6.1.5 Counselling on Infontfeedlng-/indlngsfrom the cohort study
Findings from this study indicate about 27% of HIV-positive women who delivered in hospital
were not given any counselling on safer infant feeding practices. In addition, the majority (85.1%)
of women who had not been counselled on infant feeding options at delivery were not certain
about which infant feeding methods they should use for their infants by the time of the interview.
This indicates the importance of infant feeding counselling on HIV-positive mothers' decision
about infant feeding choices. Coutsoudis A, et 01 reported that as much as 42% of MTCT of HIV
among children with known timing of the infection was due to breastfeeding [32], therefore in
order to optimize the PMTCTservices in our study settings there is an urgent need to improve on
counselling about infant feeding options ..
5.6.1.6 Reported actual Infant feeding practices during the follow up
Definitions of infant feeding options were adopted from the National PMTCTguidelines of 2007
[37]. (See Box 5-1). The proportion of infants who were not mixed fed decreased gradually from
83.3% at the first month follow up to 71.8% at the fourth month follow up visit (Table 5-12).
However, this proportion would have been increased by 9% if these women were aware that
giving their infants traditional medicine and water constitutes mixed feeding according the
definitions that were used as shown in Table 5-11. By the end of the four months follow up, only
42.2% reported practising EBF.
5.6.2 Piot-Fransen models
5.6.2.1 Completion of PMTCTInterventions
An analysis of the cumulative number of fall off at each step of the PMTCT-services was
conducted using the information that was collected at recruitment and at each follow up visit. As
described in Table 5-14 and figure 5-4 above. The largest fall-off occurred between testing and
using ARV for PMTCT. Factors that are associated with this finding are discussed in Chapter 6.
Overall, 41.4% of HIV-positive women successfully completed all the steps in PMTCT.
5.6.3 Maternal syphilis screening and treatment services
5.6.3.1 Keyfindings from the record review at ANC
In total, 8169 women were screened for syphilis over a period of one year. This total is slightly
higher than the number of women attending ANC facilities for the first time during the current
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pregnancy indicating that other women were referred from other ANC facilities for syphilis
screening as the case for HIV testing. For this reason, again it was not possible to estimate the
proportion of women who were screened when attending the ANC for the first time. Five
hundred and thirty eight (6.6%) women were RPRpositive but only 35.5% were treated before
delivery. It was learnt that the main reason for not being treated was the fact that sometimes
there were no medication at the facilities and women were asked to buy their medication; on the
other hand treatment rate might be underestimated since it is not known how many women after
getting their results were treated somewhere else other than at the testing facility.
5.6.3.2 Syphilis screening and treatment key findings from the cross-sectional study
The majority (88.1%) of pregnant women attending ANC at least once during pregnancy were
screened for syphilis. For those who were screened for syphilis, 5.6% were RPRpositive. Of those
who were RPRpositive, 17% were not treated during pregnancy. The reasons for not being
treated are assumed to be similar to those given above from the record review study.
It is recommended[106] that women who missed an RPRtest during antenatal care should be
tested during delivery and the test results should be obtained as soon as possible so that early
treatment could be given to the infant of women who test positive and to the mothers. However,
this was not done at both maternity wards and the reasons for unavailability of any services
related to the prevention of congenital syphilis were unknown.
All women who were RPRpositive during pregnancy had live births; However, none of these
infants was treated prior to discharge from the hospital. In reality, from what was observed
during the five months period the research team worked at these two main hospitals in Mwanza
city, there was no treatment for both RPRpositive pregnant women who were not treated at ANC
facilities and infants who were born to RPRpositive women at the maternity wards. The only
cases that were treated were infants born with congenital syphilis who were referred to the
paediatric wards. This finding is of concern because it is not known how many of these women
seek treatment for their infants after discharge from the hospital and it is not known if these
infants are offered treatment when they attend the under-five clinic at one month after birth.
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5.6.3.3 Completion 0/syphilis screening and treatment during pregnancy
From the cross-sectional study, Table 5-15 and Figure 5-5 were produced to show the fall off at
each step of the syphilis screening and treatment services among pregnant women in Mwanza
City. The majority (88.1%) of our study participant were screened for syphilis and those found to
be RPRpositive, the majority (72.9%) were treated. Nevertheless, due to lack of infant treatment
at the maternity ward in Mwanza, none of these women was considered to have completed these
services.
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CHAPTER6: FACTORS INFLUENCING THE COMPLETION OF PMTCT AND
MATERNAL SYPHILIS SCREENING AND TREATMENT PROGRAMMES
AMONG PREGNANTWOMEN
6.1 Introduction
This chapter examines the factors influencing the completion of PMTCT and maternal syphilis
screening and treatment programmes among pregnant women in Mwanza City. To address this
aim, data from the cross-sectional study and the cohort study were used. For both these studies
women were interviewed at the labour ward when they were admitted for delivery
6.1.1 Definition for PMTCTcompletion
Completion of PMTCTwas defined in three different ways. First, completion of Stage 1 included
women receiving an HIV test in pregnancy. Completion of Stage 2 was defined as receiving and
taking any ARV during pregnancy. Completion of Stage 3 of PMTCTwas defined as receiving all
four key PMTCTinterventions. These steps are considered separately below.
6.1.1.1 Completion o/Stage I-HIVtestlng In pregnancy
For both HIV negative and positive pregnant women, completion of Stage 1 (testing for HIV in
pregnancy) was defined if they were tested for HIV during pregnancy either at the ANC or at the
labour ward when they were admitted for delivery. Based on this definition, women who were
tested for HIV and who had their HIV status indicated on their ANC cards during the current
pregnancy was compared with women who were not tested to identify factors that were
associated with failure to be tested for HIV during pregnancy. This was done using the data from a
cross-sectional study at the maternity wards at two hospitals in Mwanza city.
6.1.1.2 Completion o/Stage 2-Receiving and taking any ARV during pregnancy
HIV-positive women were considered to have completed Stage 2 of PMTCT if they received and
used any ARVfor PMTCT. In this definition, HIV-positive women regardless when they tested HIV-
positive for the first time, who received and used any ARV, including those who either had started
using HAART before this pregnancy or who started using HAART during this pregnancy or who
received ARV only for PMTCT,were compared with HIV-positive women who did not use ARV for
PMTCTduring the current pregnancy.
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Data were obtained from 356 HIV-positive women enrolled in a prospective cohort at admission
for delivery at two large hospitals in Mwanza city. These women had tested HIV-positive for the
first time either before the current pregnancy, during the current pregnancy at the ANC or at the
maternity ward when they were admitted and tested before delivery. Women tested after
delivery were excluded from this analysis.
6.1.1.3 Completion of Stage 3-Receiving all pre and post-delivery key PMTCT interventions
An HIV-positive woman was considered to have successfully completed Stage 3 of PMTCT if she
used ARV for PMTCT and her infant was also given ARV for PMTCT and she was counselled on
infant feeding and she did not practise mixed feeding to her infant by four months post-delivery.
Data from 295 HIV-positive women participating in the cohort study and who were seen at the
four-month follow up visit were used for this analysis. Women who successfully completed these
four key PMTCT interventions were compared with women who did not complete some of the
interventions.
6.1.2 Syphilis screening and treatment
Factors associated with maternal syphilis screening and treatments were examined using the data
from the cross-sectional study. Women screened for syphilis during the current pregnancy were
compared with women not screened for syphilis. In addition, for women who were RPRpositive,
women who were treated were compared with women who were not treated for syphilis during
pregnancy.
6.2 General characteristics 0/ the cross-sectional study participants
Enrolment procedures for the 1157 women enrolled in the cross-sectional study at the maternity
ward have been described in section 4.5. Twenty women had no ANC cards during admission to
the labour ward for delivery and these are excluded from this analysis.
Four hundred and twenty-six participants were interviewed at Bugando Medical Centre (BMC)
and 711 (62.5%) were interviewed at Sekou-Toure Regional Hospital (STRH)(Table 6-1) between
SthSeptember and iz" October 200S. The 1127 participants had a mean age of 25.1 years (range
14 to 46 years). Ten women did not know their age. Approximately 60% were aged between 20 to
29 years. Most women were Christian with 40.0% being Roman Catholics and 35.5% other
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Christians. The majority (76.4%) had received primary school education. Thirty-six percent were
from the Sukuma tribe. Five hundred and forty-three (47.8%) were housewives, 548 (48.2%)
reported doing unskilled work and only 46 (4.0%) had skilled work. Approximately 88.0% were
married.
The majority of women (85.8%) attended ANC facilities located in Mwanza city (Table 6-2).
Approximately 68.0% of 1137 women attended ANC government facilities whereas 17.8% of all
women attended ANC private facilities in Mwanza City. One hundred and sixty-one participants
(14.2%) attended an ANC outside Mwanza city. It was not known if these were government or
private ANC facilities. Ninety- five (8.4%) attended an ANC only once during the current
pregnancy. Four hundred and seventy- two (41.5%) had four or more ANC visits during the
current pregnancy.
Three hundred and fifty-three (31.0%)were primigravidae, 428 (37.6%) were secundigravidae and
356 (31.3%) were multigravidae (3 or more pregnancies) (Table 6-3). Three hundred and forty
eight (44.4%) participants with two or more pregnancies reported attending the same ANC facility
during the previous pregnancy. Six hundred and forty seven (56.9%) reported having been tested
for HIV sometime before the current pregnancy.
Two hundred and thirty-four women (20.6%) did not test for HIV during the current pregnancy, of
these 176 (76.1%) were women who had been pregnant two or more times and 116 (65.9%)
among these reported to have tested for HIV before the current pregnancy.
Of 234 women who did not receive an HIV test for PMTCT,148 (63.3%) reported that they had an
HIV test but they did not know why the results were not documented on their ANC cards and 86
(36.7%) women knew that they did not test HIV during the current pregnancy. Reasons for not
testing for HIV during the current pregnancy were given by the 86 women who actually
understood that they were not tested during pregnancy. Some women gave more than one
reason and these included; test not offered 39 (45.3%), lack of the HIV test kits 39 (45.3%),
refused the test 6 (7.0%) and 16 (18.6%) reported to have tested for HIV before, thus no need to
repeat the test.
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6.3 Factors associated with failure to test for HIV during pregnancy (Stage 1)
6.3.1 Univariate analysis
Two hundred and thirty four (20.6%) pregnant women admitted for delivery at BMC and STRH
were not tested for HIV during the current pregnancy. To examine the factors associated with
failure to test for HIV during pregnancy, women who had tested for HIV during the current
pregnancy were compared with women who were not tested for HIV.
Table 6-1 shows the association of failure to be tested for HIV during pregnancy and selected
socio-demographic characteristics and their crude odds ratios. There was little association
between failure to test for HIV in pregnancy and the selected socio-demographic characteristics.
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Table 6-1 Univariate association between selected socio-demographic characteristics and
failure to test for HIV during pregnancy
Total Not tested
Variables n=1137 % n=234 %
Crude OR.
95%CI P
Delivery site 0.21
BMC 426 37.5 96 22.5 1
STRH 711 62.5 138 19.4 0.83 0.61-1.11
Age groups 0.48
< 20 years 188 16.5 39 20.7 1
20-24 years 401 35.3 86 21.6 1.04 0.68-1.60
25-29 years 277 24.4 62 22.4 1.10 0.70-1.73
30-34 years 171 15.0 26 15.2 0.69 0.40-1.18
~ 35 years 90 7.9 18 20.0 0.96 0.51-1.79
Age not known 10 0.9 3 30.0 1.64 0.40-6.62
Religion 0.67
Roman Catholics 455 40.0 90 19.8 1
Other Christians 404 35.5 91 22.5 1.18 0.85-1.64
Muslim 266 23.4 51 19.2 0.96 0.66-1.41
No religion 12 1.1 2 16.3 0.81 0.17-3.77
Education level
Secondary school 181 15.9 32 17.7 1
0.45
or above
Primary school 874 76.9 187 21.4 1.28 0.84-1.92
education
No formal education 82 7.2 15 18.3 1.04 0.53-2.05
Tribe 0.69
Sukuma 411 36.1 82 20.0 1
Other 726 63.9 152 20.9 1.06 0.79-1.43
Marital status 0.81
Married 996 87.6 204 20.5 1
Single 106 9.3 24 22.6 1.14 0.70-1.84
Divorced/separated 27 2.4 4 14.8 0.67 0.23-1.97
widowed 8 0.7 2 25.0 1.29 0.26-6.46
Occupation 0.72
House wife/at home 543 47.8 116 23.4 1
Unskilled work 548 48.2 111 20.3 0.93 0.69-1.25
Skilled work 46 4.0 7 15.2 0.66 0.29-1.52
Table 6-2 shows the association between failure to test for HIV in pregnancy and the ANC
characteristics. Failure to test for HIV in pregnancy was strongly associated with a pregnant
woman attending the ANC facility that is located outside Mwanza city during the current
pregnancy (OR 1.93, 95%CI 1.31-2.87). There was a strong association between failure to test for
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HIV in pregnancy and whether the woman attended a government or a private ANC facility (OR
2.09, 95%CI 1.48-2.99). Comparing women tested for HIV during pregnancy and those not tested,
there was a significant difference in proportions of women who had 4 or more ANC visits during
the current pregnancy compared to those who had a single ANC visit or those with two ANCvisits
during the current pregnancy (that is, women with 2 or less ANC visits were more likely to fail to
test HIV during pregnancy compared with women with 4 or more visits).
Table 6-2 Association between ANC characteristics and failure to test for HIV during
pregnancy
Total Not tested lRT P
Variables n=1137 % n=234 % Crude OR 95%CI value
location of the ANC facility <0.001
Mwanza city Government 773 68.0 129 16.7 1
Private 203 17.8 60 29.6 2.09 1.48-2.99
Outside Mwanza city 161 14.2 45 27.9 1.93 1.31-2.87
Number of ANCvisits <0.001
during pregnancy
4 visits or more 472 41.5 82 17.4 1
3 visits 348 30.6 60 17.2 0.99 0.69-1.43
2 visits 222 19.5 55 24.8 1.57 1.06-2.31
1 visit 95 8.4 37 39.0 3.03 1.88-4.88
Secundigravidae and multigravidae (3 or more pregnancies) were at higher risk of failure to test
HIV during the current pregnancy compared with primigravidae (16.4% vs. 23.8%; OR 1.59, 95%CI
1.11-2.28 and 28.8%; OR1.33, 95%CI0.91-1.95) (Table6-3).
There was no difference in failure to test for HIV in pregnancy among women who had ever had
an HIV test before this pregnancy and those who had never tested for HIV. In addition, for women
who had been pregnant before the current pregnancy, there was no association between failure
to have an HIV test and whether the woman attended the same ANC facility in her previous
pregnancy.
There was a significant decrease in proportion of women who failed to have an HIV test as the
number of ANCvisits increased (p-value for trend<O.OOl)
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Table 6-3 Association between gravidity and previous HIV testing and failure to test for
HIV during pregnancy
Total Not tested lRT PVariables n=1137 % n=234 % Crude OR 95%CI value
Gravidity 0.04
Primigravidae 353 31.1 58 16.4 1
Secundigravidae 428 37.6 102 23.8 1.59 1.11-2.28
Multigravidae 356 31.3 74 28.8 1.33 0.91-1.95
Ever had an HIV test before this 0.31
pregnancy
Yes 647 56.9 140 21.6 1
No 490 43.1 94 19.2 0.86 0.64-1.15
Attended the same clinic 0.12
during the previous pregnancy!
Yes 348 44.4 69 19.8 1
No 436 55.6 107 24.5 1.31 0.93-1.85
!Womenwithmorethanonepregnancy(N=784)
6.3.2 Multivariate analysis
All variable that showed evidence of an association with failure to test for HIV in pregnancy on
univariate analysis at p-value<O.l were included in a multivariate logistic regression model (Table
6-4).
After controlling for age, it was found that there was a strong independent association between
failure to test for HIV in this pregnancy and the type of ANC facility attended during pregnancy
(OR 2.37; 95% Cl 1.64-3.42). There was a significant difference in the proportions of women not
testing HIV for PMTCT among women attending government ANC facilities in Mwanza city
compared to those attending private ANC clinics in Mwanza city or ANC facilities outside Mwanza
city.
Women who had few ANC visits during the current pregnancy were at a higher risk of not testing
for HIV compared to women with four or more ANC visits. Women who had been pregnant more
than once were at 2-fold higher odds of failure to test for HIV in this pregnancy compared to
primigravidae women.
107
RB1010
Table 6-4 Independent factors associated with failure to test for HIV in current pregnancy
Not tested
Variable n=234 % OR
i 95%CI P
Facility attended <0.001
Government ANC in Mwanza 129 16.7 1
Private ANC in Mwanza city 60 29.6 2.37 1.64-3.42
ANCoutside Mwanza city 45 27.9 2.13 1.42-3.19
Total number of ANCvisit <0.001
Four or more ANCvisits 82 17.4 1
Three ANCvisits 60 17.2 0.94 0.65-1.38
Two ANCvisits 55 24.8 1.53 1.02-2.28
One ANCvisit 37 39.0 3.27 1.98-5.38
Number of pregnancies 0.003
One pregnancies 58 16.4 1
More than one pregnancy 176 22.4 1.86 1.23-2.82
1Adjusted for age, type of ANC facility attended, number of ANC visits and number of pregnancies.
6.4 General characteristics oj the cohort study participants
Overall, 403 HIV-positive women who delivered at BMC and STRH over a five month period
between e" September 2008 and zo" February 2009 were recruited into the cohort study. Forty
seven (11.7%) HIV-positive women who were tested for HIV after delivery are excluded from this
analysis. Of the remaining 356 HIV-positive women, 161 (45.2%) were recruited at BMC and 195
(54.8%) were recruited at STRH(Table 6-5). Participants had a mean age of 28.3 years (range 16 to
48 years). Sixwomen did not know their age. More than 50% were aged between 20 to 29 years.
Most women were Christian with 41.6% being Roman Catholics and 34.5% other Christians. The
majority (74.5%) had primary school education. One hundred and fifty nine (44.7%) were from the
Sukuma tribe. One hundred and sixty eight (47.2%) were housewives, 173 (49.1%) reported doing
unskilled work and only 3.7% reported doing skilled work. Two hundred and forty six (69.1%)
were married, 42 (11.8%) were single, 50 (14.0%) were divorced or separated and approximately
5%were widowed.
6.5 Factors associated with jailure to useARVjor PMTCT(Stage 2)
To determine the factors associated with Stage 2 of PMTCT completion, data from 356 HIV-
positive women who were enrolled in a prospective cohort at admission for delivery in Mwanza
city were used. These women were tested for HIV either before pregnancy or during pregnancy
108
RB2010
when they attended ANC or on admission to the labour ward but before delivery. They were
followed up for four months post-delivery to gather information on uptake and compliance with
feeding advice and other post-delivery PMTCTinterventions.
6.5.1 Univariate analysis
Factors associated with not using ARV for PMTCT among HIV-positive women who were tested
before delivery were assessedby comparing 260 HIV-positive women who received and used ARV
for PMTCT (including pregnant women who were on HAART prior to pregnancy or who were
started on HAART during pregnancy) with 96 HIV-positive women who did not use ARV for
PMTCT.
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Table 6-5 Association of failure to use ARV for PMTCT with selected demographic
characteristics
Failed to use
ARVfor
Total PMTCT(n:::96)
Variable n:::356 % n % Crude OR 95%CI P
Delivery site 0.19
BMC 161 45.2 38 23.6 1
STRH 195 54.8 58 20.7 1.37 0.85-2.21
Age groups 0.09
< 20 years 19 5.3 10 52.6 1
20-24 years 78 21.9 26 33.3 0.45 0.16-1.24
25-29 years 112 31.5 26 23.2 0.27 0.10-0.74
30-34 years 74 20.8 16 21.6 0.25 0.09-0.71
~35 years 67 18.8 16 23.9 0.28 0.10-0.82
Age not known 6 1.7 2 33.3 0.45 0.07-3.07
Religion 0.45
Roman Catholics 148 41.6 45 30.4 1
Other Christians 124 34.8 29 23.6 0.71 0.41-1.22
Muslims 84 23.6 22 26.5 0.82 0.45-1.50
Education level 0.08
Primary school education 265 74.4 79 29.8 1
No formal education 35 9.9 8 22.9 0.69 0.30-1.60
Secondary school or above 56 15.7 9 16.1 0.45 0.21-0.96
Tribe 0.24
Sukuma 159 44.7 38 23.9 1
Other 197 55.3 58 29.4 1.33 0.82-2.14
Marital status 0.59
Married 246 69.1 65 26.4 1
Single 42 11.8 9 21:4 0.76 0.34-1.67
Divorced/separated 50 14.0 17 34.0 1.43 0.75-2.75
Widowed 18 5.1 5 27.8 1.07 0.37-3.12
Occupation 0.07
House wife/at home 168 47.2 55 32.7 1
Unskilled 175 49.2 38 21.7 0.57 0.35-0.92
Skilled 13 3.6 3 23.1 0.61 0.16-2.33
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Table 6-5 shows the association of not using ARV for PMTer and selected socio-demographic
characteristics and their crude odds ratios. There was no association between not using ARVfor
PMTer and recruitment or delivery site, respondent's religion, tribe and marital status.
Overall, 16.1% of HIV-positive women who were tested for HIV before the current pregnancy did
not use ARVmedication for PMTer {Table 6-6}. This proportion is low compared to the proportion
of women who did not use ARV for PMTer among women tested at ANC during the current
pregnancy {29.2%, OR 2.14, 95% Cl 1.15-3.97} and those who were tested at the maternity ward
before delivery (47.8%, OR4.77, 95%CI1.77-12.79). Women with two or one ANCvisit were more
likely to fail to use ARV for PMTer when compared with women with more than two ANC visits
during pregnancy.
Table 6-6 Association of failure to use ARV for PMTCTand timing of the HIV test,
previous HIV testing and number of ANC visits
Failed to use
ARVfor Crude
Total PMTCT(n=96) OR
Variables N=356 % n % 95% Cl P
Timing of an HIV test 0.004
Before current pregnancy 93 26.1 15 16.1 1
During current pregnancy at 240 67.4 70 29.2 2.14 1.15-3.97
ANC
During the current pregnancy
at the maternity ward before 23 6.5 11 47.8 4.77 1.77-12.79
delivery
Ever had an HIV test before this 0.020
pregnancy
Yes 176 49.4 38 21.6 1
No 180 50.6 58 32.2 1.72 1.07-2.78
Total number of ANC visits during <0.001
current pregnancy'
S2 135 38.7 52 38.5 1
~3 214 61.3 43 20.1 0.40 0.25-0.65
Excluding women who had no ANC cards (n=7)
One hundred and sixty-seven (50.1%) among 333 HIV-positive women who tested for HIV before
the current pregnancy or at the ANCduring the current pregnancy attended a erc before delivery
(Table 6-7), 64 {75.3%} of 85 who did not use ARV for PMTCTwere among 166 women who did
not attend a erc before delivery and 21 {24.7%} were among 167 women who attended a erc
before delivery. Women who did not attend a erc before delivery were 4 times more likely not to
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use ARV medication for PMTCT when compared with women who attended to a CTC before
delivery. Failure to use ARVfor PMTCTwas associated with disclosure of HIV status to any person
and/or husband/partners. However, there was no evidence of association between not using ARV
for PMTCTand disclosing HIVstatus to the partner or husband only.
Table 6-7 Association of failure to use ARV for PMTeT with attendance at a eTe before
delivery and disclosure of HIV status
Failed to
use ARV
for PMTCT
Total (n=96) Crude
Variables n=356 % n % OR 95% Cl P
Attended a CTCbefore
<0.001
dellverv'
Yes 167 50.1 21 12.6 1
No 166 49.9 64 38.5 4.36 2.51-7.59
HIV status disclosed to
0.210
husband/partner
Yes 175 49.2 42 24.0 1
No 181 50.8 54 29.8 1.35 0.84-2.16
HIV status disclosed to any
other person and/or 0.040
husband/partner
Yes 228 64.0 53 23.3 1
No 128 36.0 43 33.6 1.67 1.04-2.70
i Excluding participants who were tested at the maternity ward (n=23)
6.5.2 Multivariate analysis
All variables that showed evidence of association with not using ARV for PMTCT on univariate
analysis that reached statistical significance (p<O.l) were examined using multivariate logistic
regression (Table 6-8). In this analysis, women who had no ANC card and those who were tested
at the labour ward were excluded.
Factors selected for inclusion in the model included attendance at a CTC,total number of ANC
visits during the current pregnancy, timing of the HIV test, having had an HIV test before current
pregnancy, disclosing her HIV status to anyone, age, education level and occupation. Failure to
attend a CTCbefore delivery was strongly associated with a risk of not using ARV for PMTCT(adj.
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OR3.52; 95%CI1.76-7.01). There was about a four-fold increased risk of not using ARVfor PMTCT
in women with primary or no formal education when compared with women who had secondary
or higher education (OR0.28; 95%CI0.09-0.86). Three or more visit to the ANC facility during the
current pregnancy was significantly associated with a reduced risk of failure to use ARVfor PMTCT
(adj. OR0.47; 95%CI0.27-0.81).
Timing of the HIV test, having had an HIV test before current pregnancy, disclosing her HIV status
to anyone, participants' age and occupation were not associated with failure to use ARV for
PMTCTamong HIV-positive women.
Table 6-8 Independent factors associated with failure to use ARV for PMTCT
Failed to use
ARVfor
PMTCT
(n=96)
Adjustedn %Variables OR1 95% Cl P
Attended to CTCbefore delivery <0.001
Yes 21 12.9 1
No 64 38.8 3.52 1.76-7.01
Education level 0.014
Primary/No formal education 80 28.6 1
Secondary or above 5 10.4 0.28 0.09-0.86
Total ANCvisits during current 0.006
pregnancy
S2 46 37.1 1
~3 39 19.1 0.47 0.27-0.81
lAdjusted for age, education level, total ANCvisits during pregnancy and whether attended a CTCbefore delivery
6.6 Factors associated with failure to complete 4-key PMTCT interventions
(Stage 3)
An HIV-positive woman was considered to have successfully completed Stage 3 of PMTCT if she
used ARV for PMTCTand her infant was given ARV for PMTCT and she was counselled on infant
feeding and she did not practise mixed feeding to her infant.
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Women who completed the four key PMTCTinterventions described above were compared with
women who did not complete all interventions {these include those who did not complete any or
some of the four key interventions}. Data from 295 HIV-positive women participating in the
cohort study and who were seen at the four-month follow up visit were used for this analysis.
6.6.1 Univariate analysis
Table 6-9 shows the association of failure to complete the four key interventions and selected
socio-demographic characteristic and their crude odds ratios. Women recruited at BMCwere less
likely to fail to complete the four key PMTCTinterventions than women recruited at STRH{53.3%
versus 68.3%; OR1.89, 95%CI1.18-3.04}.
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Table 6-9 Association of failure to completion of four key PMTCT interventions with
selected demographic characteristics
Failed to
completed 4 key
PMTCT
interventions
Total
n=181
Crude
Variables n=29S % n % OR 9S%CI P
Delivery site 0.008
BMC 137 46.4 73 53.3 1
STRH 158 53.6 108 68.3 1.89 1.18-3.04
Age groups 0.12
S 20 years 16 5.5 14 87.5 1
20-24 years 60 20.7 39 65.0 0.26 0.05-1.28
25-29 years 88 30.4 50 56.8 0.19 0,04-0.88
30-34 years 63 21.7 38 60.3 0.22 0.05-1.04
~ 35 years 63 21.7 35 55.6 0.18 0.04-0.85
Religion 0.18
Roman Catholics 123 41.7 73 59.3 1
Other Christians 104 35.3 71 68.3 1.47 0.85-2.55
Muslims 67 22.7 37 55.2 0.84 0.46-1.54
No religion 1 0.3 0
Education level 0.002
Primary/No formal 248 84.1 162 65.3 1
education
Secondary or above 47 15.9 19 40.4 0.36 0.19-0.68
Tribe 0.48
Sukuma 131 44.4 78 59.5 1
Other 164 55.6 103 62.8 1.10 0.83-1.46
Marital status 0.16
Married 206 69.8 124 60.2 1
Single 37 12.5 23 62.2 1.08 0.53-2.23
Divorced/separated 36 12.3 27 75.0 1.98 0.88-4.43
Widowed 16 5.4 7 43.7 0.51 0.18-1.43
Occupation 0.44
House-wives/at home 131 44.4 85 64.9 1
Unskilled work 152 51.5 90 58.8 0.78 0.48-1.27
Skilled work 12 4.1 6 50.0 0.54 0.16-1.77
1 Excluding women with unknown age (n=5)
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On univariate analysis, women with no formal education or with primary education were more
likely to fail to complete the four key PMTCT interventions compared to women with higher
education (secondary school or above) (65.3% vs. 40.4%; OR 2.78, 95%CI 1.47-5.25). However,
failure to complete all four key PMTCTinterventions was not associated with age, religion, tribe,
occupation or marital status.
There was a high proportion of women who failed to complete the four key PMTCTinterventions
among women who were tested for HIV at the maternity ward compared to both women who
were either tested at ANC during the current pregnancy or tested before the current pregnancy
(85.7% versus 61.6% and 54.8% respectively) (Table 6-10). There was no association between
failures to complete the PMTCT interventions and the total number of ANC visits during that
pregnancy.
Table 6-10 Association of failure to complete Stage 3 and timing of the HIV testing, previous
HIV testing and number of ANCvisits.
Failed to
completed 4
Total
%
key PMTCT
n=295 interventions
n=181 Crude
Variables n % OR 95%CI P
Timing of an HIV test 0.020
Before current pregnancy 84 28.5 46 54.8 1
During current pregnancy at ANC 190 64.4 117 61.6 1.32 0.7-2.23
Testing at the maternity ward 21 7.1 18 85.7 4.96 1.35-18.11
before delivery
Ever had an HIV test before this 0.030
pregnancy
No 149 50.5 100 67.1 1
Yes 146 49.5 81 55.5 0.6 0.38-0.98
Total ANC visits during current 0.340
pregnancy'
S2 109 37.8 70 64.2 1
~3 179 62.2 105 58.7 0.79 0.48-1.29
1Excluding women whose ANC cards were not seen n=7
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In total, 127 of 264 (48.1%) women who were tested at ANC during or before the current
pregnancy and who were seen four months after delivery had not attended a CTCbefore delivery
(Table 6-11). Of these 127 women, 90 (70.9%) failed to complete the four key PMTCT
interventions compared with 49.7%women who did attend a CTC(OR2.47, 95%CI1.49-4.07).
There was no difference in failure to complete PMTCT interventions among women who had
disclosed their HIV status to their partners/husband compared to those who had not disclosed
(59.7% versus 64.0%, OR 0.83, 95%CI 0.57-1.35). However, there was an association between
failure to completion of four key PMTCT intervention with disclosure of HIV status to any other
person including husbands/partners (54.7%versus 71.9%, OR0.47; 95%CI0.28-0.78)
Table 6-11 Association of failure to complete Stage 3 with attendance to a CTC before
delivery and disclose of HIV status.
Failed to
completed 4
Total
%
key PMTCT
n=295 interventions
(n=181) Crude
Variable n % OR 95%CI P
Attended to CTCbefore dellverv' 0.001
Yes 147 53.6 73 49.7 1
No 127 46.4 90 70.9 2.47 1.49-4.07
HIV status disclosed to 0.452
partner/husband
Yes 181 61.4 108 59.7 1
No 114 38.6 73 64.0 1.20 0.74-1.95
HIV status disclosed to any other 0.003
person including husband/partner
Yes 243 82.4 140 57.6 1
No 52 17.6 41 78.8 2.74 1.34-5.59
1Excluding participants who were tested at the maternity ward and seen 4 months after delivery (n=21)
6.6.2 Multivariate analysis
On univariate analysis, failure to complete PMTCTinterventions was associated with delivery site,
education level, timing of an HIV test, previous HIV testing, attendance at a CTCbefore delivery
and disclosure of her HIV status to any other person including husband/partners. These variables
were then examined using multivariate logistic regression (Table 6-12).
117
RB20l0
After adjusting for age and timing of the HIV test it was found that there was a strong association
between failure to complete the four key PMTCT interventions and attending a CTC before
delivery (adj. OR 2.68; 95%CI 1.46-4.93). There was a four-fold increased risk of failure to
complete the PMTCT interventions in women with primary or no formal education when
compared with women with secondary or higher education (adj. OR0.26; 95%CI0.12-0.56). There
was no association between failure to complete PMTCT interventions and other variables that
showed an association on univariate analysis.
Table6-12 Independent factors associated with failure to complete four key PMTCT
interventions.
Failed to
completed 4 key
PMTCT
interventions
(n=158)
Variable n %
Adjusted
OR1 95%CI
Attended to CTCbefore delivery
Yes 73 49.0 1
No 87 70.2 2.68 1.46-4.93
Education level
Primary or no formal education 145 63..4 1
Secondary or higher 13 33.3 0.26 0.12-0.56
lAdjusted for age, education level, and whether attended a eTC before delivery
P
0.001
<0.001
6.7 Factors associated with failure to receive syphilis screening and treatment
during pregnancy
In total, 135 (11.9%) of 1137 pregnant women admitted at BMC and STRHhad not been screened
for syphilis during the current pregnancy. Fifty-nine out of 1002 pregnant women who were
screened for syphilis during pregnancy were found to be RPRpositive. Of the 59 who were found
to be positive, 16 (27.1%) were not treated for syphilis before delivery.
6.7.1 Univariate analysis
Table 6-13 shows the association of not being tested for syphilis and selected socio-demographic
characteristics and their crude odds ratios. Apart from a weak association between not screening
for syphilis during pregnancy and tribe (OR0.77; 95% Cl 0.50-1.04)' there was no evidence of an
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association between syphilis screening status during this pregnancy and other selected soclo-
demographic characteristics.
Table 6-13 Univariate association between failure to receive syphilis screening during
pregnancy and selected socio-demographic characteristics.
Total Not Crude%
Variables n=1137 n= % OR 95% Cl P
Delivery site 0.62
BMC 426 37.5 48 11.3 1
STRH 711 62.5 87 12.2 1.09 0.75-1.60
Age groups 0.70
< 20 years 188 16.5 27 14.4 1
20-24 years 401 35.3 42 10.5 0.70 0.41-1.17
25-29 years 277 24.4 31 11.2 0.75 0.43-1.31
30-34 years 171 15.0 20 11.7 0.79 0.43-1.47
~35 years 90 7.9 13 14.4 1.01 0.49-2.06
Age not known 10 0.9 2 20.0 1.49 0.30-7.40
Religion 0.32
Roman Catholic 455 40.0 57 12.5 1
Other Christian 404 35.5 50 12.3 0.99 0.66-1.48
Muslim 266 23.4 25 9.4 0.72 0.44-1.19
No religion 12 1.1 3 25.0 2.33 0.61-8.85
Education level
Secondary school or 15.9
0.21
181 15 8.3 1
above
Primary school education 874 76.9 11 12.7 1.61 0.91-2.83
No formal education 82 7.2 9 11.0 1.36 0.57-3.26
Tribe 0.08
Sukuma 411 36.1 58 14.1 1
Other 726 63.9 77 10.6 0.77 0.50-1.04
Marital status 0.15
Married 996 87.6 11 11.3 1
Single 106 9.3 13 12.3 1.09 0.59-2.01
Divorced/separated 27 2.4 7 25.9 2.73 1.13-6.61
Widowed 8 0.7 2 25.0 2.60 0.52-13.06
Occupation 0.27
House wife/at home 543 47.8 56 10.3 1
Unskilled work 548 48.2 72 13.1 1.31 0.91-1.91
Skilled work 46 4.0 7 15.2 1.56 0.67-3.65
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Table 6-14 shows the association between not being screened for syphilis and ANC
characteristics. Not being screened for syphilis during pregnancy was strongly associated with
attending an ANC facility outside Mwanza city during pregnancy (OR 4.9; 95%CI 3.22-7.40).
However, there was no difference in the proportion of women who failed to be screened and who
attended a government or a private ANC in Mwanza city (8.7% vs. 8.4% respectively). There was a
strong evidence of association between not screening for syphilis during pregnancy and attending
2 or lessANCvisits during pregnancy (p<O.OOOl)
Table 6-14 Association between not screening for syphilis during pregnancy and ANC
characteristics.
Variables
Total
n=1137
%
Not Screened
n=135 % P
Crude
OR 95%CI
location of the ANCfacility
Government
Mwanza city Private
Outside Mwanza city
773 68.0
203 17.9
161 14.1
<0.001
67 8.7 1
17 8.4 0.96 0.55-1.68
51 31.7 4.9 3.22-7.40
Number of ANC visits during
pregnancy
4 visits or more 472 41.5
348 30.6
222 19.5
95 8.4
3 visits
2 visits
1 visit
<0.001
34 7.2 1
34 9.8 1.39
37 16.7 2.58
30 31.6 5.95
0.85-2.29
1.57-4.23
3.41-10.37
6.7.2 Multivariate analysis
Variables that showed evidence of association with not screening for syphilis during pregnancy at
p<=O.l were then examined using multivariate logistic regression (Table 6-15). There was a strong
association between not screening for syphilis during pregnancy and attending 2 or lessANC visits
in that pregnancy. There was a six-fold increased risk of failure to screen for syphilis during the
current pregnancy among women who attended ANC facilities located outside Mwanza city
compared to those who attended ANC facilities within the city. On a multivariate analysis, there
was no evidence of an association between not screening for syphilis during pregnancy and tribe.
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Table 6-15
Variables
Independent factors associated with not screening for syphilis during pregnancy.
Not Screened Adjuste
n=135 % d OR1 95% Cl P
Number of ANCvisits during pregnancy <0.001
4 visits or more 34 7.2 1
3 visits 34 9.8 1.29 0.77-2.17
2 visits 37 16.7 2.79 1.66-4.69
1 visit 30 31.6 7.54 4.15-13.70
Location of the ANC facility <0.001
Mwanza city 84 8.7 1
Outside Mwanza cit~ 51 31.7 5.86 3.82-8.97
lAdjusted for age, total ANCvisits during pregnancy and location ofthe ANCfacility
6.8 Discussion
6.S.1 Factors associated with failure to test for HIV during pregnancy
The findings from the cross-sectional study indicate that a high proportion (79.4%) of pregnant
women admitted for delivery at BMC and STRHwere tested for HIV during pregnancy either at
the ANC or when they were admitted for delivery before or after delivery. HIV testing for PMTCT
among pregnant women in Mwanza city was mainly associated with the number of ANC visits
during that pregnancy, the type and location of the ANC facility where the woman attended
during pregnancy and whether the woman had ever been pregnant before the current pregnancy
(Table6-4).
Although it was not clear from documented information on the women's ANC cards when the HIV
test was done, the finding that women who attended an ANC only once during the current
pregnancy were at a higher risk of failure to have an HIV test for PMTCT suggests that other
pregnant women may not test HIV during the first ANC visit, despite this being the
recommendation in the national PMTCTguidelines [37]. Reasons for this might include attending
an ANC facility that does not offer PMTCTservices, arriving at the ANCfacility for the first visit late
in the day or simply not being offered the services when they attend for the first visit due to other
reasons such as lack of resources (including test kits and human resources).
Although more than 70% of pregnant women, who attended ANC at private facilities in Mwanza
city had an HIV test for PMTCTit was not possible to determine whether the test was done at that
actual private facility because this was not indicated on their ANC cards. However, the association
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between attending a private ANCfacility and failure to have an HIV test during pregnancy reveals
the fact that HIV testing for PMTCTmay not be offered consistently in private facilities in Mwanza
city. This fact is supported by the findings of the record review (section 5.2.1.1) indicating that
women who attend private facilities may get referral or do a self-referral to the government ANC
clinics to have an HIV test for PMTCT.This led to higher numbers of women being documented as
testing for HIV compared with the number of women being documented as attending
government ANCsfor the first time during the current pregnancy.
At this stage of the scaling-up of PMTCTin Tanzania, it is expected that PMTCTcoverage is higher
in urban areas compared to rural areas, explaining the association between attending ANC facility
located outside Mwanza city and failure to have an HIV test during pregnancy.
Women who had had two or more pregnancies were more likely to not be tested HIV for PMTCT
compared with primigravidae. However, more than 60% of women who had had previous
pregnancies reported to have had an HIV test previously and therefore might not want to test for
HIV again. Others might have not been tested for PMTCTpreviously and therefore if the service is
not offered to them in this pregnancy do not think to ask for a referral to test.
Finally, the findings that there was no association between many socio-demographic
characteristics and testing for HIV during pregnancy suggests that offering HIV testing during
pregnancy as an opt-out services in ANC reaches and is accepted by a range of pregnant women
equally.
6.8.2 Factors associated with failure to complete Stage 2 and Stage 3
The study found that failure to use ARVfor PMTCT(Stage 2) and failure complete four key PMTCT
interventions among HIV-positive women was associated with failure to attend a CTC before
delivery, low educational level and fewer number of ANCvisits during the current pregnancy.
More than 50% of HIV-positive women who were tested before the current pregnancy or at the
ANCduring the current pregnancy did not attend a CTCbefore delivery. Failure to attend at a CTC
before delivery was found to be strongly associated with both not using ARV for PMTCT and
failure for completion of four key PMTCT interventions. Presumably HIV-positive women who
attend a CTChad an opportunity to learn more about the interventions available to them and are
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better motivated to look after their own health therefore have an opportunity to benefit from
these interventions. Characteristics of pregnant women identified through PMTCTwho attended
CTCswill be discussed in chapter 8.
Participants' low education level was associated with both not using ARVfor PMTCT(Stage2) and
failure to complete four key PMTCT interventions (Stage 3). Improving the information that is
given to HIV-positive pregnant women during the individual HIV post-test counselling is essential
to ensure that women clearly understand all the interventions that are available after being
tested and the importance of each intervention as far as preventing the infant from getting HIV
infection is concerned. In addition, on-going support and counselling to encourage uptake and
adherence to PMTCTinterventions is vital.
From the cohort study, it was found that women who attended an ANCclinic once or twice during
the current pregnancy were at a higher risk of failure to use ARV for PMTCTwhen compared with
women who had three or more ANC visits during the current pregnancy. It is recommended that
pregnant women who are HIV-positive should be given ARV for PMTCT starting at 28 weeks
gestation or any time after that. We were not able to determine when women in this cohort were
given ARV for PMTCT and why others were not given any ARV for PMTCT. Seemingly, women
who test HIV-positive at ANC might not want to come back to the ANC or may not have time to
come back if they attend the ANC late in pregnancy and may end up in the maternity ward with
no PMTCTmedication
In addition, 11.8% of women were actually given ARV for PMTCTbut did not use the medication,
as it was required (see section 5.5.2). When asked why the medication was not used as required,
the women reported that they did not understand the instruction that they were given. This
finding suggests that these women did not get on-going support at ANC and when they were
admitted for delivery. Clear explanations on when the medication should be used are of crucial
importance.
We found missed opportunities to implement a number of PMTCT steps among women who
delivered in hospital such as testing for HIV before delivery. This calls for an urgent need of a
more reliable PMTCT system in the maternity wards to fill the gap for those who deliver in
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hospitals and who did not get all or some of the PMTCT interventions. PMTCThealth workers in
the maternity suites should be available in order to support these HIV-positive women to check
whether they have received earlier PMTCT interventions and to take them through the
interventions that are available at the maternity ward to maximize the successful completion of
the program.
6.8.3 Factors associated with not screening for syphilis during pregnancy.
We found that failure to screen for syphilis during pregnancy was associated with attending an
ANC outside Mwanza city and the fewer number of ANC visits during pregnancy (Table6-1S).
Apparently, health facilities in rural areas have many shortcomings and therefore these findings
should be expected.
Failure to screen for syphilis during pregnancy was associated with one or two visits to the ANC
facility during pregnancy compared to three or more visits. Although early and multiple visits to
the ANC facilities during pregnancy are recommended [106], this finding calls for a more effective
management of pregnant women when they attend ANC clinics for the first time in that
pregnancy including reinforcing the recommendation to screen for syphilis at the first visit in
pregnancy. If they fail to be screened at the first visit, health workers should be educated to
routinely check the ANC card for syphilis test results at later ANC visit and offer screening if
necessary.
Unlike HIV testing for PMTCT, there was no association between failure to screen for syphilis
during pregnancy and the facility type (private versus government). If private ANC facilities can
offer syphilis screening then HIV testing services could be adopted in the same private facilities if
training is given.
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CHAPTER 7: EFFECT OF ANTENATAL HIV EDUCATION ON CLIENTS' KNOWLEDGE
OF HIV, MTCT AND PMTCT
7.1 Introduction
This chapter focuses on the effect of ANC HIV education on pregnant women's knowledge about
HIV, MTCT and PMTCTof HIV. Data presented in this chapter were obtained from the observation
study at the ANCfacilities and from the cross-sectional study at the maternity ward.
7.2 Overview of observation of ANC HIV education sessions
Pregnant women attending ANCfor the first time during the current pregnancy receive education
on general knowledge about HIV and specific knowledge on mother-to-child transmission of HIV
(MTCT) and prevention of mother-to-child transmission of HIV (PMTCT). Details of the steps in
providing ANCHIV education are described in Box 7-1.
Box 7-1 Suggested steps in providing HIV pre-test information in the ANC setting
Assessthe clients' knowledge of HIV/AIDSand MTCT.
o Share information on benefits for counselling and testing in PMTCT.
o Provide information about HIV infection in pregnancy and the risk of MTCT.
o Discussthe meaning of HIV testing and the possible implications of negative and
positive results.
o Discussthe window period and the possibility of repeat HIV testing later in pregnancy
o Talk about the benefits and possible disadvantages of sharing the HIV test results with
sexual partners.
o Discussthe persons with whom clients should share HIV test results (e.g. mother,
sister, in-laws).
o Discussthe interventions available to prevent MTCTand care for the mother and child
if the test results are positive.
o Provide information about how to prevent HIV infection, including safer sex practices.
o Explain when the test results will be available.
o At the end of the session, allow enough time for questions and clarifications.
Encourage and support clients to ask questions.
Source: Tanzania National PMTCT guidelines: May 2007
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The aims of these ANC HIV education sessions are to increase the women's understanding and
awareness of HIV and support informed decision-making about HIV testing and PMTCTservices
[37] According to the PMTCT guidelines, all women should participate in ANC HIV education
session at their first ANCvisit during the current pregnancy or as soon as possible thereafter [37].
This chapter presents a review of the observations of ANCHIV education talks and the procedures
that were used to deliver information about HIV, MTCT and PMTCT of HIV to pregnant women
attending ANC. In addition the content of the health education that was delivered and the
participation of the pregnant women in the discussion were assessed using a modified tool
adapted from the 2007 UNAIDStools for evaluating HIV VCTmanual [112], (Annex 1). Questions
and issues that women were keen to learn about during these sessionswere documented.
7.3 Findings from the observation of health education sessions
Between zs" November 2008 and 22nd July 2009, nine ANCHIV education sessionswere observed
at Makongoro, Nyamagana and Igoma RCHclinics. Three sessions were observed at each of the
above-mentioned RCH clinics, which offer ANC services. All 9 sessions were facilitated by the
nurses and were observed by the study principal investigator (a PhD student). In total 134
pregnant women attended the ANC HIV education sessions that were observed. The average
length for the session was 26 minutes but ranged between 15 minutes to 35 minutes. The average
number of participants in each session was 15 and the minimum and maximum number of
participants in each session was 7 and 22 respectively. All sessions were conducted in Swahili.
At Makongoro RCHclinic, the sessions took place in a designated room known as the "PMTCT
room". At Nyamagana, these ANC HIV education sessions were held at the ANC waiting area
situated outside the ANC examination room along the long corridor of the main outpatient
department (OPD) building. At Igoma, these sessions were held outside at the back of the Health
Centre building in an open space near the footway to the neighbourhood.
7.3.1 Group relationship and participation
In all but one session, women were greeted and welcomed to participate in the HIV health
education session. In 7 out of 9 sessions, facilitators introduced themselves to the group and
recognised the presence of a researcher among the group. Pregnant women attending the ANC
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HIV health education talks were not given an opportunity to introduce themselves in any of the
sessions (Table 7-1).
In all sessions, facilitators allowed all women to participate in the discussion. In 5 out of 9
sessions, each woman was asked to contribute either by asking a question or by answering a
question and this went around the circle although most women did not say anything. At the end
of the session, a summary of the main issues that were discussed was given briefly in 5 sessions
and in detail in one session. In 3 sessions, facilitators did not summarise the main issues that were
discussed by the group.
In 6 out of 9 sessions, facilitators used clear and simple terms while in 3 sessions, the
terminologies that were used were slightly complicated for the audience and the use of a mixed
language (Swahili and English) was frequent. In all sessions, very little time was given to
participants to understand the information that was discussed. Five facilitators had a very good
up to date knowledge about PMTCT, could explain clearly all the concepts regarding HIV
transmission routes, MTCT and PMTCTof HIV, and answered most of the questions that were
asked correctly.
Only in 2 out of 9 sessions, facilitators reinforced important information and in 1 session, a
facilitator checked on understanding and mis-understanding of the issues that were discussed by
asking questions that addressed some of the common myths about HIV, MTCTand PMTCTof HIV.
In 6 sessions facilitators talked about the sensitive issues clearly and appropriately
In all sessions facilitators assumed that all participants understood Swahili, therefore they did not
ask if there was anyone who had problem with that language.
7.3.2 Contents of the health education
In all sessions but one, knowledge about HIV transmission was covered in detail. In 3 sessions,
issues on misconceptions about HIV transmission were explained in detail but were not
mentioned at all in two sessions.
In 4 sessions, the HIV testing procedure was not explained at all, thus participants were not told
how the blood sample would be taken, how many blood samples would be taken and how long it
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would take before receiving their HIV results. In 4 sessions, the HIV testing procedure was
explained briefly whereas in one session, the procedure was explained in detail and participants
in this session were relieved to understand that they will not need to come for their results on a
different day (Table 7-1).
In 4 sessions the "window period" concept was explained in detail. Women were advised that if
they will be tested and found to be HIV negative they would need to consider having a repeat HIV
test after three months. In 2 sessions, the concept was mentioned briefly and in 3 sessions, this
was not mentioned at all. Furthermore, in 2 sessions, women were not given any information
regarding the meaning and possible implication of HIV-positive and HIV negative results (Table 7-
1).
The value of getting the partner involved in the ANC HIV testing during pregnancy was not
mentioned at all in 3 sessions, was only mentioned briefly in 3 sessions and was explained in
details in 3 sessions that also emphasised the possibility of HIV discordant couples (Table 7-1).
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Table 7-1 HIVtopics and how they were covered during the ANC HIVhealth education talks at each
facility.
Number of sessions
Topic NDH Makongoro Igoma Total
Not covered 0 0 0 0
HIV and HIV transmission Covered but not in detail 0 1 0 1
Covered in detail 3 2 3 8
Misconception about HIV
Not covered 1 1 0 2
transmission
Covered but not in detail 1 2 1 4
Covered in detail 1 0 2 3
Not covered 3 1 0 4
HIV testing process Covered but not in detail 0 1 3 4
Covered in detail 0 1 0 1
Not covered 3 0 0 3
Window period Covered but not in detail 0 0 2 2
Covered in detail 0 3 1 4
Meaning and implication of
Not covered 2 0 0 2
Covered but not in detail 1 0 3 4
results Covered in detail 0 3 0 3
Value of getting the partner
Not covered 3 0 1 4
Covered but not in detail 0 0 2 2
involved Covered in detail 0 3 0 3
Potential needs and available
Not covered 2 1 1 4
Covered but not in detail 1 1 2 4
support Covered in detail 0 1 0 1
7.3.3 PMTCT related issues
The fact that HIV testing during pregnancy was not mandatory, that antenatal care and other
services would not be denied if woman decided not to be tested for HIV during pregnancy was
clearly explained to pregnant women in 1 session only. In 3 sessions this was mentioned briefly
and in 5 sessions this was not mentioned at all (Table 7-2).
Information about HIV in pregnancy and the risk of transmission to the infant was explained in
detail in 4 sessions, explained briefly in 4 sessions but was not mentioned at all in 1 session.
Possible benefits of knowing one's HIV status and the interventions available if the woman tested
HIV-positive during pregnancy was explained in details in 6 out of 9 sessions. In these sessions,
women were informed on the availability of ARV for PMTCT for HIV-positive mothers during
pregnancy, labour and delivery and for their infants soon after delivery. In these sessions, a brief
explanation on infant feeding options for HEIwas given (Table 7-2).
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In 7 out of 9 sessions, it was briefly explained that ARVfor PMTCTwas not a cure or treatment for
mothers. In 2 sessions, ARVfor PMTCTwas not mentioned at all (Table 7-2).
Table 7-2 PMTCT topics and how they were covered during the ANC HIV health education talks at
each facility.
Number of sessions
Topic NDH Makongoro Igoma Total
Not covered 1 0 0 1
HIV in pregnancy and the risk of C d b t t l d t '1 2 1 1 4overe u no In e al
MTCT .
Covered in detail 0 2 2 4
Benefits of knowing HIV status Not covered 1 0 0 1
and interventions available for Covered but not in detail 1 0 1 2
HIV-positive pregnant women Covered in detail 1 3 2 6
Not covered 3 1 1 5
HIV testing is not mandatory Covered but not in detail 0 2 1 3
Covered in detail 0 0 1 1
ARVtherapy not a
Not covered 2 0 0 2
Covered but not in detail 1 3 3 7
cure/treatment for mothers Covered in detail 0 0 0 0
The need to attend maternity
Not covered 2 0 0 2
Covered but not in detail 1 1 2 4
ANCservices regularly Covered in detail 0 2 1 3
Not covered 3 3 3 9
Known adverse effects and drug Covered but not in detail 0 0 0 0
interactions Covered in detail 0 0 0 0
7.3.4 Issues noted during the observation
Key issues that were observed during the ANCHIV education talks included:-
1. In 4 out of 9 sessions, pregnant women did not ask any questions;
2. Most questions raised during these sessions were focused on the preventing the baby from
getting HIV infected and it was interesting to note that women were relieved when told about
the effectiveness of the ARV for PMTCT. However, there were no questions about
interventions that focused on the woman's own health if she tested positive and this was not
covered in all the sessions;
3. Only one couple attended the ANCHIV education talk during the observed sessions. fast track
services (where the woman and her partner were not required to wait on a queue for any of
the ANC services) were offered to couples who attended ANC in order to encourage male
participation by reducing the time spent at the ANC;
4. In one observed session at Nyamagana RCHclinic, the facilitator did not mention anything
about PMTCTalthough she was aware of the ongoing observation;
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5. During the observation of sessions at Nyamagana and Igoma ANC facilities, a number of
distractions were noted including women being called to by friends passing by and women
concentrating in other things apart from listening to the talk. This was due to the fact that the
sessionswere conducted in an open space outside the building.
7.4 Overview 0/ the cross-sectional study
Data were obtained from 1157 women who were admitted for delivery at Bugando Medical
Centre (BMC) and Sekou-Toure Regional Hospital (STRH)between 8th September 2008 and iz"
October 2008 and who participated in the face-to-face interviews that were conducted by the
research assistants (clinical officers/nurses). Knowledge about HIV, MTCT and PMTCT were
measured by a set of questions on knowledge about HIV prevention, MTCT and PMTCT of HIV
(Annex 9). In addition, women who attended the ANC clinic during pregnancy were asked if they
attended to the ANC HIV health education sessions that are offered to a" pregnant women when
they attend at the ANC clinic.
In regard to HIV prevention knowledge, women were required to explain how someone can
protect her/himself from being infected by HIV and they were encouraged to mention all the
possible measures to protect oneself from HIV. Ten pre coded answers including "others" code
were included on the questionnaire.
Knowledge about MTCTof HIVwas measured using four questions. First, women were asked if an
HIV-positive woman can transmit HIV to her baby. Those answering "yes" to this question were
then asked about the specific timing of the transmission using the following three questions
1. Can HIV-positive pregnant woman transmit HIV to her baby while in the womb?
2. Can HIV-positive pregnant woman transmit HIV to her baby during labour and delivery?
3. Can HIV-positive woman transmit HIV to her baby during breast-feeding?
Responses were "yes", "no" and "don't know". "No" and "don't know" were considered as
incorrect answers.
For PMTCTknowledge, women were asked to mention steps that can be done to prevent an HIV-
positive woman from transmitting HIV infection to her baby. After each response, the interviewer
continued to probe until there was no further response from the respondent. Five pre-coded
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answers including "others" were included in the questionnaire and wrong answers were not
considered.
For the descriptive and bivariate analysis, knowledge was examined considering each variable
separately and by reporting the proportion of women who gave right answer on those specific
questions.
In multivariable analysis each respondent's level of knowledge was determined with a scoring
system developed for each of the three topics, i.e. general HIV prevention (10 questions), MTCT
of HIV (four questions) and PMTCT of HIV (five questions). Each right answer in each topic
attracted one point. A person's knowledge was therefore scored out of 19 points, representing 19
questions and this was then converted in percentage.
Linear regression was used to compare the mean knowledge score among pregnant women
receiving ANC HIV education sessions with those who did not to examine the effect of ANC HIV
education on pregnant women's knowledge about HIV, MTCTand PMTCTof HIV.
7.5 Findings from the cross-sectional study at the maternity wards
All 1157 women who participated in the cross-sectional study at the maternity wards between 8th
September 2008 and iz" October 2008 responded to the knowledge questions during the
interviews.
7.5.1 HIV, MTCT and PMTCT knowledge among pregnant women - descriptive analysis
All participants were aware of HIV and AIDS.The majority (81.8%) were able to mention 2-4 out of
10 methods by which people could protect themselves from being infected with HIV. Only 15.2%
were able to mention between 5 to 9 ways for someone to protect him/herself from being
infected by HIV.
Overall, 1134 (98.0%) women knew that an HIV-positive woman could transmit HIV to her baby.
Of these 846 (73.4%), 961 (83.1%) and 1089 (94.1%) knew that an HIV-positive woman can
transmit HIV to her baby while in the womb, during labour and delivery and during breastfeeding
respectively. Overall, 719 (62.1%) of all the participants answered all four MTCT knowledge
questions correctly.
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In total, 51.9%, 1.5%, 25.0%, 60.0% and 5.9% of all respondents knew that MTCT of HIV could be
prevented by giving ARV medication to the mother during pregnancy, delivering by caesarean
section, giving ARV to the infant soon after delivery, not breastfeeding the baby and using
exclusive breastfeeding respectively. Only 45 (4.0%) of all respondents who knew that an HIV-
positive mother could transmit HIV to her baby were able to mention up to four methods to
prevent MTCTof HIV.
7.5.2 HIV, MTCTand PMTCTknowledge among pregnant women- bivariate analysis
Table 7-1 shows the proportion of women who answered some of the selected HIV, knowledge
questions correctly stratified by whether the respondent received an ANC HIV education sessions
at ANCor not.
In general, women who received ANC HIV education were more knowledgeable compared to
women who did not receive ANC HIV education during pregnancy. Specifically to avoid sharing
sharp edges and having one faithful HIV-negative partner as a way to protect from HIV infection
was mentioned by a significantly higher proportion of women who received ANC HIV education
compared to those who did not receive ANC HIV education (33.5% vs. 21.7 and 55.2% vs. 38.1%
respectively) (Table 7-3).
Table 7-3 Knowledge on HIV by whether a woman received ANC HIV health education
during pregnancy.
Variables
Received ANCHIV health education
Yes (n=931) No (n=226)
n % (95% Cl) n % (95% Cl) p
What can a person do to protect
her/himself from HIV infection
Use of condom
Avoid sharing sharp edges
Have one/few partners
Having one faithful HIV-
partner
665 71.4 68.4-74.3
312 33.5 30.4-36.6
253 27.2 24.4-30.2
151 66.8 60.3-72.9 0.172
49 21.7 16.5-27.6 0.001
54 23.9 18.5-30.0 0.316
514 55.2 52.0-58.4 86 38.1 31.7-44.7 <0.001
Understands that a person who
looks healthy could be HIV 864 92.8 91.0-94.4
infected
203 89.8 85.1-93.4 0.229
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There was no significant difference in the proportion of women who received ANCHIV education
and those who did not receive ANC HIV education in terms of awareness that condom use during
sexual intercourse and having one or few sexual partners could prevent against HIV infection
(71.4% vs. 66.8% and 27.2% vs.23.9% respectively) (Table 7-1)
Table 7-4 shows the proportion of women who answered MTCT and PMTCTknowledge questions
correctly stratified by whether the respondent received an ANC HIV education talk at ANCor not.
These included women who knew that HIV can be passed from an HIV-positive mother to her
baby (N=1134).
There was no significant difference in proportion of women who received ANCHIV education and
those who did not in terms of understanding that HIV can be passed to the infant while in the
womb and during labour and delivery (76.0% vs. 70.5% and 85.7% vs. 80.9% respectively).
However, a slightly higher proportion of women who received ANC HIV education compared to
those who did not receive ANC HIV education understood that HIV could be passed to the baby
born to an HIV-positive woman through breastfeeding (97.0% vs. 91.8%)
While in general PMTCT knowledge was low, a significantly higher proportion of women who
received ANC HIV education knew that HIV from an HIV-positive mother to her baby could be
prevented by not breastfeeding the baby (64.2% vs. 48.2%) and giving ARV medication to the
mother during pregnancy (56.1% vs. 40.0%). Generally, knowledge about other post-delivery
interventions (Le. giving ARV to the baby soon after birth and using exclusively breast-feeding)
was low in both groups.
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Table 7-4 Knowledge on MTCTand PMTCTby whether a woman received ANCHIV health
education during pregnancy.
Received ANCHIV health education
Yes (n=914) No (n=220)
Variables n % (95%CI) n % (95%CI) p
Knows that HIV can be
transmitted from an HIV+
mother to her baby
Before birth in the womb 694 76.0 73.0-78.7 155 70.5 63.9-76.4 0.173
During labour and
783 85.7 83.2-87.9 178 80.9 75.1-85.9 0.161
delivery
During breastfeeding 887 97.0 95.7-98.0 202 91.8 87.4-95.1 0.003
Knows that MTCT of HIV can
prevented by
Giving ARVto the mother
513 56.1 52.8-59.4 88 40.0 33.5-46.8
<0.00
during pregnancy 1
Giving ARVto the infants 248 27.1 24.3-30.1 41 18.6 13.7-24.4 0.025
soon after delivery
Not breastfeeding the 587 64.2 61.0-67.3 106 48.2 41.4-55.0 <0.00h"hv
Exclusively breastfeed the 118 12.7 10.8-15.3 15 6.8 3.9-11.0 0.031
baby
7.5.3 Factors associated with overall knowledge on HIV prevention, MTCT and PMTCT of HIV
among pregnant women.
A percentage on the overall score on all three subjects (Le. HIV prevention, MTCT and PMTCT)
was obtained for each respondent and this was compared among women who received and those
who did not receive ANC HIV education during the current pregnancy. Table 7-5 shows the crude
and multivariable analysis comparing the mean overall knowledge among pregnant women.
The univariate analysis showed evidence of significant association in the mean overall knowledge
for the following variables; receiving ANC HIV education during the current pregnancy (p<O.OOl),
respondent's HIV status (p<O.OOl), respondent's age (p<O.OOl), education level (p<O.OOl),
respondent's parity (p=0.020), respondent's occupation (p<O.OOl), respondent's religion
(p<O.OOl), respondent's tribe (p=O.002) and whether the respondent had tested for HIV before
the current pregnancy (p<O.OOl)
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All variables in the univariate analysis were significant and there were all included in the
multivariable analysis. It was found that after adjusting for all other variables knowledge
decreased in women who did not receive ANC HIV education during the current pregnancy
(adjusted difference=-3.8; 95% CI-S.7 -2.0, p<O.OOl),in women who were HIV-negative and those
with unknown HIV status (adjusted difference=-2.1; 95% Cl -4.6 0.2 and -5.2; 95% Cl -7.9 -
2.S,respectively p<O.OOl), in women with no formal education or those who attained primary
education (adjusted difference=-3.9; 95% Cl -5.8 -1.9, p=O.OOl)and in women who never had HIV
test before the current pregnancy regardless of whether they were tested during the current
pregnancy (adjusted difference=-2.3; 95% Cl -3.6 -1.0, p<O.OOl).
In addition knowledge score increased in women of "other" tribes other than Sukuma women
(adjusted difference=1.9, 95% Cl 0.6 3.3; p=0.015) and in older women when compared with
women aged below 20 years, however, there was a significant decrease in overall knowledge on
HIV, MTCTand PMTCTamong women who did not know their age (adjusted difference=-7. 2; 95%
Cl -14.0 -1.0, p=0.02).
On a multivariable analysis, there was no association between knowledge about HIV, MTCT and
PMTCTand the participants' parity and occupation.
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Table 7-5 Multiple linear regression models predicting mean score of HIV, MTCT and
PMTCTknowledge among pregnant women.
Crude analysis Multivariable analysis
Total 95%CI Adjusted 95%CI
Variable n=1157 Mean Lower Upper p difference' Lower Upper P
Overall mean 49.2 45.8 52.5
Received ANCHIV education <0.001
Yes 931 44.5
No 226 38.6 37.0 40.3 -3.8 -5.7 -2.0
HIV status <0.001
Positive 90 46.1
Negative 829 44.2 41.9 46.7 <0.001 -2.1 -4.6 0.2
Unknown 238 39.0 36.3 41.8 -5.2 -7.9 -2.5
Age groups 0.019
< 20 years 193 40.4
20-24 years 406 43.3 41.4 45.2 1.3 -0.6 3.1
25-29 years 279 44.6 42.5 46.7 3.2 1.2 5.2
30-35 years 173 44.8 42.5 47.1 <0.001 3.3 1.1 5.5
~ 35 years 94 43.9 41.1 46.1 2.9 0.2 5.6
Unknown 12 32.9 26.3 39.5 -6.7 -13.0 -0.4
Education level <0.001
Secondary 183 47.7
44.3 <0.001
0.0
Primar~ or none 974 42.5 40.8 -4.2 -5.9 -2.4
Parity 0.133
Primigravidae 360 42.1 0.020 0.0
Multigravidae 797 43.3 42.1 45.2 1.3 -0.4 3.0
Occupation 0.317
House wives 552 42.9 0.0
Unskilled work 558 43.1 41.8 44.5 <0.001 0.2 -1.1 1.4
Skilled work 47 50.3 46.9 53.7 2.9 -0.6 6.5
Religion 0.006
Roman Catholics 466 44.0 0.0
Other Christians 410 42.1 40.7 43.7 000 -2.0 -3.4 -0.6
Muslims 269 44.4 42.7 46.1 <. 1 -0.3 -1.9 1.4
No religion 12 32.4 26.4 39.4 -7.2 -14.0 -1.0
Tribe 0.061
Sukuma 424 41.9 0.002 0.0
Other 733 44.1 42.7 45.4 1.9 0.6 3.2
Ever tested for HIV before pregnancy 0.001
Yes 654 44.9 0.0
No 503 41.3 40.0 4 <0.001 -2.3 -3.7 -1.1
lAdjusted for age, HV status, education level, parity, occupation, religion, tribe whether have ever had and HIV test
before,
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7.6 Discussion
7.6.1 Observation of the ANC HIV education sessions
Generally, a reasonable length of time was spent on the ANC HIV education sessions when the
woman attended ANC for the first time during the current pregnancy. It was found that women
were not given an opportunity to introduce themselves to the group, although this would add
time to busy clinic schedules. However, this may have reduced tension among participants and
assisted in facilitating the discussion, since relatively low number of women answered or asked
questions.
In addition, the findings that most women did not participate in the discussion might be due to
the fact that they did not understand the talk or they were not interested in discussing issues
around HIV/AIDS openly in a group especially if others might think that discussing issues around
HIV/AIDS will prompt others to think that they were HIV-positive.
Some facilitators lacked information on HIV, MTCT and PMTCT and as a result, some important
take-home messages for pregnant women were not either mentioned at all or were mentioned
but not emphasised. This finding highlights an urgent need for training/refresher of health
workers to equip them with updated information about HIV, MTCTand PMTCT.
We observed that women were not told that the HIV test during pregnancy was not mandatory
and it was noted that women were denied services in the under-five clinics if their HIV status was
unknown. In addition, statements such as "If you do not test HIV now, you will be tested during
delivery because nobody will be willing to deliver you with unknown HIV status" were common
during the ANC HIV education talks. This is contrary to the PMTCT National guidelines [37).
Women who test due to these circumstances might be more likely to fail to adhere to other
PMTCTinterventions since they take up the test but they might not understand the importance of
other following interventions.
7.6.2 Cross-sectional study
In general, women who received ANC HIV education during the current pregnancy had a high
knowledge of HIV, MTCT and PMTCT. After adjusting for other variables in the multivariable
analysis, receiving ANC HIV education during the current pregnancy was strongly associated with
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pregnant women's overall knowledge on HIV prevention, MTCT and PMTCT of HIV. It was also
found that women who had a high score in knowledge about HIV, MTCT and PMTCTwere more
likely to have had an HIV test compared to those whose knowledge was low.
Pregnant women should be encouraged to attend to the ANC HIV education sessions and trained
personnel should be made available in order have optimal results from these education talks and
from the PMTCTprogram as a whole.
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CHAPTER 8: REFERRAL AND CARE FOR HIV-POSITIVE PREGNANT WOMEN
8.1. Introduction
This chapter explores the referral system, uptake and attendance at a care and treatment clinic
(CTC) among HIV-positive women tested for the first time during the current pregnancy. To
address this aim data from the health worker interviews and from 403 HIV-positive women
enrolled in a prospective cohort at admission for delivery at two large hospitals in Mwanza city
were used. Before going into details of the results, an overview of the procedure that pregnant
women attending CTCfollows is given in section 8.2 Results from the health worker interviews
will be covered in section 8.4 and results from the cohort study will be covered in section 8.6.
8.2 Procedure at the ere
When HIV-positive pregnant women attend a CTC,a blood sample is taken for a confirmatory HIV
test and CD4 cell count, before the pregnant women meets with a counsellor and a clinician. CD4
test results are typically not available on the same day; therefore, pregnant women are scheduled
for a follow-up visit with a clinician to discuss clinical staging and the CD4test results.
After consultation with a clinician at the follow up visit (CD4test results should be available at this
time), pregnant women eligible for and who agree to initiate therapy meet with a counsellor to
discuss issues related to adherence, medication dosing and adverse event management. A blood
sample is also taken for tests that help inform the treatment protocol and identify baseline values
for monitoring toxicity. When they start taking the medication, pregnant women are scheduled for
a follow-up visit after two weeks, then monthly for adherence counselling follow up and clinical
care and monitoring of their response to therapy. After six months, they are requested to continue
to visit the clinic once a month for adherence counselling and medication refills.
CD4counts and basic blood tests are performed at six months intervals. Those who are not eligible
for treatment require regular monitoring and assessment of clinical staging and CD4count every 6
months.
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8.3 Overview of the health worker interviews
The health worker interviews described in Chapter 4, section 5, provided data on the proportion
of health workers who were involved in the implementation of PMTCT and who referred HIV-
positive women identified through PMTCT for further services outside their facilities. Sites
selected included two delivery suites and three ANC clinics that have PMTCTservices. In addition,
the health workers' data provided information on the referral system available at the health
facilities, the reasons for referrals and the health workers' views on the current referral of HIV-
positive pregnant women to a CTCand other services after an HIV-positive test at the ANC or at
the maternity ward.
8.4 Findingsfrom the health worker interviews
In total, 89 health workers were interviewed, 24 at Bugando Medical Centre (BMC), 33 at Sekou-
Toure Regional Hospital (STRH),13 at Makongoro Regional RCHclinic, 10 at Nyamagana District
Hospital (NDH) and 9 at Igoma Health centre. Table 8-1 shows the cadre of the health workers
that were interviewed at each health facility. The majority of the health workers interviewed were
nurses (71.9%) followed by medical attendants (18.0%). Only three medical doctors were
interviewed and all were at BMC.
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Table 8-1 Cadre of health workers participating in the study
Name of health facilities, n
Formal training All BMC STRH Makongoro NDH Igoma
Medical Doctors 3 3 0 0 0 0
Clinical officers 3 0 0 1 1 1
Laboratory technicians 2 0 0 1 0 1
Pharmacy assistants 1 0 0 0 0 1
Medical attendants 16 3 7 4 1 1
Nurses 64 18 26 7 8 5
Total 89 24 33 13 10 9
8.4.1 Background information on PMTCThealth workers
Since referral to HIV care and treatment centres is initiated at ANC services as well as at the
maternity wards that offer PMTCT, background information on the training of PMTCT health
workers was collected. Overall, 30 (33.7%) health workers who were interviewed reported that
PMTCT implementation was their main daily work activity. All 3D-health workers were females,
trained as nurses, with a median age of 43 years (range 26-55 years).
Twenty-six (86.7%) health workers involved in the implementation of PMTCT reported receiving
training in HIV testing, 25 (83.3%) reported receiving training in voluntary counselling and testing
(VCT)and 22 (73.3%) reported receiving training in the provision of ARV prophylaxis for PMTCT. In
addition, 25 (83.3%) reported receiving training in infant feeding counselling for HIV-positive
women, 19 (63.3%) reported receiving training in optimal obstetric care, 20 (66.7%) reported
receiving training in PMTCT record keeping and 22 (73.3%) reported to have received training in
the national PMTCT guidelines of 2007. Table 8-2 shows the number and proportion of health
workers who reported receiving training in different PMTCTsubjects at each facility.
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Table 8-2 Number and proportion of PMTCT health workers reporting training in different
PMTCTsubjects by health facilities
Facilityname BMC STRH Makongoro NOH Igoma Total
PMTCThealth 12 10 4 2 2 30
workers (N)
Subject No. trained (%)
HIVtesting 12 (100.0) 8 (80.0) 4 (100.0) 1 (50.0) 1 (50.0) 26 (86.7)
VCTfor PMTCT 11 (91.8) 9 (90.0) 4 (100.0) 1 (50.0) 0 25 (83.3)
Provisionof ARVfor
10 (83.3) 7 (70.0) 4 (100.0) 1 (50.0) 0 22 (73.3)
PMTCT
Infant feeding 10 (83.3) 9 (90.0) 4 (100.0) 1 (50.0) 1 (50.0) 25 (83.3)
counselling
Optimalobstetric
8 (66.7) 7 (70.0) 3 (75.0) 1 (50.0) 0 19 (63.3)
care
PMTCTrecord
7 (58.4) 8 (80.0) 4 (100.0) 1 (50.0) 0 20 (66.7)
keeping
NewPMTCT
10 (83.3) 6 (60.0) 4 (100.0) 0 2 (100.0) 22 (73.3)
guidelines(2007)
Eighteen (66.7%) of the PMTCT health workers reported receiving training in 6 or 7 of the 7
PMTCT topics listed in Table 8-2 above. At Makongoro, three of four PMTCT health workers
reported receiving training in all aspects of PMTCT (Table 8-3). One health worker at NDH
reported not receiving any training in PMTCT at all though she was involved in the
implementation of PMTCTas part of her daily activities.
Table 8-3 Training in PMTCT subjects among health workers at each health facility that
participated in the health worker interviews
Health Facilities
BMC STRH Makongoro NDH Igoma Total
PMTCTHealth worker 12 10 4 2 2 30
Number of PMTCT No. trained (%)
subjects
None (zero) 0 - 0 - 0 1 50.0 0 1 3.3
1-2 subjects 1 (8.3) 1 (10.0) 0 0 - 2 100.0 4 13.3
3-5 subjects 2 (16.7) 3 (30.0) 0 0 - 0 5 16.7
6-7 subjects 9 (75.0) 6 (60.0) 4 100.0 1 50.0 0 - 18 66.7
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8.4.2 Report on referral of HIV-positive women identified through PMTCT
Of the 30 health workers who were working on implementation of PMTCT, 21 (70.0%) reported
giving referrals to HIV-positive women to attend services related to their HIV infection. The main
referral reason that was mentioned by the health workers was to send women to CTC12facilities
nearer their residential areas (57.1%). Other reasons for referral included initial referral to a CTC
(from facilities that do not offer care and treatment services) (14.3%), referral for infant diagnosis
(14.3%), for a CD4test (9.5%) and to psychosocial support groups (4.8%).
Health workers were asked an open-ended question requiring them to describe the referral
system that was in place. Nineteen of the 21 health workers mentioned using a specific referral
form (Annex 6) that was given to the woman detailing her HIV status. This form should be
completed when a woman is sent to another health facility for any service regarding her HIV
status. However, it is most commonly completed during the HIV post-test counselling session
when the woman is provided with information about all available interventions and the facilities
that offer those interventions and she is given an opportunity to choose a facility that is
convenient for her. When the woman attends the referral facility, the health worker at the new
facility completes section B of the referral form to show that the woman has attended and the
type of services that she received at the facility. Section B is given back to the woman who is then
supposed to take it back to the original ANC facility where she was tested for HIV. This process
was clearly described by all the health workers who reported giving referrals to HIV-positive
women.
According to the national PMTCT guidelines, HIV-positive women identified through PMTCT
should be referred for assessment of eligibility for ART treatment as soon as possible after a
positive HIV test [37]. Assessment for eligibility for ARV treatment is then done at a CTC.
However, few of the PMTCThealth workers interviewed did not know the appropriate timing of
referrals to CTCfor HIV-positive women identified through PMTCT.One health worker at Igoma
RCHclinic said
liThe woman has to come back to the under-five clinic 6 weeks after delivery and she is given a letter (referral
form) to be submitted to a eTC at STRH".
12 Following the introduction of more CTCs,women were referred to their local CTCfacilities.
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In addition, one of the PMTCTcounsellors at NOHsaid
" ...When we find that the woman is HIV-positive, if her pregnancy is above 28 weeks, we give her a tablet to
keep and we instruct her to use the tablet when labour pain starts. We normally ask these women to come to
the clinic after delivery and it is when we give them a referral letter to take to the CTCwhere they get more
. "services ...
This is clearly contrary to the PMTCTguidelines that emphasise the importance of the assessment
for the eligibility for ARVtreatment that is normally done at the CTC[37].
8.4.3 Challenges of the referral system
PMTCThealth workers who participated in the interview reported the following weaknesses and
problems in the referral system:-
1. Lack of coordination between ANC clinics and CTCs,which result in HIV-positive pregnant
women failing to attend a CTC.This was perceived to be due to lack of tracking system as
women moved from the ANCto a CTC.It was suggested that this could be done if ANC health
workers accompanied women to a CTC.In addition, health workers at the ANC often did not
know whether HIV-positive pregnant women referred to CTCactually attended a CTCbefore
or after delivery because most referred women do not bring Section B of the referral form
back to the ANC.
2. Pregnant women attending a CTChave to go through the same normal procedures as other
new non-pregnant HIV-positive individuals, which cause delay in accessing CTCservices pre
delivery.
3. Pregnant women do not attend CTCswhen they are referred because they are not sick and
some of them do not understand the importance of attending before delivery.
One health worker at BMC reported that women referred to a CTCfrom an ANC or from the
maternity ward are sometimes being sent back by the health workers at CTCto the maternity
ward PMTCT section without being enrolled at a CTC and therefore do not get assessed for
eligibility for ARV treatment during pregnancy. This is because some health workers at a CTC
assumed that HIV-positive pregnant women should receive all the care they needed at the
PMTCTsection in the ANCor in the maternity ward.
There was also a concern that HIV-positive women identified through PMTCTservices are being
sent to CTCfacilities that are already overloaded. As a result, they do not get enrolled at the CTC
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or assessed for eligibility to ARV treatment during pregnancy because of a high number of
patients waiting for the same service. A nurse from BMC stated
"We are sending them to these facilities so that they can get better services, yet these facilities have so many
clients and therefore these women do not get the required services."
8.5 Overview of the cohort study
The proportion of women who were referred to a CTCfollowing an HIV-positive test at PMTCT
screening was obtained from 403 HIV-positive women enrolled in a prospective cohort at
admission for delivery at two large hospitals in Mwanza city.
All women tested for HIV during the current pregnancy, either at ANC or at the maternity ward
when they were admitted for delivery, were asked if they were referred to a CTCfollowing a
positive HIV test. This was part of the interview at cohort recruitment and at each of the monthly
follow-up visits for 4-months post-delivery. Women, who reported any written or oral referral,
were then asked if they actually attended the CTC.Women reporting attendance at a CTCwere
asked to show the interviewer their CTCcard. The CTCcard has recorded information on: - date of
attendance, CD4 counts, date of CD4 counts, whether the woman was started on HAART
following the CD4test results and the date of initiation of ARVtreatment.
8.6 Findingsfrom the cohort study
Ninety-three women who tested HIV-positive before the current pregnancy were excluded from
this analysis. Three hundred and ten (76.9%) of 403 HIV-positive women in the cohort were tested
for HIV during or just after the current pregnancy. Of these 240 (77.4%) were tested at ANC, 23
(7.4%) were tested at the maternity ward before delivery and 47 (15.6%) were tested at the
maternity ward after delivery.
8.6.1 Referral to CTCamong cohort women attended ANC at clinics that participated in the
health worker Interviews.
Ninety-three (38.8%) HIV-positive pregnant women out of 240 women, who tested for HIV at ANC
during the current pregnancy and were recruited into the cohort, attended ANC at Makongoro,
NDH and Igoma health centre. These are the ANC facilities that participated in the health worker
interviews. In order to confirm the findings reported in section 8.3.2 regarding the
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misunderstanding of the referral timing that was revealed by the health worker at NOH ANC
clinic, the cohort study data were examined.
It was found that all 16 HIV-positive women in the cohort study who attended the ANC at NOH
were not given any referral to CTCbefore delivery (Table 8-4). Thirty-four women out of 51
(66.7%) and 13 out 26 (50.0%) who attended ANC at Makongoro and Igoma RCHclinics reported
receiving a referral to CTCbefore delivery (Table 8-4).
Table 8-4 Cohort data indicating reported referral to CTC before delivery among HIV-
positive pregnant women attending ANC at Makongoro NOH and Igoma RCH
clinics
ANC facility name
Makongoro NOH Igoma Total
Total in the cohort at recruitment 51 16 26 93
Number reported receiving referral at 34 0 13 47
ANC
Proportion receiving referral at ANC 66.7% 0 50.0% 50.5%
8.6.2 Proportion of women referred to CTC
Overall, 123 (51.3%) of 240 pregnant women identified as HIV-positive during or just after the
current pregnancy at ANC reported receiving referral to a CTC before delivery. In addition, 70
(22.6%) of 310 women who were identified as HIV-positive at the maternity ward did not receive
referral to CTCbefore discharge from the maternity ward.
Table 8-5 shows the number of women who were seen at each follow-up visit and the proportion
who received referral to a CTCbefore or after delivery. At each follow-up visit though the number
of women seen was declining, the number of women reporting referral to CTCafter delivery
increased from 37 women at one month post-delivery to 98 women 4 months after delivery, this
means that women who continued seeking health services were eventually referred to a CTC
post-delivery.
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Table 8-5 Referral to crc before and after delivery
Total number Received referral to eTC
Follow up visit seen (%)
N=3101 Pre-delivery Post-delivery Total
Month 1 271 (87.4) 111 37 148 (54.6)
Month 2 245 (79.0) 103 48 151 (61.6)
Month 3 233 (75.2) 100 53 153 (65.7)
Month 4 244 (79.0) 102 97 199 (81.6)
1Women identified asHIV-positivefor the first time through PMTCTHIVscreening
Two hundred and seventy-one (87.4%), 245 (78.0%) and 233 (75.2%) of 310 women who were
identified as HIV-positive through PMTeT HIV screening during the current pregnancy were seen
at first, second and third follow-up visits respectively. Of these, 148 (54.6%), 151 (61.6%) and 153
(65.7%) reported receiving referral to a eTC before or after delivery when they were see at first,
second and third follow-up visits respectively.
Of the 310 women who were identified as HIV-positive during or just after the current pregnancy,
244 (79.0%) were seen during the fourth month post-delivery follow-up visit. Of these, 199
(81.6%) reported receiving referral to a eTC. These included 102 (82.9%) women out of 123
women who received referral before delivery and 97 women who received referral when they
attended the under-five clinics or when they visited the maternity wards for infant diagnosls".
8.6.3 Proportion of women attending a crc pre and post-delivery
8.6.3.1 In/ormation at cohort recruitment
Among 123 HIV-positive women who were tested at ANC and who were referred to a eTC before
delivery, 85 (69.1%) reported having attended a eTC before delivery. Of the 85 women reported
attending a eTCbefore delivery, 36 (42.3%) confirmed the attendance at a eTCby providing a eTC
card at cohort recruitment. Forty-nine (57.7%) women who reported attending to a eTC before
13 At the maternity ward before discharge from the hospital after delivery, HIV-positive women who were counselled
were advised on the importance of knowing the HIV status of their infants and they were asked to bring them to the
maternity ward 4 weeks later so that a blood sample for the infant diagnosis (HIV DNA and RNA peR) could be collected.
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delivery and who did not provide their CTCcard at cohort recruitment were seen at least once
during the follow-up visits and from information collected at follow up visit by examining their
CTCcard it was found that in reality 71 (57.7%) women out of 123 had attended to CTCbefore
delivery, 12 (9.8%) attended after delivery, 28 (22.8%) did not attend to CTCand 12 (9.8%) were
lost to follow up before attending a CTC,therefore it is not known if they attended a CTCor not.
8.6.3.2 Attendance ta a ere during the follow-up visits
Table 8-6 shows the number of HIV-positive women who were seen at each follow-up visit, the
number who reported receiving referral to a CTCand the number and proportion of those who
attended aCTC before or after delivery.
Table 8-6 Attendance to a crc before and after delivery
Total number
Total number
Attended a CTC
Follow up seen (%) referred to a
visit N=3101 CTC Pre-dellverv/ Post-delivery Total
Month 1 271 (87.4) 148 60 8 68 (45.9)
Month 2 245 (79.0) 151 68 23 91 (60.3)
Month 3 233 (75.2) 153 72 32 104 (68.0)
Month 4 244 (79.0) 199 74 49 123 (61.8)
iWomen identified as HIV-positive for the first time through PMTCT HIV screening
2 This includes women who made a self-referral to a CTCbut who were referred to CTCafter delivery who are not
among 71 (at cohort recruitment)
At the first follow-up visit, 68 (45.9%) of 148 women who reported receiving referral to a CTChad
attended to a CTC.Of these 68 women, 60 had attended a CTCbefore delivery and 8 attended
after delivery. During the second follow-up visit, the number of women reporting to have
attended to a CTCincreased to 91 (60.3%) out of 151 women who received referral to a CTC.Of
these 91, 68 attended a CTCbefore delivery and 23 attended a CTCafter delivery. Similarly for the
third follow-up visit 104 (68.0%) of 153 women who received referral to a CTChad attended to a
CTC,72 attended before delivery and 32 attended after delivery. Finally, at the 4th follow-up visit,
123 (61.8%) of 199 women who reported receiving referral to a CTC had attended to a CTC,of
these, 74 attended to a CTCbefore delivery and 49 attended to a CTCafter delivery. As expected,
the number of women attending a CTCafter delivery increased from 8 at the 1st follow-up visit to
49 at the 4th follow-up visit.
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It is also important to note that 11 (5.9%) of 187 women who reported not receiving referral to
CTC at cohort recruitment, made a self referral to a CTC and attended a CTC before or after
dellverv". However, these women reported to have received a referral to a CTCat some point
during the follow-up visit, therefore, for these women referral was done after attending a CTC
and as a result we have more women attending a CTCbefore delivery during the follow-up visit
compared to the number at cohort recruitment. (This is because initially we only considered those
who reported to have received any referral (oral or written) from the health worker).
8.6.4 Proportion of women having a CD4count test done
During the cohort recruitment and at each follow-up visits, women who reported to have
attended to a CTCwere asked to show their CTCcard to the interviewer so as to record the
information on services that the woman received at a CTC.However, other women did not bring
their CTCcard at the maternity ward when they were admitted for delivery. Women were asked
to bring their CTCcard at the follow-up visit, but still some women were not able to bring their
CTCcards. Table 8-7 shows the number of women who reported attending a CTC;the number
who had a CTCcard and the number whose CD4count test results was shown in their CTCcard at
cohort recruitment and at the follow-up visit. Cumulatively, 94 women had CD4 test done and
among these, nine (9.6%) had a repeat CD4 test done and indicated on their CTCcard. Therefore,
for women with CD4 results at recruitment, this was shown as having had CD4 count at all
subsequent visits and most of them had one CD4test result on their CTCcards because they were
not yet eligible for a repeat test during the study period (l.e. they had had their first CD4 test for
less than six months)
During the cohort recruitment, 71 women had attended a CTC,36 women brought their CTCcard
at the maternity ward when they were admitted for delivery, of those, 30 (83.3%) had a CD4 test
done and indicated on a CTCcard (Table 8-7).
During the t", 2nd, 3rd and 4thfollow-up visits the information on CD4 count test were obtained for
63,74,79 and 101 women respectively. Of these, 42 (66.7%),48 (64.9%), 53 (67.1%) and 78
14 Ten attended a CTCbefore delivery and 1 attended after delivery; However, all of them reported being referred to a
CTCafter they had actually attended following a self referral.
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(77.2%) had CD4count test done and CD4counts were indicated on their CTCcards that were
reviewed during the r", 2nd, 3rd and 4thfollow-up visit respectively (Table 8-7)
Table 8-7 CD4count test done and indicated on a CTCcard
Visit
Total number Total number of CTC Total number with CD4 test
attended a CTC card seen (%) results (%)
Cohort recruitment 71 36 (50.7) 30 (83.3)
Month 1 follow-up 68 63 (92.6) 42 (66.7)
Month 2 follow-up 91 74 (81.3) 48 (64.9)
Month 3 follow-up 104 79 (76.0) 53 (67.1)
Month 4 follow-up 123 98 (79.7) 78 (79.6)
Among the 30, 42, 48,53 and 78 women who attended a CTCand who had a CD4 count test done
and indicated on the participants' CTCcards at cohort recruitment, 1st, 2nd, 3rd and 4thfollow-up
visits,S (16.7%), 10 (23.3%), 8 (16.7), 12 (22.2) and 18 (22.5%) women respectively had CD4count
of less than 200 cells/mm'. Among those 5, 10, 8, 12 and 18 women with CD4 less than
200cell.mm3 and whose CTCcard were seen during the respective visits, 3 (60.0%), 5 (50.0%), 4
(50.0%), 7 (58.3%) and 10 (55.6%) respectively were started on HAART(Table 8-8).
Table 8-8 CD4count less than 200 cells/mm3 and initiation to HAART
Total number with Total number CD4 Total number CD4 Total number
Visit CD4test results count >200 count S200 started on
(%) cells/mm" cells/mm" HAART(%)
Cohort recruitment 30 25 5 3 (60.0)
Month 1 follow-up 42 32 10 5 (50.0)
Month 2 follow-up 48 40 8 4 (50.0)
Month 3 follow-up 53 41 12 7 (58.3)
Month 4 follow-up 78 60 18 10 (55.6)
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8.7 Piot Fransenmodel of completion of referral and CTC attendance steps
Using the cohort data, a model was built up to show the fall-off at each step of the referral system
using women who tested HIV-positive for the first time during the current pregnancy and who
were seen at the 4thfollow-up visit. The use of women seen at the 4thfollow-up visit will allow for
the inclusion of women who have complete information up to the end of the study.
8.7.1 Selection of women to include in the model
Figure 8-1 shows the number of pregnant women who were seen during the 4thfollow up visit and
those who were lost to follow up (LTFU)before the 4thfollow up visit. In total 66 (21.5%) out of
310 who were identified as HIV-positive for the first time through PMTCTHIV screening were not
seen during the 4thfollow up visit, these included 39 women who prior to LTFUhad reported have
not received any referral to a CTCand 27 who had reported receiving referral to a CTC.Among 27
women who reported receiving referral to a CTCbefore LTFU, 10 had actually attended a CTC
before LTFU. However, what happened to these women after LTFU regarding their referral to a
CTCis not known, therefore all 66 women are excluded from this analysis.
For the 244 women who were seen at the end of the four month post delivery follow-up visit, 45
(18.4%) reported that they did not receive any referral to a CTCsince when they were tested up to
four month post delivery. These 45 women included 20 (8.3%) women out of 240 HIV-positive
women who tested HIV-positive for the first time when they attended the ANCduring or just after
the current pregnancy and 25 (35.7%) women out of 70 HIV-positive women who tested HIV-
positive for the first time at the maternity ward when they were admitted for delivery and tested
before or after delivery.
One hundred and ninety-nine (81.6%) of 244 women who were seen at the end of four month
follow up had been referred to a CTCbefore or after delivery. Among these 199 women, 123
(61.8%) reported to have attended a CTCby the end of the four month follow-up visit. However,
CTCcard for 13 (10.6%) women out of 123 who reported attending a CTCwere not seen for the
entire period of the study and therefore it was not known if they actually attended a CTCand
therefore these are removed from the denominator for women who had CD4count test done (Le.
the denominator will be 123-13=110 women whose CTCcard were seen)
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Seventy-eight (70.9%) women out of 110 whose CTCcards were seen at least once during the
follow-up visit had their CD4count test done and clearly indicate in their cards. Of these, 18 had a
CD4count of less or equal to 200 cell/mm" and 10 of them were started on HAARTbefore delivery
or within the four-month period post delivery.
Figure 8-1 Women with data up the fourth follow-up visit who are included in the Piot's
Fransenmodel
N
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Table 8-9 is the summary of Figure 8-1 above that explains the number and denominators for
each of the proportions that are in the model.
Table 8-9 Number and proportion for the Piot's Fransen model of referral and attendance to a crc
Service Description of the denominator
Number (%)
OverallNumber receiving the
proportionservice
244 199(81.6) ~(81.6%)
244
199 110 (55.3) ~(45.1%)
244
Referral to eTC All women who were seen at 4
1 follow-up
visit
Attend to a eTC All women seen at 4
1 follow up visit and
referred to a eTC
eD4 count test Women attended a eTCand who had a eTC
card 110 78 (70.9) ~(34.6%)231done
i Assuming that equal proportion of women who did not attend a CTC would have had CD4 count <200 as those who attended a CTC
then if all 244 women had attended a eTC and had a CD4 test done, 56 (23.1 %) of all women would have been eligible to start HAART
Women with eD4 count less than 200
Started on HAART 18 10 (55.6) .!£ (17.9%)1cell/mm" 56
Figure 8-2 shows the model of referral and uptake of care among HIV-positive women who are
identified through PMTCT screening. This figure is a summary of the information described in
Figure 8-1 and Table 8-9. Overall, 17.9% of HIV-positive women identified through PMTCTwere
referred to a CTCand received care for their own health before delivery or within the four months
post-partum period. (Le. 17.9% of HIV-positive women in our cohort who tested HIV-positive
during the PMTCTscreening were started on HAARTduring pregnancy or within 4 months post-
delivery)
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Figure 8-2 Proportion of HIV-positive women identified through PMTCT who were referred and
attended to CTC
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B.B Discussion
8.8.1 Key findings from the health worker interviews
From the interviews, we found that a high proportion of health workers participating in the
implementation of PMTer received training in basic components of PMTer. However, this finding
was not consistent at all the facilities participating in the study. More health workers at
Makongoro RCHclinic reported to have received training in PMTer basic components compared
to health workers at NDH and Igoma RCHclinics. Makongoro clinic was one of the five national
PMTCT pilot sites in 2000 and a pilot site for the infant diagnosis procedure that was done by
ICAP TZ in 2006. These two pilot studies increased the exposure to PMTer training among staff
at Makongoro clinic and it might explain the observed differences.
The majority of health workers were aware of the HIV referral system. Nevertheless there were
misunderstandings concerning when women identified through PMTer should be referred to ere.
This resulted in a missed opportunity for referral during pregnancy to a erc among all HIV-
positive women who attended the ANCat NDH. This finding suggests a need for sustained training
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of health workers and that close supervision is needed with checks on the specific information
that is being given by the health workers to women who test HIV-positive during pregnancy. In
addition, there is a need to standardize important messages that are delivered by health workers
during post-test HIV counselling to address interventions available to women after a positive HIV
test.
Health workers pointed out some weaknesses of the current referral system and a need for a
system that will allow coordination between ANCs and CTCsto minimize the number of women
who fail to attend a CTC before delivery. Health workers suggested there was a need for a
designated CTCfor pregnant women to make it possible for them to be assessedfor eligibility to
ARV treatment before delivery, which is not always possible when attending currently
overbooked CTCs.
8.8.2 Keyfindingsfrom the cohort study
8.8.2.1 Referral to etc
Only 51.3% of HIV-positive women who were tested at ANC during the current pregnancy were
referred to a CTCbefore delivery. The fact that some health workers did not know that women
should be referred to a CTCas soon as possible after being given their HIV results probably
contributed to this low referral rate. Refresher training among health workers is of importance as
some might not be aware of the new development in the management of HIV during pregnancy
that has been happening recently.
None of the HIV-positive women tested at the maternity ward received a referral to a CTCbefore
discharge from the hospital after delivery. At discharge all HIV-positive women who had babies
were asked to bring them for infant diagnosis after 28 days (4 weeks). Only 40.0% of women
tested at the maternity ward reported to have received referral when they attended to the under-
five clinic or when they went back to the hospital maternity wards for infant diagnosis. This
means that women who did not have an opportunity to come again to the maternity ward for the
infant diagnosis (one month after delivery) and those who did not attend under-five clinics that
offer on-going counselling to HIV-positive women did not get referral to a CTC.Again this finding
suggests a need of strengthening PMTCT in the maternity suites to allow for enough time for
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counselling so that HIV-positive women receives information on available important interventions
regarding their HIV-positive status before discharge from the labour ward.
8.8.2.2 Attendance at a eTe
Another fall off in the model of completion of referral and CTC attendance occurs between
referral and attendance at the CTC.This may be due to individual factors such as fear of disclosing
their HIV status and fear about using ARV. Other reasons for this were mentioned by health
workers. These included the perceived lack of coordination between ANC clinics and CTCand also
the fact that women have to go through all the CTC procedures like other non-pregnant HIV-
positive individuals.
Interestingly for those who attended a CTC,about 70% had their CD4 test done before or after
delivery. This is a good sign of service availability for those who attend a CTC.However, this needs
to be backed-up with a strong system that will inform HIV-positive women on the importance of
referral uptake and a system that will help them get to a CTC and benefit from the available
services. This could be achieved by promoting a supermarket approach in the health facilities that
will allow having all the services under one roof, or where this is not possible, then an
accompanied referral. Only 30.0% of HIV-positive women identified through PMTCTwho were
assessed and found to be eligible for HAART were started on HAART before delivery. This
proportion might be improved by increasing the number of women who access CTCservices as
soon as possible after the HIV-positive test as suggested above.
Overall, a small proportion (17.9%) of HIV pregnant women identified through PMTCT was
successfully taken through the referral system to attend an adult HIV care and treatment centre.
This finding prompts an urgent need for a more integrated system that will allow HIV-positive
women to receive the services that they require for their own health as soon as possible after
being identified as HIV-positive.
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CHAPTER 9: FAMILY PLANNING UPTAKE AMONG HIV-POSITIVE WOMEN
9.1 Introduction
Family planning (FP) use among HIV-positive women can help to prevent future unwanted
pregnancies and thus reduce the number of HIV-infected babies. It is recommended in the
national PMTCTguidelines[37) that HIV-positive women should be counseled on FPuse during the
postpartum period. This chapter documents the use of FPamong HIV-positive women prior to the
current pregnancy, the proportion of HIV-positive women receiving counseling on FPuse and the
proportion of HIV-positive women using FPafter delivery. The role FPcounseling on uptake of FP
after delivery was also investigated. For the purpose of this study, the FP methods that were
considered included oral pills, injectable hormonal contraception, male or female condoms,
calendar or safe period, the intrauterine contraceptive device (IUCD), traditional medicines,
withdrawal method and norplantor other implants.
Data were obtained from 403 HIV-positive women enrolled in a prospective cohort study at
admission for delivery at two large hospitals in Mwanza City. These women had tested HIV-
positive for the first time either before their current pregnancies or during the current
pregnancies at the antenatal care (ANe) clinic or at the maternity ward when they were admitted
and tested before or after delivery.
Information on whether or not the current pregnancy was planned and if there was use of
contraceptives prior to this current pregnancy was collected from all participants during the
cohort recruitment. This information was used to estimate the unmet need for FPuse among HIV-
positive women. Unmet need for FP use was defined as the proportion of HIV-positive women
who were not intending to become pregnant and who were not using any contraception prior to
this current pregnancy. In addition, information collected during the cohort recruitment was used
to determine the proportion of HIV-positive women who experienced FPmethod failure (Le. the
proportion of women who did not intend to become pregnant but became pregnant even though
they reported using some form of contraceptive prior to the current pregnancy).
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FP use prior to the current pregnancy, unmet need for FP use and FP method failure was
compared among women who tested HIV-positive prior to the current pregnancy and those who
tested for HIV during the current pregnancy.
Women recruited into the cohort were followed up monthly for 4 months post-delivery. At each
follow up visit women were asked if they had ever received FP counselling after delivery and if
they were currently using any form of FP method. If so, women were asked to describe all FP
methods that they had used prior to the current pregnancy and after delivery. Information was
also collected on reasons for not using FPmethods. Factors associated with failure to uptake FP
post-partum were determined.
9.2 Family planning useprior to the current pregnancy
Of the 403 HIV-positive women recruited in a cohort study, 208 (51.6%) reported to had ever
used FP before, out of whom, 189 (90.9%) reported using FP prior to this current pregnancy.
Twenty-nine (15.4%) women reported using more than one FP methods prior to this current
pregnancy.
9.2.1 Proportion of HIV-positlve women using FPprior to the current pregnancy
A higher proportion of HIV-positive women tested before the current pregnancy reported to have
had ever used FP methods compared to women who tested HIV-positive during the current
pregnancy (p=0.033). Differences in the use of FP prior to the current pregnancy between HIV-
positive women who tested before the current pregnancy and those who tested during the
current pregnancy were non-significant (Table 9-1).
At cohort recruitment, 342 (84.9%) of 403 HIV-positive women reported an intention to use FP
after delivery. These included 151 women out of 195 (77.4%) who reported to have never used FP
before. Of these 151 women, 118 (74.2%) were women who tested HIV-positive during the
current pregnancy and 33 (91.7%) were women who tested HIV-positive before the current
pregnancy (Table 9-1). A significantly high proportion of women who tested for HIV before the
current pregnancy reported an intention to use FPmethods after delivery compared to women
who tested for HIV during the current pregnancy (p=0.024).
159
RB1010
Table 9-1 Family planning methods used prior to the current pregnancy by timing of the
HIV test.
Timing of the HIV-positive test
Before current During current
Total pregnancy (n=93) pregnancy (n=310)
Variables N=403 n % n % P
Ever used FP
Yes 208 57 61.3 151 48.7
No 195 36
0.033
38.7 159 2l.3
Used FP prior to the current
pregnancy'
Yes 189 49 86.0 140 92.7
No 19 8
0.132
14.0 11 7.3
Intending to use FPafter deliverl
Yes 151 33 91.7 118 74.2
44 3
0.024
No 8.3 41 25.8
1Only those reporting to have ever used FP before (n=208)
20nly those who have never used FP before (n=195)
9.2.2 Family planning methods used prior to the current pregnancy
The most frequent FP method that was used by HIV-positive women prior to the current
pregnancy was injectable hormonal contraception (Depo-Provera (medroxyprogesterone
acetate), which contains enough Progestin to prevent pregnancy for three months). This method
was reported to have been used by 132 (69.8%), followed by oral contraceptive pills reported by
57 (30.2%) of HIV-positive women. Use of condoms was reported by 16 (8.5%) of the HIV-positive
women. Other methods including IUCD, implant, traditional methods, the withdrawal methods
and use of safe days were reported by 16 (8.5%) women.
Figure 9-1 shows the proportion of women who reported using various FP methods among
women who were tested for HIV before the current pregnancy and those who were tested for HIV
during the current pregnancy. A similar proportion of women who tested for HIV before the
current pregnancy and those who tested during the current pregnancy reported using injectable
contraception (71.4% vs. 69.3%; p=0.778), pills (28.6% vs. 30.7%; p=0.778) and other methods
(8.2% vs. 8.6%; p=0.833).
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Of the 16 HIV-positive women who reported to have used condoms as a FPmethod prior to the
current pregnancy, 10 (62.5%) were women who tested HIV-positive before the current
pregnancy. Women who tested HIV-positive prior to the current pregnancy were more likely to
report to have used condoms as a FP method compared to women who tested HIV-positive
during the current pregnancy (20.4%vs.4.3%; p<O.OOl)
9.2.3 Unmet need for FP use among HIV-positive women
Overall, 201 (49.9%) of all HIV-positive women recruited into the cohort study reported that the
current pregnancy was not intended/planned. A significantly higher proportion of women who
were tested for HIV before the current pregnancy reported that the current pregnancy was not
intended compared to women who were tested for HIV during the current pregnancy (81.7%
vs.40.3%; p<O.OOl)(Table 9-2).
Among 201 HIV-positive women who reported unintended pregnancy 99 (49.3%) were not using
any form of FPmethod prior to the current pregnancy. These included 58 (46.4%) of 125 women
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who tested HIV-positive during the current pregnancy and 41 (53.9%) of 76 women who were
tested HIV-positive before the current pregnancy.
Although a higher proportion of HIV-positive women who were tested for HIV before the current
pregnancy reported an unintended pregnancy compared to women who were tested for HIV
during the current pregnancy (81.7% vs. 40.3%, p<O.OOl), there was no difference in the
proportion of unmet need for FPuse among the 2 groups (46.4% vs. 53.9%; p;:;0.3).
Table 9-2 Unmet need for FP use and fP methods failure among HIV-positive women by
timing of the HIV test.
Timing ofthe HIV-positive test
Total Before current During current
pregnancy (n;:;93) pregnancy (n;:;310)
Variables N;:;403 n % n % p
Pregnancy was intended
Yes 202 17 18.3 185 59.7
<0.001
No 201 76 81.7 125 40.3
Unmet need for FPuse1,2 99 41 53.9 58 46.4 0.3
FPmethod failure" 102 35 46.1 67 53.6 0.3
'Denominator is the number of women reporting unintended current pregnancy (n=201; 76 tested before pregnancy and 125 tested
during current pregnancy)
2Women who were not intending to become pregnant and who were not using any contraception prior to this pregnancy.
'Denominator is the number of women reporting unintended current pregnancy (Women who did not intend to become pregnant
and who reported using contraceptive prior to the current pregnancy)
9.2.4 family planning method failure among HIV-positive women
Ofthe 210 HIV-positive women who reported unintended pregnancies, 102 (50.7%) reported that
they were using contraceptives for FP before the current pregnancy and these women were
considered to have experienced FP method failure. Among 102 who experienced FP method
failure, 67 (53.6) had tested HIV-positive for the first time during the current pregnancy and 35
(46.1%) had tested HIV-positive prior to the current pregnancy (p;:;0.3).
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FPmethod failure occurred among 32/59 (56.1%) women who reported using oral pills, 72/132
(54.5%) women who reported using injectable contraception, 11/16 (68.6%) women who
reported using condoms and 6/12 (50.0%) of women who reported using other contraception
methods.
9.3 Family planning counseling and use among HIV-positive women after
delivery
Overall, 367 (91.1%) of the 403 HIV-positive women in the cohort were seen at least once during
the four follow up visits post-delivery. Of these, 287 (78.2%) reported receiving counseling on FP
after delivery and within the four months after delivery. Of the 403 women who were recruited
into the cohort study, 360 (89.3%), 330 (81.9%), 316 (78.4%) and 328 (81.4%) were seen at first,
second, third and fourth monthly follow-up visits respectively.
9.3.1 Reported FPcounseling and use during follow up visits
Table 9-3 shows the number and proportion of HIV-positive women seen during each follow-up
visit who reported receiving counseling on FPuse and who were using FPafter delivery. Women
were asked if there were using any family planning method regardless of whether they received
counseling on FPuse after delivery or not.
During the first month follow up visit, 360 HIV-positive women were seen, of those 217 (60.7%)
reported to have been counselled on FPuse after detlverv" and 19 (5.3%) of women seen one
month post-delivery reported the use of FP.Of the 19 women reporting the use of FP, 10 (52.6%)
were using condoms and one woman reported using condom and another FP method (dual
protection).
Three hundred and thirty women were seen at two months post-delivery, of whom 242 (73.3%)
reported to have received counseling on FPuse and 70 (21.1%) reported that they were using FP.
Among 70 women reporting using FP,44 (62.9%) reported using condoms and only one woman
reported using condom and another FPmethod (Table 9-3).
15 This included whether they were counselled at the maternity ward after delivery before discharge or if they received counselling on
FP use when they visited any of the heaith facilities for services regarding their HIV-positive status Le. CTC's, maternity ward/under-five
clinic for infant diagnosis etc.
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Table 9-3 Post-delivery FPcounselling and uptake among HIV-positive women.
Follow up visit
t-month 2-months 3-months 4-months
# of women seen at each visit (N) 360 330 316 328
n % n % n % n %
Counseling on FP
Yes 217 60.3 242 73.3 237 75.0 259 79.0
No 143 39.7 88 26.7 79 25.0 69 21.0
Using Fpl
Yes 19 5.3 70 21.2 103 32.6 140 42.7
No 341 94.7 260 78.8 213 67.4 188 57.3
1All women regardless of whether they were counselled or not
Similarly, at the third month follow-up visit, 316 women were seen, 237 (75.0%) reported
receiving counseling on FPuse but only 103 of 316 (32.6%) reported using FP.Among these 103
women who reported the use of FP,66 (64.1%) reported using condoms. Only 2 women reported
using condoms and another FPmethod (Table 9-4).
In total 328 women were seen during the last follow-up visit (four months post-delivery). Of
these, 259 (79.0%) reported receiving counseling on FP use and 140 (42.7%) reported using FP.
Eighty-eight (62.9%) of those reporting using FPwere using condom, and 6 women reported using
condom and another method.
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Table 9-4 FP methods that were used by HIV-positive women after delivery.
Follow up visit
# of women seen at each
1-month 2-months 3-months 4-months
visit (N) 360 330 316 328
n % n % n % n %
Women using FP 19 5.3 70 21.2 103 32.6 140 42.7
FPmethods'
Oral pills 4 21.1 8 11.4 9 8.7 14 10.0
Injection 3 15.8 13 18.6 23 22.3 32 22.9
Condoms 10 52.6 44 62.9 66 64.1 88 62.9
Others! 4 21.1 5 7.1 7 6.8 12 8.6
Using dual protection" 1 5.3 1 1.4 2 1.9 6 4.3
Denominator is women reporting using FP and some women mentioned more than one FP method.
2 Other FPmethods included IUCD, implants, traditional methods, withdrawal, safe periods and sterilization.
3 Using condoms and another FP method.
9.3.2 Reasons for not using FP after delivery among HIV-positive women
Reasonsfor not using FPwere investigated during the interview at each visit. The majority of these
women indicated that they had not resumed sexual intercourse after delivery.
Table 9-5 shows the number and proportion of women who reported various reasons for not
using FPmethods post-delivery. These included the belief that they could not get pregnant while
breastfeeding, a need to discuss FP with their husbands and that their husbands had refused
them to use FP. A small proportion (3-4%) of those not using contraception believed that
contraception was not safe and could cause cancer and infertility
165
RB2010
Table 9-5 Reasons for not using FP
Follow up visit
# of women seen at each visit (N)
1-month
360
2-months 3-months
330 316
4-months
328
n % n % n % n %
Number of women not using FPat
each visit 341 94.7 259 78.5 213 67.4 188 57.3
Re.~~~_~<?~_~~~ _~~~~~_ ~~ _~~~~_<?9_~~ __
--~~;:,~~:~~~~;;~~_~~~~~I~-------~ -~----~ :~----~~~._~_ ~~:~ _ _~:~__
Cannot get pregnant while 17 28 26 28
._~!~~~~f~_~~j~_lt ~:~ ~~._~ ~~:~ ~_~:~_.
Need to discuss with the
husband
11 3.2 8 3.1 11 5.2 4 2.1
Husband do not wish their
5 1.5 6 2.3 5 2.3 6 3.2wives to use FP
......... -oO" _ __ __ __ __ __ .. __ .. __ __ .
Wanted more children 2 0.6 4 1.5 4 1.9 7 3.7
Believed that contraception is
not safe
4 1.8 3 1.2 4 1.9 3 1.6
Other reason 14 4.1 17 6.6 13 6.1 13 6.9
Women were reporting more than one reason
9.4 Effect of FPcounselling on FPuptake 4-months post delivery
Three hundred and twenty-eight HIV-positive women who were recruited in the cohort study
were seen during the follow-up visit four months post-delivery. Of these 259 (79.0%) reported
receiving counselling on FPuse post-delivery.
9.4.1 Association between FPcounselling and FPuptake after delivery
Table 9-6 shows the association between failure to use FP in 328 women four months post
delivery and FPcounselling adjusting for other socio-demographic factors. The variables that were
tested for association with FP uptake on a univariable analysis included timing of the HIV test,
number of pregnancies, education level, age, marital status and disclosure of the HIV status to the
husband/partner.
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Table 9-6 Association of failure to use FP with counselling provision and selected socio-
demographic factors
Not usingFP
Total (n=188) Univariate analysis Adjusted analysis
N=328 n % OR 95% Cl P ORi 95%CI P
Received FP <0.001
Yes 259 129 49.8 1 1
<0.001
No 69 59 85.5 5.9 2.9-12.1 6.0 2.8-12.9
Timing of the HIV test 0.04
Prior this pregnancy 84 41 48.8 1 0.067 1
During this QregnanQi 244 147 60.3 1.6 1.0-2.6 1.9 1.0-3.4
Parity 0.02
Primigravidae 57 18 31.6 1 1
0.059
Multigravidae 217 122 45.0 1.7 1.0-3.3 2.7 1.2-6.3
Education level 0.27
Primary/No 276 157 56.9 1 1
education 0.714
Secondary 52 31 59.6 0.9 0.5-1.6 1.5 0.7-3.0
Age groups 0.02
< 20 years 18 8 44.4 1 1
20-24 years 70 31 44.3 1.0 0.3-2.8 0.6 0.2-1.9
25-29 years 100 50 50.0 1.3 0.5-3.4 0.3 0.1-1.2
30-34 years 71 29 40.9 0.9 0.3-2.4 0.315 0.2 0.1-0.9
~ 35 years 64 20 31.5 0.5 0.2-1.7 0.1 0.0-0.6
Age not known 6 2 40.0 0.8 0.1-6.3 0.3 0.0-3.3
HIV status disclosed 0.45
to husband
Yes 198 103 52.0 1 10.017
No 130 85 63.4 1.7 1.1-2.7 1.2 0.7-2.1
Marital status 0.008
Married 234 121 51.7 1 10.001
other' 94 67 71.3 2.3 1.4-3.9 2.2 1.2-3.9
IAdjusted for age, timing of the HIV test, parity, education level, marital status and whether the women disclosed her HIV status to the
husband/partner
2 These included women who were single (n=40), divorce (n=38) and widowed (n=16)
On a univariate analysis it was found that failure to use FP4 months after delivery was associated
with not receiving FPcounselling after delivery, (OR5.9; 95%CI 2.9-12.1), a woman not disclosing
her HIV status to the husband/partner (OR1.7; 95% CI1.1-2.7) and being unmarried (OR2.3; 95%
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Cl 1.4-3.9}. Other variables that showed a significant difference at p<O.l that were retained for
the multlvarlable analysis included timing of the HIV test, number of pregnancies and woman's
age.
After adjusting for all variable included in the multivariate model HIV-positive women who did not
receive any counselling on FPuse 4 months after delivery had six fold higher odds of not using FP
after delivery compared to those who received counselling on FP use within 4 months after
delivery.
Furthermore, failure to use FP 4-months post-delivery among HIV-positive women was
significantly associated with testing HIV-positive for the first time during that pregnancy and
having more than one pregnancy.
Although age was not significantly associated with failure to use FP4 months after delivery on a
univariate analysis, when adjusted for other variables it was found that younger women (aged<20
years) were more likely to use FPcompared to older women. Unmarried women were at a 2.3
times odds of failure to use FPwhen compared with married women.
9.5 Discussion
The findings that HIV-positive women who were tested for HIV before the current pregnancy
were more likely to have ever used FPcompared to women who were tested for HIV during the
current pregnancy may be because women may prefer to delay or stop childbearing if they know
they are HIV-positive.
We found that hormonal FP methods were used more commonly than barrier methods in the
cohort. Injectables contraceptive methods allow women the opportunity to receive contraception
without telling their partners. Injectable contraceptives are therefore useful and give an
opportunity to women who do not want more children while their husbands think contrary. In
the era of HIV, it is recommended that HIV-positive women should be counselled and encouraged
to use dual protection. Although there was an increase in condom use among HIV-positive
women 4 months after delivery (26.8%) when compared with condom use prior to the current
pregnancy (8.5%), overall condom use was relatively low. This prompts an urgent need to address
168
RB1010
the reluctance of condom use among HIV-positive women and their partners. FP counselling
among HIV-positive women should work towards increasing condom acceptability and encourage
women to see condoms as a means of preventing pregnancy while protecting re-infection with
different strains or different types of HIV and/or provide protection to HIV-negative partners.
A high proportion (49.9%) of HIV-positive women in this study reported an unintended pregnancy,
and therefore there was a high rate of unmet need for family planning and/or a high rate of
family planning method failure. The findings that a higher proportion of HIV-positive women who
were tested for HIV before delivery reported unwanted pregnancies compared to HIV-positive
women who were tested during the current pregnancy (81.7% vs. 40.3%) was expected due to the
reality explained above that women who knew that they were HIV-positive may prefer to delay or
stop childbearing.
Unmet need for family planning use and FP method failure in HIV-positive women who were
tested before the current pregnancy was as high as in HIV-positive women who were tested
during the current pregnancy (that is, there was no difference between women who knew that
they were HIV-positive before becoming pregnant with those who did not know their HIV status
before pregnancy). This indicates an urgent need of counselling on FPuse to both HIV-negative
and HIV-positive women by providing tailored information to every woman, so that the woman
can make an informed choice about her future reproductive needs.
A high proportion of women reported an intention to use FP after delivery, however, the large
gap between intentions to use FP(84.9%) at cohort recruitment and to FPuse four months post-
delivery (42.7%) suggests that the reported willingness to use FPmay not always be explained in
action. This might possibly be due to courtesy bias from respondents at cohort recruitment (Le.
women telling the interviewer something she knows that he/she would like to hear). However,
the fact that only 81% of our cohort members attended the 4 months follow up visit should not
be ignored, since women who were seen may not be representative of the whole cohort and
therefore some biases in these findings.
HIV-positive women who did not receive counseling in FP use after delivery weremore likely to
fail to use FP4 months after delivery compared to HIV-positive women who received counseling
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on FP use. This finding indicates the importance of strengthening FP counseling among HIV-
positive women in order to remove barriers to FPuse among women who have ever used family
planning. Similarly, it is important to discuss reasons for not using FP among women who have
never used FP, identify barriers to FPuse and highlight the importance of FPutilization especial
among HIV-positive women.
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CHAPTER10: INTEGRATION OF PMTCT SERVICES AND MATERNAL SYPHILIS
SCREENINGAND TREATMENT
10.1 Introduction
The introduction of prevention of mother-to-child transmission (PMTCT) of HIV in the antenatal
care (ANC) was considered an excellent opportunity to strengthen other maternal health related
interventions that are implemented in ANC such as maternal syphilis screening and treatment,
family planning and malaria preventions. Furthermore, the epidemiology and transmission of HIV
and syphilis are closely correlated and therefore integration of services to prevent HIV during
pregnancy with maternal syphilis and screening services would be cost-efficient by saving
providers' and clients' time and thus providing the potential to increase uptake of the
interventions and therefore leading to improved maternal and reproductive health.
Ideally, integration results in a service that is more efficient and user-friendly through, the
provision of an integrated package of services provided by one provider, at one point of delivery.
According to Hardee [114], Integration can occur at several levels. At the policy level, integration
could be in the form of policies that are formulated to guide the delivery of services for example
in this case, guideline on how to include maternal syphilis screening and treatment in PMTCT
services and vice verse. At the health facility level, integration may also take various forms and it
may require training of health workers in multiple skills to enable them to deliver all the services
within the same facility using a "supermarket approach" whereby services are offered by the
same provider in the same unit or in different units but within the same building [114].
This chapter documents the extent of integration of PMTCT and maternal syphilis screening
programmes at the facility level in three reproductive and child health (RCH) clinics and two
maternity wards in Mwanza city. Data presented in this chapter were obtained from the health
worker interviews, from the observation of the activities and client flow at the ANC clinics and
from the observation of the ANC HIV health education sessions. Furthermore, the field notes
taken by researchers on their experience in the maternity ward regarding the care of women
admitted for delivery and who were not screened for syphilis during pregnancy were presented in
this chapter.
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10.2 Overview 0/ the health worker interviews
Methodology for the health worker interviews was described in Chapter 4, section 5. As part of
the interviews, we collected information on formal and informal training received by the health
workers as well as departments or section within the facilities where the health workers were
working.
As mentioned above, in order to effectively integrate PMTCTand maternal syphilis screening and
treatment services, there is a need for health workers, in the ANCand in the maternity wards who
are trained in skills required to implement the key components of the two programs (Le. health
workers trained in PMTCTimplementation, syndromic management of STD,syphilis diagnosis and
management of a positive syphilis blood test). Therefore, for the purpose of this chapter, the
proportions of health workers who reported receiving training in different key PMTCT
components, syndromic management of STls and syphilis testing and who were working in the
ANC and in the maternity wards (labour rooms or postpartum wards) are presented. At
Nyamagana district hospital (NOH) interviews were conducted with staff who reported working in
the ANC clinic aswell as staff who reported working in the maternity ward.
10.2.1 Findings from the health worker interviews
In total, 89 health workers were interviewed at Bugando Medical Centre (BMC), Sekou-Toure
Regional Hospital (STRH),Nyamagana District Hospital (NOH), Makongoro Regional RCHclinic and
Igoma Health Centre. Overall, 76 (85.4%) reported that they were working in the ANC or in the
maternity wards (labour rooms or postpartum wards), 61 (80.3%) in the maternity wards (23 at
BMC, 33 at STRHand 5 at NOH) and 15 (19.7%) in the ANC clinics (six at Makongoro, three at NOH
and six at Igoma health Centre) (Table 10-1).
In total, 59 (77.6%) of 61 health workers at the maternity ward and ANC reported receiving some
training in PMTCT. Forty-three (56.6%) health workers at the maternity ward and ANC reported
receiving training in HIV testing, 40 (52.6%) reported receiving training in voluntary counselling
and testing (VCT) for PMTCTand 29 (38.2%) reported receiving training in the provision of ARV
prophylaxis for PMTCT.
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Also, 32 (42.1%) reported receiving training in infant feeding counselling for HIV-positive
women, 25 (32.9%) reported receiving training in optimal obstetric care, 24 (31.6%) reported
receiving training in PMTCT record keeping and 35 (46.1%) reported to have received training
in the national PMTCTguidelines of 2007 (Table 10-1).
Training in syphilis testing was reported by 22 (28.9%) of the 76 health workers who were
working in the ANC and in the maternity ward (Table 10-1). Of these, 15 (24.6%) were health
workers who reported working in the maternity ward and seven (46.7%) were health workers
who reported working in the ANC clinics (Table 10-1).
Only one quarter (25.0%) of health workers in the maternity ward and in the ANC reported
receiving training in both PMTCT and syphilis testing. Nine (39.1%) and three (9.1%) health
workers in the maternity wards at BMC and STRH respectively reported receiving some
training in PMTCT and syphilis testing. There was no health worker who was trained in both
PMTCT and syphilis testing in the maternity ward at NOH. In the ANC, two (33.3%), one
(33.3%) and four (66.7%) of health workers reported receiving training in PMTCT and syphilis
testing at Makongoro, NOH and Igoma health centre respectively. Health workers in the ANC
were more likely to report receiving training in both PMTCT and syphilis testing compared to
health workers in the maternity ward, though the total number interviewed were relatively
small and this difference was not statistically significant.
10.3 Overview 0/ the observation 0/ the /Iow 0/ activities within ANC clinics
Observation of the flow of activities within the ANC was described in chapter 4, section 3.2.1.
Data collected provided information on different stations in the ANC where pregnant women
attending ANC for first time during the current pregnancy receive different services regarding
their pregnancy, the average time (in min) the woman had to wait before receiving different
services, the average time (in minutes) the woman spent receiving different services at each
station and the distance covered (in metres) from one station to another within the clinic
while accessing different services.
10.3.1 Findings from the observation of the clinic flow
At each of the ANC clinics two observations were conducted one on a Monday when the ANC
clinics are very busy and one on a Thursday when the clinics are less busy. Findings that
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summarized in boxes for observation on busy days and findings that are presented in the
pictorial format are for the less busy days. These findings are presented differently for each of
the three ANC facilities that participated in this study.
10.3.1.1 Flow of ANC clinic activities at NDH
Box 10-1 Observation case study I-First day at NOH ANC clinic
Aisha arrived at the clinic on a Monday morning at 08.15 hrs. She waited for the
services in the waiting area (which is also used for the health education). The nurse
arrived at this station at around 11.15 hrs. The nurse introduced herself and gave a
short talk on general health including HIV and PMTCT for 15 minutes. After the
talk, Aisha waited for 20 minutes and at 11.50 hrs, Aisha entered the examination
room and exited the examination room at 12.00 hrs. Aisha then waited at the
waiting area for 50 minutes before she was called in the second room where the
blood sample for RPRand for an HIV test was taken. Aisha came out of this room at
12.55 hrs and waited on a bench at the waiting area until she was called back for
her syphilis and HIV results at 13.25 hrs. She came out of the counselling room at
around 13.40 hrs and she went to the waiting area for the tetanus toxoid (TI)
vaccination, she waited on a bench for 5 min then she was called for the
vaccination and she came out of the vaccination room at 13.50 hrs. Overall, she
spent 335 minutes at the clinic, 285 minutes (85%) waiting for the services and 50
minutes (15%) having the services
In Box 10-1 which is presenting the flow of the clinic activities of day 1 (Monday) at NOH. It
was found that Aisha (not real name) was in the clinic for 5 hours and 35 minutes. She waited
for 180 minutes (3hours), before receiving any service. The waiting time between services
ranged between 5 minutes to 50 minutes (this excludes the waiting time before the initial
contact with the health worker), and the total waiting time after the first contact with the
health worker was 105 minutes. Only 50 minutes was used having the health education and
other clinical contact with the nurse, this ranged between 5 to 15 minutes per service contact.
RB20JO
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Figure 10-1 shows the movement of Julia at NOH ANC on day 2 (Thursday), a less busy day,
Julia was in the clinic for 4 hours and 35 minutes. She waited for 135 minutes (2 hours and 45
minutes) before receiving any service. After the first contact with the health worker, the
waiting time between services ranged between 5 minutes to 30 minutes, The total time that
Julia spent waiting for different services in the clinic was 75 minutes. The total time that Julia
spent accessing different services was 65 minutes and this ranged between 5 to 30 minutes
per service contact. During the movement from one station to another in order to access
different services at the clinic, Julia covered a distance of 107 meters (O,lkm),
Figure 10-1 Client movement at NOH ANC clinic - first ANC visit during the current pregnancy
135 min
~
I Entry ANC education
(General and PMTCT) (30 min)
• ~ II I
W I I0 I I
3 I 10m 14m IS' I I
I .... I
I 0 I
3 w0
Examination room (10 min) S' 3 Vaccination
:::l (5 min),.
Blood sample for the HIV &
5min ,,,
syphilis test (5 min) ,, 35 m
l Post-HIV test counselling (15 min) r
Key: For figures 10-1 to 10-3, the numbers on the solid arrows indicate the average waiting times
(minutes), the number on the dashed arrows indicates the distance from one station to another in
meters and the numbers in the boxes indicates the time spent at each station (minutes)
Overall, women at both days experienced longer waiting hours before being seen by the
health worker and the reasons for this phenomenon was not clear.
10.3,1.2 Flow of ANC activities at Makongoro RCH
Box 10-2 presents the observation of the clinic flow at Makongoro on day 1 (Monday). Mwasi
was in the clinic for 4 hours and 10 minutes. She waited for 20 minutes before the start of the
clinic activities. However, between the services she had long waiting times that ranged
between 7 minutes to 60 minutes. The total waiting time after the first contact with the
health worker was 187 minutes. The total time that the woman spent accessing different
services was 73 minutes and this ranged between 3 to 25 minutes per service contact.
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Box 10-2 Observation case study 2-First day at Makongoro ANC clinic
Mwasi arrived at the clinic on a Monday morning at OB.10 hrs. The general health
education started at OB.30hrs and lasted for 23 minutes. After the health education
talk Mwasi waited for 30 minutes before she was called to the registration table
where she was given the ANC card and her details were documented. After the
registration, Mwasi was sent to the examination room. Both registration and
examination lasted for 7 minutes. Mwasi was then sent to the laboratory. She waited
at the laboratory waiting area for 40 minutes before she was called into the room
where a blood sample was taken. She was in the laboratory for 5 minutes. From the
laboratory she went straight to the PMTCT room 1 for the ANC HIV education (group
counselling), Mwasi sat in the room for 1 hour waiting for the session to start. The
session started at 11.15 hrs. The ANC HIV education lasted for 25 minutes. Mwasi sat
in the PMCTCwaiting area for 50 minutes. Then she was called into PMTCT room 2 for
individual HIV post-test counselling. She spent 10 minutes in the PMTCT room 2. After
the HIV post-test counselling Mwasi went to the vaccination room, located outside
the main building. She waited for the service there for 7 minutes, when she entered a
room she spent 3 minutes and she left the ANC facility at 12.50. In total, she spent
2BO minutes at the clinic, 207 minutes (74%) waiting for the services and 73 minute
(26%) receiving various services
Figure 10-2 Client movement at Makongoro ANC clinic - first ANC visit during the
current pregnancy
Vaccination
(3 min)
212 m
PMTCTroom 2
HIV post-test
counselling (5 min)
Examination
room
(5 min)
PMTCTroom 1
10m
30 min 20min
General health education
Registration
Measurements
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Figure 10-2 shows the movement of Maria at Makongoro ANC on day 2 (Thursday). Maria was
in the clinic for about 3 hours. She waited for 30 minutes before receiving any service. The
waiting time between services ranged between 0 minutes to 30 minutes. The total time that
Maria spent waiting for different services in the clinic was 80 minutes. The total time that
Maria spent accessing different services was 68 minutes and this ranged between 5 to 30
minutes. Moving from one station to another in the clinic while accessing different services
Maria covered a distance of 354 meters (0.35km).
Women attending at Makongoro had longer waiting times between the laboratory services
and the PMTCT group counselling session and this is because all women were supposed to
have their blood sample taken before the PMTCTgroup counselling session could start.
10.3.1.3 Flow 0/ANC activities at Igoma RCHclinic
Box 10-3 presents the flow of the clinic activities of day 1 at Igoma RCHclinic. The woman was
in the clinic for 4 hours and 15 minutes. She waited for 45 minutes before receiving any
service. The waiting time between services ranged between 5 minutes to 60 minutes and the
total waiting time was 140 minutes. The total time that the woman spent accessing different
services was 65 minutes and this ranged between 3 to 20 minutes.
Box 10-3 Observation case study 3-First day at Igoma ANCclinic
Nyanjige arrived at the clinic 09.30hrs. The general health education started at 1O.15hrs,
and it lasted for 15 min. After the health education, she waited for 60 minutes before she
was called at the registration table where she was given the ANC card and her details were
documented. Immediately after the registration, Nyanjige entered the examination room
at 11.35hrs where palpation and head-to-toe examination were done. This examination
room was also use for the n vaccination; therefore, Nyanjige was vaccinated before
leaving this room. Examination and vaccination took 15 minutes. Nyanjige came out of the
examination room at 11.50hrs and she was asked to go to the back of the building to
gather with other women who were waiting for the ANC HIV education session. Her ANC
card was taken to the laboratory. The ANC HIV education session started at 11.55hrs and it
lasted for 20min. At 13.00hrs, Nyanjige entered the laboratory and a blood sample for HIV
test and syphilis testing was taken, Nyanjige came out the laboratory at 13.03hrs. Nyanjige
was called back to the laboratory after 30min for the HIV post-test counselling and syphilis
results. Nyanjige came out of the laboratory at 13.40hrs. Overall, Nyanjige was at the clinic
for 255 minutes, 190 minutes (75%) was spent waiting for the services and 65 minutes
(25%) accessing various services
RB2010
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Note: At Igoma the laboratory is used as a HIVpost-test counselling room
Figure 10-3 shows the movement of Rhoda at Igoma ANC on day 2 (Thursday). Rhoda was in
the clinic for 3 hours and 37 minutes. She waited for 20 minutes before receiving any service.
The waiting time between services ranged between 26 minutes to 70 minutes. The total time
that Rhoda spent waiting for different services in the clinic was 136 minutes. The total time
that Rhoda spent accessing different services was 71 minutes and this ranged between 4 - 28
minutes. During the movement from one station to another in order to access different
services at the clinic, Rhoda covered a distance of 53 meters (0.05km).
pregnancy
Client movement at Igoma ANC clinic - first ANC visit during the currentFigure 10-3
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Table 10-2 summarises the time spend and the distance covered in the ANC facilities during
the two days of observation of the clinic activity flow. In general, women attending ANC for
the first time during the current pregnancy spent approximately 3hours to 5hours and 30
minute at the clinic. Women at NDH waited for 2 to 3 hrs before they could get any service
whereas at Makongoro and Igoma the waiting time before receiving any service was between
20 minutes to 45 minutes. After the initial contact with the health worker (when they start
receiving the services), the total waiting time from one station to another was longer for the
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busy days compared to the less busy days at NDH and Makongoro RCHclinic. At Igoma, the
difference between the busy day and the less busy day was 9 minutes only (Table 10-2).
It was found that in all clinics, the total time a client waits is 42 minutes up to 235 minutes
longer than the time she spends receiving services. At NDH clinic, much of the waiting time is
explained by a long delay before starting to receive any service, but even when that waiting
time (before starting to receive any service) is excluded, the woman spend on average 10
minutes to 114 minutes more time waiting between stations than receiving services. There
was no difference between the time the woman spend while accessing the services when
compared the busy and less busy days.
Table 10-2 Time spend and distance covered in the ANC by first ANC attendees in
Mwanza
NDH Makongoro Igoma
Day 1 Day 2 Day 1 Day 2 Day 1 Day 2
Total time the woman spent at the
facility (min)
335 275 280 178 255 217
Waiting time before receiving any
service (min)
180 135 20 30 45 20
Total waiting time from one station
to another (min)
105 75 187 80 145 136
Range of the waiting time between
station (min)
5-50 5-30 7-60 0-30 5-60 26-70
Total time spend accessing services
at different stations (min)
50 65 73 68 65 71
Range of time spending accessing
services (min)
5-15 5-30 3-25 3-30 3-20 4-28
Difference between time spent
waiting for the services and time
used to access services
235 145 134 42 125 85
Difference between time spent
waiting for the services and time
used to access services excluding the
waiting time before starting to
receive services
55 10 114 12 80 65
Total distance covered within the
clinic (km)
0.10 0.35 0.05
With the exception of women attending at Makongoro clinic, the distance covered while
accessing the services was short and this is because these two health facilities are small and
all the services were offered within the premises and with few movements. Generally, the
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total distance covered while accessing various services at all the clinics was shorter. However,
at Makongoro, the distances the women had to walk was relatively longer than at the other
facilities because vaccination services were offered outside the main ANC premises.
10.3.2 PMTCT and syphilis screening and treatment activities that are integrated in ANC
Table 10-3 shows the activities that are integrated in the ANC clinics that participated in this
study. The information presented below was based on the principal investigator's
observations at these facilities during the seven months period of the study and not only what
was observed during the two days of the observation of the activity flow in the ANt.
Activities were done slightly different at each ANC facility except for the record keeping
whereby at all ANC facilities, information on access to PMTCT services were documented in
designated register books for PMTCT. These a special registers with pre-written columns
indicating the information that should be documented for all women who are tested for HIV
at that particular facility. Information on syphilis screening and treatment services were
recorded in ordinary handwritten register books, some were of low quality and sometimes
torn. Information recorded in these syphilis screening and treatment register books were
different at each facility,
Linking PMTCT and syphilis screening and treatment services was not possible when looking at
the register books only. This was because the numbering system for the PMTCT register was
different to that used in the other ANC records and therefore the woman in the PMTCT book
was given a different identification number.
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Table 10-3 Integrated PMTCT and maternal syphilis screening and treatment activities
Activity
Facility name
NOH Makongoro Igoma
Syphilis education is
part of the general
Syphilis education is part of
education, but for
Health education is always theANC HIV
given once but did not cover!
the general health education education sessions
and it was not mentioned at
both syphilis and HIV instead!
all in ANC HIV-education talk.
that were observed
,Health the two topics and other
However, although not often
the counselor while
:education major topics in ANC (e.g.
HIV general education was
explaining the "opt-
Malaria prevention, FP)are also touched on during the
out" concept she
being alternated on a daily
general ANC health education
touched on issues
bases.
during the observed sessions
around syphilis
screening and
treatment during
pregnancy.
For women who attend ANC
for the 1st time at Makongoro ,
the one blood sample is taken:
in the lab by the lab At Igoma ANC clinic
technician. After doing the one blood sample
RPRtest the lab technician was taken by the lab
Blood One blood sample collected
takes the tube containing the assistant (if she was
~ample remaining blood to the available) or by the
collectlon
by the counselor counselor in the PMTCT room PMTCT counselor.
for HIV testing. However, the (The lab assistant
counselor has to do a finger was working part
prick for women referred to time)
Makongoro from other ANC
facilities that do not offer
PMTCT
RPRtest was done in lab and
RPRtest done by the:
Both syphilis test and HIV HIV test was done by the
lab assistant (when !,
test were done by the same present) otherwise !Testing counselor in the PMTCT room
person. 2
both test (HIV & RPR)!
done by a counselor !
Both syphilis and HIV results Both RPRand HIV
are given by the same health PMTCT counselor does the results are
worker, in case of RPR post-test counseling and communicated back
positive and if the medicine gives HIV results while RPR- to the pregnant
Giving
is available at the clinic, this positive women are sent back , woman by the
health worker is the one to see the nurse in the
, PMTCT counselor.
,results who give the treatment also examination room who gives RPRpositive women :,,
the woman contact(s) who the RPRresults and treat are sent to the STD
came for syphilis treatment both woman and her clinic based within
are being attended at the contact(s) the health centre for:
same station. treatment.
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10.3.3 PMTCT and syphilis screening and treatment at the maternity ward
According to the Tanzanian PMTCTguidelines [37], all pregnant women admitted for delivery
with unknown HIV status should receive "opt-out" HIV testing. After routine pre-test
education if the woman consents, a rapid HIV test is performed so that ARV prophylaxis for
PMTCT can be administered before delivery in case the woman found to be HIV-positive.
During this study, we observed that this was often happening at both BMC and STRH
maternity wards and as a result, 70 (17.4%) of HIV-positive women who were recruited in the
cohort were tested for HIV at the maternity ward.
Similarly, maternal syphilis screening is a national policy in Tanzania [106] and it is
recommended that at the time of delivery, syphilis test results should be reviewed, and the
infant evaluated for signs of CS. Furthermore, the guidelines recommend that women who
missed a RPRtest during antenatal care should be tested during delivery and the test results
should be obtained as soon as possible so that early treatment can be given to the infant of
women who test RPRpositive and to the mothers. However, neither recommendation was
being implemented at the two maternity wards in this study; therefore this demonstrated a
total failure in the integration of PMTCTfor HIV and syphilis at delivery.
10.4 Discussion
Adapting the definition that was given by Hardee[114] to this study, facility integration refer
to facilities or sites at which both syphilis screening and PMTCT services are available and
offered at the same time by the same provider or referred to another provider within the
same premises. From this modified definition, we can conclude that at the ANC facilities that
participated in this study syphilis screening and PMTCT services were integrated. However,
from the observation of the activities that were conducted in the ANC facilities, there is still a
room for improvement. For example, this study found that women were spending longer
waiting hours in the ANC facilities. Ideally integration should aim at reducing the time spent
while accessing the services and for the case of this study, strategies such as combining the
health education (general and PMTCT) so that these could be given once by the same health
worker, will lead in reduced waiting times and human resource needed for these services
compared to when they are offered differently as it is now. This also applies for other services
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such as testing for HIV and syphilis as well as giving results and treatment when applicable.
Other strategies that could be considered include encouraging women to attend at ANC on
less busy days when the waiting times are shorter. There is also a need to start offering the
services promptly at the official clinic opening hours.
In Tanzania, both PMTCT and maternal syphilis screening and treatment services are
documented policies. However, the absence of integrated guidelines and protocols regarding
syphilis screening within PMTCT services and vice versa it might be a challenging for direct
service providers. This study found that attending a private ANC facility was associated with
failure to test for HIV during pregnancy, though this was not the case for syphilis screening
during pregnancy (Result presented in Chapter 6). This implies that syphilis was prioritised
equally in both private and public facilities whereas PMTCT was "ignored" in some of the
private ANC facilities. The absence of integrated policy regarding these two important
maternal services hinder the successful implementation of the programmes and give a loop
hole for other providers not to consider offering some of these important services to pregnant
women.
At the service delivery level (i.e. ANC and the maternity wards) integration of PMTCT and
maternal syphilis screening is very important, from the client's point of view; it may be
difficult to separate PMTCT and syphilis screening during pregnancy. The client is
disadvantaged if offered PMTCTwithout being screened for syphilis and vice versa. However,
this is also the level whereby for the integration to be successful, availability of trained and
motivated health workers remains crucial. This study found that a very small proportion
(12.5% and 47%) of health workers in maternity ward and in the ANC facilities respectively
reported receiving some training in syphilis screening and PMTCT. This finding is an indicator
of a challenge in the implementation of integrated services. As Hardee and Yount [114]
indicated, adequacy of trained staff has been documented as an obstacle for integrated
services. For a successful integration of these two important reproductive and maternal
health programs, there is an urgent need of a phased onsite training where health workers at
all levels should be taught on new skills apart from their formal training without interrupting
the services by sending health workers away from their workstations for retraining.
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CHAPTER 11: DISCUSSION
This chapter discusses the key findings of this research and compares our findings with the
findings from other studies conducted elsewhere. Strength and limitations of the study, and
key recommendations are also presented in this chapter.
11.1 Research key findings
11.1.1 Completion of PMTCT steps
Drop out from PMTCT interventions occurs at every step after testing. Results revealed that by
the end of four months post-delivery, only 41% of HIV-positive women had successfully
completed all PMTCT steps. Other studies that were conducted in sub-Saharan Africa also
reported a cumulative drop out of up to 70% over four months after delivery and about 81%
over a period of six months after delivery [79, 115-116].
Ideally, PMTCT facilities in ANC or in the maternity wards would offer HIV testing to all
pregnant women. However, we found that more than 20% of pregnant women who attended
ANC during pregnancy and who delivered in hospitals that offered PMTCT services in Mwanza
city left the maternity ward with unknown HIV status. In addition, we found that 13%, 26%
and 48% of HIV-positive women participating in the cohort study who were tested before
pregnancy, at ANC during the current pregnancy and at the maternity ward before delivery
respectively, did not receive any ARV prophylaxis for PMTCT. These findings indicate a failure
in the implementation of PMTCTsince such women had an opportunity to delivery in hospitals
that provide PMTCT services. A qualitative study conducted in South Africa found that a high
proportion of pregnant women accessing maternal services at facilities that offer PMTCT are
not offered the services due to reasons such as shortage of counsellors or unavailability of test
kits or PMTCT forms[117]. In our study sites, test kits stock-outs, unavailability of counsellors,
especially in the maternity wards, and lack of ART drugs at ANC and in the maternity wards
were often reported.
Review of records at the ANC found that a high proportion (97.5%) of pregnant women who
received PMTCT HIV pre-test counselling accepted an HIV test, tested at ANC and 8.3% were
HIV-positive. However, about half of these HIV-positive women were not given any ARV for
PMTCT. This finding is consistent with the results from other operational studies conducted in
185
RB2010
Sub-Saharan Africa that found that only about 50% or less of HIV-positive pregnant women
received ARV to prevent HIV transmission to their infants [118-119].
Overall, 83% of HIV-exposed infants in this study received ARV prophylaxis for PMTCT. In
Tanzania, it is recommended that infants born at facilities that have the capacity to initiate
ARV treatment should receive sdNVP supplemented with the more efficacious, longer term
AZT prophylaxis regimen [37]. Both Bugando Medical Centre (BMC) and Sekou-Toure Regional
Hospital (STRH) have delivery suites that include ARV initiating facilities in Mwanza city.
However, 28% of the infants who received ARV for PMTCT were only given sdNVP.
Presumably, this was due to unavailability of AZT syrup for the infants in the maternity ward
or lack of knowledge on the new recommended infant regimen among health workers
dispensing ARV in the maternity ward.
Counselling women to make an informed choice on infant feeding is of crucial importance and
various studies have documented the importance of infant feeding counselling on improved
adherence to infant feeding recommendations [120-122]. According to the Tanzanian
guidelines in PMTCT, counsellors who are health workers need to assess each individual
woman's situation in order to establish what is most feasible and safe for her infant before
discharge from the hospital [37]. In this study, we found that about 27% of women who
delivered in hospital were not counselled on infant feeding methods and 40% of women who
had not been counselled on infant feeding options at delivery were unsure about the feeding
method to use for their infants.
During infant feeding counselling time is required to explain the factors that increase
postpartum HIV transmission through breast milk and the risk of morbidity from replacement
feeding and how to reduce such risks. This requires a counsellor who is knowledgeable and
who can translate complex scientific concepts of such risks into a simple message that is
understood by women. Often these requirements are rarely fulfilled in many African countries
and as a result counselling on infant feeding in many African countries, including Botswana,
Kenya, Malawi and Uganda, has been reported to be suboptimal [123]. Among 73% of HIV-
positive women in our cohort study who reported receiving counselling on infant feeding
choices, 28% of them were practising mixed feeding for their infants four months after
delivery. We found that one of the most important reasons for this common practice of mixed
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feeding among HIV-positive women is lack of knowledge about the risks involved by practising
mixed feeding to their HEI. Other reasons included lack of disclosure of the HIV status and
insufficient breast milk.
11.1.2 Factors associated with failure to complete different PMTCT interventions
There was no association between failure to test for HIV during pregnancy and most of the
women's socio-demographic characteristics in this study. In this regard, our findings differ
from several studies that reported the association between HIV testing during pregnancy and
marital status, education level and age [84, 124-127]. However, these studies were conducted
when HIV testing was offered as opt-in and when women were supposed to come back for
their HIV test results after one month. Our study indicates that HIV testing offered as a
routine service (opt-out) with the same day results is acceptable and in Mwanza city it reaches
women of different socio-demographic characteristics equally as it has been also documented
in other studies [79, 125, 128].
Currently in Tanzania, the PMTCT programme is still at a scaling-up stage, with higher
coverage in health facilities located in urban areas compared to health facilities in rural areas.
This fact explains the association we observed between attending an ANC facility located
outside Mwanza city and failure to have an HIV test during pregnancy. Similar findings were
reported by a study conducted in Uganda [76].
Less than three ANC visits during pregnancy was found to be a strong determinant of failure
to test for HIV during pregnancy as well as failure to use ARV for PMTCT. Such a patterns was
also reported in studies that were conducted in Burkina-Faso and Western Kenya [129-130]. In
Tanzania, it is recommended that pregnant women should be offered an HIV test during the
first ANC visit [37]. However, obstacles to this include attending an ANC facility that does not
offer PMTCT services, arriving at the ANC facility for the first visit late in the day or not being
offered the services when attending for the first visit.
Association between attending a private ANC facility and failure to have an HIV test during
pregnancy reveals the fact that HIV testing for PMTCT may not be offered consistently in
private facilities in Mwanza city and such findings need to be investigated more.
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High knowledge of the health services users may possibly increase communication between
the health services users and providers. Also it improves retention of provided information
and thus better adherence to recommended interventions. This study, found out that failure
to use ARV for PMTCTwas associated with educational level, similar to studies in Zambia and
Kenya. Both studies reported that non-adherence to sdNVP was associated with no high
school education or with a low educational level [130-131].
In this study, it was found that failure to use ARV for PMTCT was associated with failure to
attend a CTC before delivery. Such findings are not widely reported by other studies.
However, in Tanzania, HIV-positive women attending a CTC before delivery have a high
chance of being assessed for eligibility for HAART initiation. Those found to be eligible should
be started on HAART and those who are not eligible should be given ARV prophylaxis from a
CTC[37]. These women also had the opportunity to receive more counselling compared to
those who did not attend a CTC.
From the cohort study, we found that failure to attend a CTC before delivery was strongly
associated with failure to complete the four key PMTCT interventions. HIV-positive women
who attend a CTCmay have more opportunities to understand their HIV illness better and to
learn more about the interventions available to them and are better motivated to take up the
interventions. Furthermore, for women who attend a CTCthey are more advantaged because
interventions such as ARV are available for them.
Unlike a number of other studies [132-133], this study found that lack of a woman's HIV status
disclosure to the partner was not associated with failure to use ARV for PMTCT. This might be
due to the fact that this study report on findings from women who delivered in hospital and
who, in most case, were given sdNVP for PMTCT. A study in Zambia reported that use of ARV
for PMTCT was associated with disclosure of HIV status among pregnant women who had
home deliveries [13l].This is because in most cases of home deliveries husbands are often
present and the women might not want to use the medication in their husbands' presence if
they have not disclosed their HIV status.
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11.1.3 ANC HIV education and women's knowledge about HIV, MTCT and PMTCT
In Tanzania, it is recommended that group pre-test HIV education and counseling should be
done in order to facilitate the integration of PMTCT services into existing sessions of ANC
services, routinely performed by the current clinic staff [37]. The PMTCT guidelines in
Tanzania also recommend that, during these sessions, a health care worker should share
information with pregnant women, but she/he should be careful to avoid dominating the
session. However, for the group counselling sessions that were observed during the
observation study, we found that pregnant women's participation in the dlscussion was
minimal. Though we did not explore what the reasons were for poor participation in these
discussions, presumably factors such as lack of understanding, having no interest in discussing
issues around HIV/AIDS openly, anxiety about the results, and being tired following long hours
in the clinic might contribute to this finding.
From the cross-sectional study of pregnant women admitted for delivery at BMC and STRH,
we found that women who received ANC HIV education during the current pregnancy had a
high knowledge of HIV, MTCT and PMTCT of HIV compared to women who did not attend.
Furthermore, in the same study it was revealed that women who had a high knowledge about
HIV, MTCT and PMTCT were more likely to have had an HIV test compared to those whose
knowledge was low. These findings indicate the importance of ANC HIV education in the
effectiveness of PMTCT programmes.
11.1.4 Referral and care for HIV-positive pregnant women
From the cohort study, we found that about 50% of HIV-positive women who were tested at
ANC during the current pregnancy did not get information or referral to attend a CTCbefore
delivery. This is one of the health systems failures that were observed in the implementation
of PMTCT in our study settings.
PMTCT is a comprehensive set of interventions that require capable health workers. Several
studies have documented the importance of health workers training in order to optimize the
effectiveness of PMTCT [117, 134-135]. We found that, due to lack of adequate training and
updates on the new PMTCT guidelines in Tanzania, some of the health workers that were
interviewed did not know when to refer HIV-positive women to a CTCand as a result, such
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women failed to attend a CTCbefore delivery. A study conducted in South Africa also reported
that incorrect instructions from the health workers to HIV-positive women about PMTCT
interventions was one of the health systems' failure which contributed to the missed
opportunities for participation in PMTCT [117]. These findings prompt an urgent need of
ongoing refresher training of health workers.
According to the current national PMTCT guidelines, women who receive HIV counselling and
testing during labour should receive post-test counselling during the postpartum period
before discharge from the hospital. Post-test counselling also consists of giving the
information on referral available to the woman, including referral to CTC services [37].
However, none of the HIV-positive women in the cohort study, who were tested at the
maternity ward, received a referral to a CTCbefore discharge from the hospital after delivery.
Although the reasons for this particular failure were not explored, presumably lack of training
(e.g. health workers at the maternity ward did not know the referral system) or high workload
in the maternity wards (e.g. no time to go through the paperwork for referral) might have
contributed to this PMTCT implementation failure.
We found that about half of the women who received referral to attend to a CTC did not
attend a CTC.This might be due to individual factors such as fear of disclosing their HIV status
and also fear about using ARV. Health workers who were interviewed in this study pointed out
that lack of coordination between ANC clinics and CTC was a major obstacle for women's
attendance to CTC before and after delivery and they recommended the integration of care
and treatment services into maternal health services. This was also recommended in a review
of multi country PMTCT programs [135].
Only 20% of HIV-positive women who were identified through PMTCT service were
successfully taken through the referral system to attend an adult HIV care and treatment
centre. This finding prompts an urgent need of a coordinated integration of maternal and HIV
care and treatment services offered to pregnant women.
11.1.5 Family planning uptake among HIV-positive women
Preventing unintended pregnancies among HIV-positive women is important in order to
achieve PMTCT goals and is the second component among four WHO strategies to prevent
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mother-to-child transmission of HIV [14]. In our cohort study about 50% of HIV-positive
women reported unintended pregnancies, and therefore, a high rate of unmet need for family
planning. This was twice as much as that reported in the general population in Tanzania[136].
It indicates a need for integrating family planning use in HIV prevention services in our
community.
The findings that HIV-positive women who were tested for HIV before the current pregnancy
were more likely to have ever used FPcompared to women who were tested for HIV during
the current pregnancy may be because women may prefer to delay or stop childbearing if
they know they are HIV-positive. This is similar to the results of the of the analysis of the
Demographic and Health surveys (OHS)data of four African countries that was conducted by
Johnson et al [137], who documented that knowledge of one's own HIV-positive status was
significantly associated with a desire to use contraceptive so as to limit childbearing.
It was found that hormonal FP methods were used more commonly than barrier methods in
the cohort. This was probably because injectable contraceptive methods allow women the
opportunity to receive contraception without telling their partners. IUCD were rarely used in
our cohort as well as in a study conducted in Rwanda [138]. A study conducted in Ghana
found that there was a small number of providers with practical experience of inserting the
device and that the product design was perceived to be unacceptable to the users. Reasons
such as fear of excessive bleeding and weight loss may also have discouraged potential
users[139].
Condom use among both HIV-positive and HIV-negative women in the era of HIV is of critical
importance. While condom use among HIV-positive women in our cohort study was generally
very low, we found that women who knew their HIV-positive status before the current
pregnancy were more likely to report using condoms as contraception before this pregnancy
compared with women who did not know their HIV status before the current pregnancy.
Similar results were also reported by Johnson et al [137]. It is also important to note that
condom use during pregnancy and breastfeeding among HIV-negative women would protect
them and their infants from incident HIV infection and therefore a need a strong need to
continue promoting condom use for pregnant and breastfeeding women.
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This study revealed that unmet need for family planning use before the current pregnancy
was similar among women who knew their HIV-positive status before delivery and those who
were tested HIV-positive during the current pregnancy. This was similar to the findings
reported in other studies conducted in Africa [137].
A high proportion (40%) of women in our cohort study reported that they were not using FP
methods four months postpartum because they had not resumed sexual activity after
delivery. However, this might be under-estimated due to the fact that about 19% of the
cohort participants had lost to follow up four months after delivery. Time to resumption of
sexual activity after delivery was estimated to be 6-8 weeks in the general population in
studies conducted in Europe [140-142]. The difference between our study and the previous
documented studies might be due to reasons such as anxiety after learning the HIV-positive
status, unwillingness to discuss sexual behavior and sometimes ill health following delivery
that should be expected among our study participants. On the other hand, delay in
resumption of sexual activity after delivery among HIV-positive women could be useful in the
sense that the women have a number of MCH visits where FP counseling could be done and
FPmethods offered before they resumes sexual activity.
Previous studies have confirmed that fears of side effects from contraception use are often a
barrier to the acceptance of contraceptive methods, and such concerns often result in a
dependence on traditional forms of contraception (for example. withdrawal, calendar/safe
days) [143]. Similarly, a small proportion of women in our cohort study reported not using any
contraception because they believed that contraceptives were not safe.
HIV-positive women who did not receive counseling in FP use after delivery were more likely
to fail to use FP methods four months after delivery compared to HIV-positive women who
received counseling on FP use. This finding indicates the importance of strengthening FP
counseling among HIV-positive women in order to remove barriers to FPuse. It is important to
identify other barriers to FP use and to highlight the importance of FP utilization particularly
among HIV-positive women.
192
RBZ010
11.1.6 Maternal syphilis screening and treatment
Prevention of congenital syphilis remains an important ongoing public health challenge. In this
study, it was found that the majority (88.1%) of pregnant women who were admitted to
hospital for delivery and who attended ANC at least once during the current pregnancy were
screened for syphilis.
Both RPRpositive women who were not treated during pregnancy and infants born to RPR
positive women were not treated for syphilis before discharge from the hospital after
delivery/birth. This is a major concern to effectiveness of maternal syphilis screening and
treatment programs in Tanzania and constitutes a missed opportunity for prevention of
congenital syphilis among infants born in hospitals. Our findings also suggest a high level of
provider non-compliance with the national policy that clearly recommends screening of
women who missed an RPRtest during antenatal care and treatment for women not treated
during pregnancy and infants born to RPRpositive women [106].
Failure to screen for syphilis during pregnancy in this study was found to be associated with
fewer number of ANC visits during pregnancy. Theoretically, women with more ANC visits
have opportunity to be screened during the subsequent visits if they missed the test at the
first or second visit. Studies conducted in another place also documented that efforts to
prevent congenital syphilis may be more effective among women who have more visits to
prenatal care [144-145].
Attending an ANC facility located outside Mwanza city was found to be a risk factor for failure
to screen for HIV during pregnancy. In reality, health facilities in many rural areas in Tanzania
and other parts of Africa have many shortcomings. Programme scale-up to rural health
facilities might take longer or might not be sustainable. A study in Malawi reported that, due
to unsustainable programmatic requirements, and despite maternal syphilis screening and
treatment being a national policy, routine antenatal syphilis screening and treatment were
suspended in many rural health facilities in Malawi [146].
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11.1.7 Integration of PMTCT and maternal syphilis screening and treatment
Adapting the definition by Hardee et 01 [114] to this study, integration of PMTCT and syphilis
screening and treatment at a facility level could refer to facilities or sites at which both syphilis
screening and PMTCT services are available and offered at the same time by the same
provider or referred to another provider within the same premises.
We found that at the ANC facility level, PMTCT and maternal syphilis screening and treatment
services were integrated in the sense that services were available at the same facilities
although sometimes not offered at the same time by the same provider but women could be
referred for the services to another health worker within the same premises.
From what was observed at the facilities, shortcomings such as two different health workers
giving two different health education talks to the same audience, testing for HIV and syphilis
separately and syphilis treatment offered by different health worker from the one who is
dispensing ART to HIV-positive women, could be easily rectified without extra resources. A full
integration of the two services is critical in order to deal with issues such as long waiting hours
in the clinics.
Availability of trained and motivated health workers is crucial for the successfulness of the
programmes. A small proportion of health workers who participated in this study reported
receiving training in basic components of the programmes. Unavailability of trained staff has
been documented as an obstacle for integrated services [114].
Independent policies for the implementation of these two programmes in Tanzania needs to
be reconsidered. The absence of integrated services guidelines and protocols is a challenge for
direct service providers {providers at the facility level}. For example in our study we found
that women who attended ANC in private ANC facilities were at a higher risk of failure to
receive PMTCT interventions compared to women who attended ANC at public ANC facilities,
while this was not the case for syphilis screening. If syphilis screening is implemented in
private ANC facilities, we need to understand why HIV testing is rarely done in these facilities.
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We are also reporting a total failure of the implementation of maternal syphilis screening and
treatment programme at the maternity wards in Mwanza city. This study was not designed to
explore the causes of these failures. However, in future it will be helpful to understand why
pregnant women admitted to hospital for delivery and who were not screened for syphilis
during pregnancy are not screened at admission for delivery and why RPRpositive women and
their infants do not receive any interventions to prevent congenital syphilis before discharge
from the hospital after delivery/birth while PMTCT services are being offered. The absence of
integrated maternal syphilis screening and PMTCT policies hamper the successful
implementation of the programmes.
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The major strengths of this study include the use of multiple data sources, which increased
the validity of the study findings by allowing different source of information to feed into
different specific objectives of the study as illustrated in Figure 11-1. The details for this figure
were also given on Table 4-1.
More than one method was use to address all the specific aims of the study, except aim 5,
which was to determine whether HIV-positive women are offered, and take up FP as an
option after delivery. For this objective, only cohort data were used.
Figure 11-1 Link between the study specific objectives and the data collection methods
Determine the proportion of pregnant women
who successfully complete the PMTCTand
maternal syphilis screening programmes.
Identify potential client and provider factors
that are likely to influence women's successful
completion of PMTCTand maternal syphilis
screening and treatment programmes.
Determine whether HIV-positive women
identified through PMTCTreceive appropriate
referral and care for their own health
concerning HIV.
Assessthe effect of the antenatal HIV education
and counselling on pregnant women's
knowledge about MTCT and PMTCT.
Determine whether HIV-positive women are
offered and take up FPas an option after
delivery.
Assessthe integration of PMTCTand syphilis
screening and treatment within public ANC/RCH
clinics.
Cross-sectional study
at the maternity wards
Health workers
interviews
Observation of the flow
of activities and HtV ANC
education
Cohort study
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The broad aim of the study was to assess the operational performance of two key maternal
and reproductive health programmes in Mwanza City. The findings and the recommendations
from this research will inform policy makers on the performance of the programmes and the
factors that hinder the successfully implementation and how best these two programmes
could be integrated to improve their effectiveness.
Information for this research was obtained from the service providers as well as the services
users. This gave an insight on the barriers to the performance of the programmes.
11.3 Limitations 0/ the study
This study was designed to be conducted in health facilities that were located in Mwanza City
and among women who attended ANC during pregnancy and who delivered in hospital. This
kind of study cannot generate findings that could be generalized to the population, especially
to pregnant women who fail to attend health services during pregnancy. However, these
findings could be representative to the situation in Tanzania where PMTCT and maternal
syphilis screening and treatment programmes are implemented. We report on programmatic
challenges in health facilities that theoretically, were meant to deliver the full package of the
interventions.
Losses to follow-up (LTFU) may bias the results of the study if not dealt with caution. About
20% of HIV-positive women in our cohort were LTFU four months after delivery and we have
no information on the interventions that they might have received elsewhere. However, the
analysis of the baseline information of these women found that women LTFU in our cohort
were not different from the women who remained in the study therefore the assumption that
our results are not biased due to LTFU.
One of the main outcomes measured in this study was the use of ARV for PMTCT. Due to
unavailability of documented prescribed ARV for women who had not attended a CTCbefore
delivery and for those who did not bring their CTCcards at admission for delivery, it was not
clear which type of ARV for PMTCT were given to the woman and we only depended on self-
reported information.
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Selection of the health workers to participate in the health workers interviews was designed to
include as many health workers in the maternity wards and in the ANC clinic as possible.
However, few senior health workers (Medical doctors (MD) and Assistant Medical Officers
(AMO)) participated in these interviews due to other commitments. On the other hand, junior
staffs are often the first contact of the health worker with pregnant women and the
information obtained from them therefore represents the actual situation in these facilities.
Measuring the maternal to infant transmission rates of HIV and syphilis are the ideal primary
outcome measures for evaluating the success of PMTCT and maternal syphilis screening and
treatment programmes. However, due to the study logistics, budget constraints and design of
the PMTCTand syphilis programmes activities it was not possible to determine the mother- to-
child transmission rates of the two infections in this study.
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CHAPTER 12: CONCLUSIONS AND RECOMMENDATIONS
While PMTCT and maternal syphilis screening and treatment are key maternal and
reproductive health interventions, these two programmes still face a significant challenge in
Tanzania. We reported on several missed opportunities among pregnant women who had
opportunity to attend for ANC during pregnancy and who delivered in hospitals in Mwanza
city. Missed opportunities regarding PMTCT ranged from HIV testing at ANC or at the
maternity ward to counselling on, and adhering to, infant feeding choices. Drop out in the
different steps of PMTCT intervention programme is high. Only 41% of HIV-positive women in
our study successfully completed the PMTCT interventions. This study found that both RPR-
positive women who were not treated at ANC and all infants born to RPR-positive women
were not treated at the maternity ward.
Lower education levels, attending less than three ANC visits during pregnancy, attending
private ANC facilities and failure to attend CTC before delivery were found to be the factors
that contributed to the failure in completing various PMTCT interventions. In addition, this
study found that attending less than three ANC visits during pregnancy and attending ANC
clinics located outside Mwanza city was significantly associated with failure to screen for
syphilis during pregnancy.
This study found that the maternity wards did not offer any services to prevent congenital
syphilis and while PMTCTservices were available in the study hospital maternity wards, about
20% of pregnant women who delivered in these study hospitals did not receive HIV testing for
PMTCT.
Women who were tested and found to be HIV-positive at the maternity wards and half of the
HIV-positive women tested at ANCwere not referred to a CTC.Also about 50% of women who
were referred to CTCbefore delivery did not attend a CTC.
In order to improve the uptake of HIV testing for PMTCT and maternal syphilis screening in
order to treat women to prevent congenital syphilis effectively, pregnant women should be
encouraged to attend ANC clinics early in pregnancy. This could be achieved by continued
promotion of early attendance to ANC (Le. attending ANC during first trimester of pregnancy)
through local mass media (radio and television). Posters promoting early ANC attendance
199
RBZOlO
during pregnancy and male partner involvement should be displayed in all government
departments. Community mobilisation events need to be considered and these should aim at
addressing different myths that hinder early attendance to ANC facilities during pregnancy in
many African communities such as a belief that talking about or revealing a pregnancy that is
not physically seen could lead to poor pregnancy outcomes (such as miscarriage)[147].
It is highly recommended that all pregnant women attending ANC at least once during the
current pregnancy should be offered HIV education, counselling and testing for PMTCT, and
those found to be HIV-positive should receive ARV for PMTCT and referral to CTC for their
own health before leaving the ANC facility. In addition, women should be screened for syphilis
and those found to be RPRpositive should be treated on the same day of their first visit. This
is of critical importance in order to improve the uptake of these services since a high
proportion of pregnant women in our communities attend ANC at least once during
pregnancy. However, it is crucial that women who miss HIV and/or syphilis testing or
treatment during the first ANC visit should be identified and offered the test and/or treatment
at the next ANC visits. This could be done simply reviewing the ANC cards of pregnant women
on repeat visits.
Furthermore, we found that syphilis prevalence in our study was 5.9%, and Swai et al on the
surveillance study of HIV and syphilis infections reported a syphilis prevalence of 7.3% among
antenatal clinic attendees in Tanzania [110]. Based on these findings and the fact that in
Tanzania Benzathine penicillin is not always available in the ANC facilities offering these
services, we would not recommend treating all women during pregnancy.
Performance of PMTCT and congenital syphilis prevention programmes need to be improved
at the maternity ward for women who failed to access these services during the antenatal
period and for those in need of after-delivery interventions (counselling and prophylaxis
treatment for infants). There is an urgent need of integration of PMTCT and syphilis screening
and treatment services in the maternity wards. This could be attained by strengthening the
current PMTCT sections in the maternity ward so that at least all women who delivery in
hospital benefit fully from these interventions. Efforts to strength the maternity ward PMTCT
sections should include: -
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1. Training of health workers in PMTCTand syphilis testing and treatment.
2. Providing screening for syphilis to
a. Women who were not screened at ANC
3. Providing syphilis treatment to
a. RPRpositive women not treated at ANC
b. Infants born to RPRpositive women
4. Increase the availability of resources e.g.
a. Test kits for both HIV and syphilis
b. ARV dugs for PMTCTfor both mothers and infants
c. Benzathine penicillin for RPRpositive women not treated during pregnancy and
for infants whose mothers tested RPRpositive during pregnancy
d. Register books and referral forms
5. Availability of dedicated, well trained health workers during all shifts.
Research on innovative technologies to diagnose HIV and syphilis would be useful in order to
improve the performance of these two programmes both at ANC and at the maternity ward.
These should include research on combined treponemal and non-treponemal test in a form of
a rapid test or POCassay that could be used in ANC clinics or in the maternity ward for syphilis
screening. There is an urgent need for scientists to consider the innovation of a POCtest that
can detect both syphilis and HIV. This will reduce the time pregnant women spend in
accessing these services and the number of staff required to offer the services.
An assessment of the woman's ANC card at admission in the maternity ward should aim at
identifying pregnant women in need of syphilis screening or treatment and any of the PMTCT
interventions and help these women to adhere to the recommended guidelines. For example,
women not tested at ANC should be counselled and offered the test, women who tested HIV-
positive at ANC should be asked about the medication and if they have been prescribed ARV,
if not, they should be given ARV prophylaxis for PMTCT. Infants born to HIV-positive and/or
RPR positive women should be given ARV prophylaxis or treated for congenital syphilis
respectively.
It is important that at admission and before discharge from the hospital after delivery, HIV-
positive women should be asked about their attendance at a CTCfor their own health, and if
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they have never attended or they were tested at the maternity ward, they should be
counselled on the importance of attending a CTC, Required information on where and now
they can access CTCservices should be provided and a referral form to a preferred CTCclinic
should be completed for them.
There is a need for longitudinal follow up of mothers and infants to ensure that they receive
quality care after discharge from the maternity ward. The mothers of all HEI should be given
their infant's MCH cards (which records the infants' health monitoring information during
attendance at the under-five clinics) before leaving the maternity wards to allow PMTCT
interventions to be recorded in their MCH card at birth. This information will therefore be
available for service providers at the under-five clinics who will be required to offer
subsequent services such as infant diagnosis or provision of cotrimoxazole prophylaxis.
There is also a need to improve the infants' MCH card to incorporate information on mothers'
syphilis results and action taken to prevent congenital syphilis for all infants of RPRpositive
women. This will prompt service providers at the under-five clinics to identify and, when
necessary, treat infants born to RPRpositive mothers.
Private providers should be involved in the implementation of PMTCT in order to improve the
uptake of HIV testing for PMTCT. It should be made compulsory that health workers in the
private health sector receive training in PMTCT components. Procurement of the HIV test kits
and ARVs for PMTCT could be done through the Ministry of Health and Social Welfare, so that
HIV testing is offered for free in the private clinics to encourage women to take up the test
without extra cost. This has worked very well for the various under-five children vaccines in
private under-five clinics in Tanzania. All vaccines used in private under-five clinics are
procured through the Ministry of Health and Social Welfare and offered to children free of
charge.
To improve counselling for PMTCT interventions uptake, women with low educational level
should be targeted for more detailed information and education and should be encouraged to
attend ANC regularly. Specifically, when counselling about infant feeding, there is a need to
stress the importance of exclusive breast-feeding (EBF), using simple terminologies. Using
pictorial diagrams should help the women to clearly understand the meaning and full benefits
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of EBF.Women should also be educated on how to produce enough breast milk for the infant.
Counselling on infant feeding should be done during each antenatal visit so that HIV-positive
women are well informed before delivery.
Women who attended the ANC HIV education sessions were more knowledgeable about HIV,
MTCT and PMTCT and were more likely to have had an HIV test when compared to women
who did not attend. However, women's participation in these sessions was found to be poor.
Introducing innovative ways of making the ANC HIV health education an interesting session to
pregnant women at ANC is an urgent requirement. These could include starting a talk with a
quick drama, self-introductions, a short story, a real case study or pictorial illustration (or
video clips when possible) of case studies.
PMTCT programs are key entry points to HIV care and treatment and this research found that
HIV-positive women who attended a CTC before delivery were more likely to adhere to the
various PMTCT interventions compared to women who did not attend. Furthermore, while
PMTCT services are integrated in maternal-child health services, HIV adult care and treatment
programs often function in parallel and as a result, HIV-positive women in Mwanza city are
required to navigate separate health care facilities in order to access the required services for
their own care. Therefore, integrating HIV care and treatment into PMTCT is required to
facilitate the initiation of ARV treatment during pregnancy to women who require treatment,
and provision of effective ARV prophylaxis for PMTCT. Strategies that could be considered
include:-
1. Training the PMTCT health workers in ANC and in the MCH clinics in HIV clinical staging
and CD4 testing. This will allow HIV-positive pregnant women identified through PMTCTto
quickly be introduced to care and treatment.
2. Further research on the use of peer counsellors and expert patients' is needed. Peer
counsellor/expert patients' could be HIV-positive women who have been through PMTCT
and referral procedures and who receive basic training in counselling and in different
PMTCT interventions and referral procedures to CTC.These can be hired by the clinics as lay
counselors and they could assist in adherence counseling and breastfeeding counseling and
support. Also they could assist in accompanying new patients to the Cl'C,
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Half of the HIV-positive women in our cohort reported unwanted pregnancies and more than
20% of them reported that they had not received any counselling on family planning (FP)since
they were tested and found to be HIV-positive up to four months after delivery. This indicates
that the PMTCT services missed an opportunity to provide FP to these women. There is an
urgent need to improve FP counselling and availability for HIV-positive women during the
antenatal period, at delivery, before discharge from the hospital and during the postpartum
period. We reported that a higher proportion of HIV-positive women in this study reported
abstaining from sexual activity for more than 16 weeks after delivery. This gives them multiple
opportunities at MCH visits to discuss FP and provide this before women resume sexual
activity.
In summary, PMTCT and syphilis screening and treatment programmes are key interventions
to improve reproductive, maternal and child health in Tanzania. To improve the performance
of these programmes and to improve maternal and infant health there is an urgent need of
integration of these two programmes at all levels. Pregnant women should be encouraged to
attend ANC early in pregnancy in order to benefit from these interventions. Training of health
workers on programme components and updates are vital to the success of the programmes.
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Annex 1: ANC-HIV health education observation checklist
Annex 17: Implementation of PMTCT & Maternal Syphilis Screening and Treatment in
MwanzaCity
Checklist· Observation of the group education talks on HIV testing and counselling for PMTCT uptake
1.3 Name and code of the RCH clinic
I-LI
A: Background information
Observation I-L-..I/I-I-I/I-I-I
1.2 Observer's code
I.-L.-'
--...j._._.
1-1.-1
1.4 Total number of participants in a group
Language used
t---t------.--.- - ..
"I
1=Yes; 2=No I~
--"---,«- .,_._."._" ,_ "..,,,..,-"..".-~-.~~-
1=Circle; 2=Teacherlclass model 1-1. .__. _.__ _ _1_ ..__ .
I
1.6 Language used agreed by the group?
1.7 i Group structure
-_ -_.j .•. _._-_ __ __ _--_._----
I Section B: Observation of the main functions
I 1=not done; ?_"'do,!, but not complete; 3=well d~'!!i.S.~fI_~._ .. __...__ .__ .._. . _
2 I Establishing group relationship .
--.------- ..- .- ·.··.··.-·.·.-.-..- _._l_-·-_.·_.·.i ~ '.•·.·.·.··.- ---1_ .. \:
f-.--+----- --.- - -.----.------.-..-.-... "-1-" ..
. 1.-1
----.l-----.---J
i 1
i 1-1 !
---'-"._-----.........j
I
2.1 Greets participants
i 2.2 , Introduce self
, i
3 i Ensuring group participation
-- ~,---"--~-~.---.-.----
3.1 Allow all members to participate
3.2 Seeks clarification about information given or discussed
3.3 Directs discussion appropriately
.-...---- --.-~~.-,•. .."-
Summarizes main issues discussed
Giving information
l-.... • .. - - .....
1 Gives information in clear and simple terms
!- ....... .------ ...--,------~"~-----.---.-.--<-.._--.-- .._-
4.2 Gives participants time to absorb information and to respond
......... w_w· __ ·... ___ ... _ .. _··~,,· ___ .. ··_· __ ·____ ·~· ____ • ______ .__ ._. ....._-- ....._.-.-- ........---....... _ .._-
4.3 Has up-to-date knowledge about HIV/MTCT
-.--.~- ._._--_ .._ ....-...,_,_._-_ ..-
4.4 Repeats and reinforces important information
--.---~----..•~---~.........-.----.-- ..~~.--.-.--
'"---8--'''1-1._ ...._-_.__._.- -----
1-1
.... "".'"." .... " ..--~.." .....,- ... '"' ..-,,- ..
I I_I
...·..-·--[1 -L.J--~
"'~···-·~·-··-·-·-··---·I
..... - -_ +-- -----· .. ·· .. ·· ..·-·..-1.•
LI I.......----.- -..·--·-----····-...-·--1
I I-I .
·....-·---·~··--·-··---·t-----·._...,.."._.. ._,.,_"._
I I-I
------r--·--I~.I· ..
_______ ._._.._ _ 1 ..
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Annex 17: Implementation of PMTCT& Maternal Syphilis Screening and Treatment in
Mwanza City
Checklist· Observation of the group education talks on HIV testing and counselling for PMTCTuptake
,---------'f' ._._ ...,,------------,-_.-- .
•.::j~~~~~_for ~~derstandl~?~~~~ls-un~erstanding
14,6 I Summarizes main issues
r--r ---'".-- --.- -- --.-.
I 5 I Handling special circumstances
____,.. _._-------_- __ . - -_._._ ...•
5.1 ! Accommodates language difficultyIdifferences in the group I-I I
--_._-,.._------
154 Manages participants' distress I_I '1- -5ectIon C: Topic covered ---.---.------------- --- -.- - -- ._- •. 1
!_ !_.!I_l?_t_m.ntioned;2 -Mentioned but not in details; 3 "~entloned in details . .~
~.~.. ~~~~~~~~ ~llIue8 covered during the talk 1,1
! 61 I Knowledge about HIVand transmission I-I ,
-.--t .---.,,--...--, !
: 6.2 ! Misconceptions about HIVtransmission I LJ If--'! ......- -.,......----------------... . .- .....--"...--,-,..-.--.---".-..---.--....----f-.-.---- --.-.-. -
:::::::::':"'" ····_-_·t :.~::~t::;;_;==~~~~'~~~~~~~j_~~:=:-!
I 7 MTCTrelated Issues
!
I _ ...- ......--- ....- -- -,--------
.. 7,1 I Full information about HIVin pregnancy and risk of transmission to the infant I 1_-'
, I .....-.-------.- - - - , -, ------ ---+--- ..--- ,--.- - .
;...77~3_+~:.;~~b~eiS~:~f:Sa~~:~:~i:~dH~~t:~:~:1ac:~~n::::~~:~:::~:::iil: :::i:e denied "J~j!' 1-..1
, I mother decide not to be tested L.I----.----.'.' - .-.- . _ ,_ .._-- -----_----- ."'._,._-_._----_ ...•.._--_ .
: 7.4 ARV therapy is not a curellreatment for mothers
(..,._. .., " -., _ .._ _ .._--_ _-,_ .."
~_Th.' ""IDaI"" m,"m;,== ffiQ"'''..IY
l.?~L~own adverse effects a~~~~gint~~a<:ti~_~~ _ ..
.. -..--.-----;---1--1--11
1
U
I
L-I __..I
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Annex 2: Ethical approval-LSTHM
LONDON SCHOOL OF HYGIENE
& TROPICAL MEDICINE
ETHICS COMMITTEE
APPROVAL FORM
Application number: 5337
Name of Principal Investigator Rebecca Balira
Department Infectious and Tropical Diseases
Head of Department Professor Simon Croft
Title: Implementation of Prevention of Mother-ta-Child Transmission of
HIV and Maternai Syphilis Screening and Treatment Programmes in
Mwanza Region. Tanzania: Uptake and Challenges
This application has been approved by the Committee
Chair
Professor Tom Meade
Date 8July 2008
Approval is dependent on local ethical approval having been received.
Any subsequent changes to the consent form must be re-submitted to tho
Committee.
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Annex 3: Ethical approval-MRCC- Tanzania
rru: L\.TIl·:D REPl 'RUC OF
T:\:--JZA'\IA
National Institute for Medical Research
P.O. Box 9653
Dar cs Salaam
Tel: ~55 ~~ ~ 121400/390
Fax: ~5'i ~~ 212USO/2121360
I, -mail: Il~~ld'i11,1rtl'rS!~1I imr.ur.t I
"'IRII<)IUlaVol. IX:707
Ministry of Health and Social Welfare
P.O. Box 9083
Dar cs Salaam
Tel: ~55 ~~ ~1~()~62-7
Fax: ~55 222110986
OJ'' July :;OOS
\h Rct.<:,',-Ol !l"br;}
"1\'R i\1 \\,,\11/;1
I' 0 Illl' I-H>2,"W:\~Z,'\
lan/ arnu
CLEAR-\!\ICE CERTIFI{',-\TE FORCO:'tiI)l'CTI!\G
"El)ICAt RESEARCUIN rANZA:'tiIA
TIllS IS 10 CCI'I!! that the research entitled, lmplcmcnrauon of Prevention of "'utlll,T-to-Chlid
Transnussion of IIIV and Maternal Syphilis Screening and Treatment 111\1w.nlla region. Uptake and
Challenges. (1l"lIra R ,'1 "f), h.IS been granted ethics clearance to be conducted III '!Jlvanl".
The Pnllclpalll1\,cstlgatnr of the studv must ensure that the j"ullo"ing conditions arc fulflllcd
I I'r"Fr~'s report IS made availublc to tbc \'llIlIqry of Health and the '\alIOI1JI 111:;1111I1,' 1'0,.
fVh:di,al R..-scurch, Regional and District Medical Officers OIlier every six months.
~ Pcmuss.on to publish the results ,s obtained from Nariunal lusututc for Medical Research
3. COP'(,s of final publicauons arc made avatlablc to the \lllllslry of Health and the \iatlOnal
Institute fur \1I:dl\.'al Research
4, AIl~ researcher. who contravenes or 1;1I1~to comply \\ ith these ';0I1d'II0I15. shall he gUilty of
an oftcncv and shall be liable on convrcuon to a fine.
:\amc: Dr Andrew Y Kitua
Signaturc
·t·
('11,\1 Rl\I\N
:m:t)lCAL RESEARCII
COOlWIN,\'IT'G CO:\l:\lITI'EE
ClIIH:\'E(}I(',\'- OFFICER
:\II:\ISTRY OF HEALTH. SO('lAL
WELFARE
cc: Into
1>:\10
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Annex 4: Cohort recruitment informed consent (English version)
Introduction:
The National Institute for Medical Research, Mwanza Centre in collaboration with the London
School of Hygiene and Tropical Medicine, The Mwanza Regional Medical Office, The Municipal
Health Office, Bugando Medical Centre and Sekou-Toure Regional Hospital, is finding out
how successful are the two services offered to pregnant women to prevent the transmission
of HIV and syphilis infections from the mothers to their unborn babies during pregnancy,
delivery and postnatal period within maternity wards in Mwanza City.
Why are we doing this study?
Studies have shown that most children who are HIV positive acquired the infection form their
mothers either during pregnancy, at delivery or through breastfeeding. About 10% of Infants
born to HIV positive mother acquire HIV during pregnancy, 20% acquire HIV during delivery
and 20% acquire the infection through breastfeeding. The introduction of prevention of
mother to child transmission of HIV (PMTCT) services in Tanzania is anticipated to reduce
mother to child transmission of HIV through giving ARV drugs to the mothers before delivery
and to the infants immediately after delivery. Women are also educated on appropriate infant
feeding. We want to know how many women successfully complete the PMTCT services, to
understand why some of them do not complete the programme and also the consequences of
not completing the programme.
What are you expected to do
Today we will talk about the study and you will be asked whether you would like to join the
study. If you agree to participate in this study, we will ask you some questions about yourself
and the services you received during pregnancy before admission for delivery. We will not
take women into the study if they are not going to stay in Mwanza city for at least four
months after delivery. This is because we are recruiting women today and we are asking them
to see us at the MCH clinic every month over a period of four months. If you agree and will be
staying in Mwanza city after delivery for the period mentioned above, we will give you a study
identity card which will show that you have joined the study. Then we will ask you more
questions on the services you received at the maternity ward and your plans for the MCH
visits for your baby. This will take about half an hour (30 min) of your time.
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What you will be expected to do at the follow-up visits
I you agree to participate in this study we will ask you to bring your baby to the MCH clinic
visits as scheduled on his/her immunization (road to health) card every month. At these visits,
for the first four months, after the normal procedure of immunization we will see you and ask
you few questions about yourself and your baby and this will always take about half an hour
(30 min) of your time. If you will not be able to attend at the MCH clinic as scheduled, one of
us, researchers will try and visit you at home to see how are you progressing with the baby,
and why you did not attend to the clinic, however this will be done if and only if you will allow
us to visit you at home.
Confidentiality
Everything you tell us will be kept secret. We are not going to record your name or your
baby's name anywhere on the form we are using to ask you the questions. Your name will
only be written on one form that has the details of where you live. This will be locked safely in
our office, and will be used to trace you in case we miss you at the clinic during your
scheduled visit. This information you are giving us will be used only for the purpose of the
study.
Participation
We hope you will agree to participate in this study. Remember your participation in this study
is voluntary and is completely your decision. If you do accept you still have the right to
withdrawal your participation if you change your mind at any time. However, we would be
grateful if you can spare the time to come for the follow-up and complete the interviews to
allow us to get the required information from you.
Action
Please read this paper carefully and take it home with you. If you have any questions, please
ask one of the project staff at any time. If you want to join the study, you will be asked to sign
a special form agreeing that you would like to participate.
For more questions
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If you have any more questions after leaving this place, please contact any member of the
project staff or the Principal investigator Ms Rebecca Balira, Mwanza Medical Research
Centre, POBox 1462, Mwanza, Tanzania;
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Informed consent form
Cohort recruitment
Study ID sticker here
1. I have read the information sheet (or it has been read to me) that explains the
objectives of the study and all the procedure that I am being asked to participate in
2. All questions I had about this study have been answered
3. I clearly understand what I will be required to do if I agree to participate in this study
4. I have understand and (agreed/refused) to be visited at home by one of the
researchers if I fail to attend my appointment at the clinic.
5. I also understand that I have the right to refuse to participate or withdrawal from the
study at any time if I don't want to continue and that my right of care at this or
another health facility won't be compromised
6. I am aware that all information I give will be kept confidential
7. I agree to participate in this study
Name of participant _
Date _
Signature of participant/Finger print --i
Name of Witness _
Signature of Witness _
Date _
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Annex 5: Cohort recruitment informed consent (Swahili version)
Utangulizi:
Taasisi ya Utafiti wa Magonjwa ya Binadamu, Kituo cha Mwanza, tukishirikiana na Chuo kikuu
cha London, Ofisi ya Afya Mkoa wa Mwanza, Ofisi ya Afya, Jiji la Mwanza, Hospitali ya Rufaa ya
Bugando na Hospitali ya Mkoa, Sekou-Toure; tunataka kujua kama akina mama wajawazito
wanapata taarifa za kutosha kuhusu, ni namna gani wanaweza kukinga maambukizi ya
UKIMWI na kaswende kwa watoto wao pale wanapohudhuria kliniki kwa uchunguzi wakati wa
ujauzito, na pale wanapojifungua, kama wamejifungua hospitalini. Vile vile tunataka kujua
kama huduma zinazotolewa kwa wanawake kuzuia maambukizi ya magonjwa haya kwa
watoto zinafanya kazi vizuri katika jiji la Mwanza.
Kwa nini tunafanya utafiti huu
Tafiti zinaonyesha kwamba watoto wengi wenye UKIMWI wameambukizwa na mama zao,
aidha wakati wa ujauzito au wakati wa kujifungua au wakati wa kuwanyonyesha. Kwa wastani
watoto watatu hadi wanne kati ya kumi waliozaliwa na mama wenye virusi vya UKIMWI, huwa
wanaambukizwa virusi hivyo. Kuna huduma mbali mbali za afya ambazo zinatolewa kwenye
kliniki ya ujauzito na wakati wa kujifungua zinazoweza kusaidia kupunguza tatizo hili. Hizi
huduma zinahusisha, upimaji wa UKIMWI wakati wa ujauzito, kumpatia mama mjamzito
aliyeathirika madawa ya UKIMWI wakati wa ujauzito na/au wakati wa kujifungua na
kuwapatia watoto wao dawa za UKIMWI mara tu wanapozaliwa. Vilevile mama walioathirika
wanapewa mafundisho na ushauri wa namna ya kuwalisha watoto wao iii kupunguza hatari ya
maambukizi ya Virusi vya UKIMWI kwa watoto kupitia maziwa ya mama. Tunataka kujua ni
akina mama kiasi gani wanapatiwa na wanakubali kutumia huduma hizi za kukinga
maambukizi ya UKIMWI na kaswende kwa watoto wakati wa ujauzito na wakati wa
kujifungua. Vile vile tunataka kujua ni nini kinachotokea kwa mama na mtoto
wanaporuhusiwa kurudi nyumbani baada ya kujifungua hospitalini. Na ni wangapi
wanakamilisha hatua mbalimbali za huduma hizi katika kliniki baada ya mtoto kuzaliwa. Hii
itatusaidia kujua ni kwanini akina mama wengine wanashindwa kupata huduma hizi kikamilifu,
na itatuwezesha kubuni njia ya kuboresha huduma hizi iii kuboresha afya ya mama na
kuwakinga watoto na maambukizi ya UKIMWI na kaswende.
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Ni nini unatarajiwa kufanya
Leo tutaongea na wewe kuhusu utafiti huu na tutakuuliza kama utapenda kushiriki kwenve
utafiti. Kama utakubali kushiriki kwenve utafiti huu, tutakuuliza maswali kadhaa kukuhusu
wewe binafsi na huduma ulizopatiwa wakati wa ujauzito kabla va kulazwa hospitalini kwa ajili
va kujifungua. Katika utafiti huu hatutawashirikisha akina mama ambao hawatakaa katika jiji
la Mwanza angalau miezi minne baada va kujifungua. Hii ni kwa sababu tunaandikisha akina
mama leo na tunawaomba watuone tena wakati wa kliniki va mama na mtoto kila mwezi kwa
muda wa miezi minne. Kama utakubali kushiriki na kama wewe utakuwepo hapa jijini baada
va kujifungua kwa muda huo tulioutaja hapo juu, tutakupatia kitambulisho kuonvesha kuwa
umejiunga na utafiti huu. Kisha tutakuuliza maswali zaidi kuhusu huduma ulizopatiwa
ulipohudhuria kliniki va mama wajawazito na zile ulizopata hapa wakati wa kujifungua na
mipango uhvonavo kuhusu mahudhurio va kliniki va mama na mtoto. Hava mahojiano
vatachukua kama nusu saa va muda wako.
Kama wakati wa ujauzito hukupimwa kaswende, tutachukua damu kutoka kwako na
tutakufanvta kipimo cha kaswende leo. Hautahitaji kulipia huduma hii. Kama tukikuta una
kaswende, tutawapatia wewe na mwanao matibabu va kaswende ambavo ni sindano moja
moja. Hii haitakugharimu kitu na itafanvika aidha hapa kabla hujaondoka hospitalini au
tutakupeleka kliniki ambapo utapata matibabu bure endapo tutapata majibu va kipimo
mapema. Kama majibu vatachelewa na ukaruhusiwa kwenda nvurnbanl, basi tutalazimika
kukufuata nvumbani kukupatia majibu vako na kuwapeleka wewe na mwanao kliniki iii
mpatiwe matibabu bure. Kama utakutwa na kaswende tunaweza vile vile kumtibu na
mume/mpenzi wako. Kipimo hiki cha damu hakitatumika kupima magonjwa mengine vovote.
Ni nini unatarajiwa kufanya wakati wa ufuatiliaji kwenye kliniki ya mama na mtoto.
Ikiwa utakubali kushiriki katika utafiti huu, tutakuomba umlete mtoto wako kliniki kama
inavvoonveshwa kwenve kadi vake va kliniki kila mwezi. Wakati huo kwa miezi minne
mfululizo baada va kujifungua, kila baada va taratibu za kawaida za kliniki na chanjo tutaonana
na wewe na kukuuliza maswali kukuhusu wewe binafsi na vilevile kuhusu mtoto wako. Hii kila
mara itachukua kama nusu saa va muda wako. Kama hautaweza kufika kliniki kwa siku
ulizopangiwa, mmoja wetu (watafiti) atajaribu kukutembelea nvurnbanl kujua unaendeleaje
wewe na mtoto na kujua kwa nini hukuweza kufika kliniki, hii itafanvlka endepo tu utakuwa
umeturuhusu kukutembelea nvumbani.
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Usiri
Kila jambo utakalotueleza litatunzwa kwa siri. Hatutaandika jina lako au jina la mtoto wako
rnahall popote katika karatasi va mahojiano. Jina lako litaandikwa tu kwenve karatasi venve
taarifa za mahali unapoishi. Hivo fomu itatunzwa kwa siri mahali salama huko ofisini kwetu na
itatumika tu iwapo tutahitaji kukufuatilia nvumbani baada va kukukosa kliniki unapotakiwa
kufika au kama utakuwa unahitaji matibabu kwa ajili va kaswende. Hizi habari unazotupatia
zitatumika kwa ajili va makusudi va utafiti huu tu.
Ushiriki
Tunaamini utakubali kushiriki katika utafiti huu. Kumbuka ushiriki huu ni wa hiari na ni uamuzi
wako mwenvewe. Kama ukikubali kushiriki bado unavo haki va kuamua kuacha kama utabadili
mawazo vako wakati wowote. Hata hivyo tutashukuru kama utaweza kupata muda wa kuja
klinlkl wakati wa ufuatiliaji na kujibu maswali vetu iii kutuwezesha kupata taarifa tunazozihitaji
kutoka kwako.
Cha kufanya
Tafadhali soma karatasi hii kwa makini na uende navo nvurnbanl. Kama unavo maswali vovote
tafadhali muulize mhusika vevote katika utafiti huu wakati wowote. Kama unataka kujiunga na
utafiti, utaombwa kuweka sahihi kwenve fomu maalumu kukubali kwamba ungependa
kushiriki
Kwa maswali zaidi
Kama unavo maswali zaidi baada va kuondoka mahali hapa tafadhali wasiliana na mfanvakazi
vevote wa mradi au mtafiti mkuu Ndugu Rebecca Balira, Kituo cha Utafiti wa Magonjwa ya
Binadamu Mwanza SLP1462, Mwanza, Tanzania; Simu: 255 28 2503012
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Consent form: Cohort recruitment
Study ID sticker here
1. Nimesoma/Nimesomewa maelezo muhimu yanayoelezea madhumuni va utafiti huu na
maelekezo va jinsi nitakavvoweza kushirikishwa.
2. Maswali vote niliokuwa navo kuhusu utafiti huu vamejibiwa
3. Ninaelewa vizuri ni kitu gani nitatakiwa kufanva kama nitakubali kushiriki katika utafiti huu.
4. Nimeelewa na (nimekubali/nimekataa) kufuatwa nvumbanl na mmoja wa watafiti kama
nitashindwa kufika kliniki ninapotakiwa
5. Vile vile ninaelewa kuwa ninayo haki va kuacha kushiriki katika mahojiano haya wakati
wowote ninapojisikia kufanva hivvo na kwamba haki vangu kupata huduma mahali hapa
haitaathirika kwa sababu hlvo
6. Ninaelewa kwamba maelezo vote nlllvovatoa vatatunzwa kwa siri.
7. Ninakubali kushiriki katika utafiti huu.
Jina la Mshlrlki _
Sahihi va Mshiriki ---l'- -'~Iama ya
dole gumba I
Tarehe _
Jina la shuhuda _
Sahihi va shuhuda _
dole gumba
Alama va
Tarehe _
Jina la rntafltl _
Sahihi va Mtaflti _
Tarehe _
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Annex 7: Patient referral form
• MINISTRY OF HEALTH AND SOCIAL WELFARE
Patient Namo: I Date of Blrth/Age:
NATIONAL HIV CARE AND TREATMENT
PATIENT REFERRAL I TRANSFER FORM
DATE: .
REFERRAL FROM: FACILITY NAME FACILITY CODE ..
REFERRAL TO: FACILITY NAME ..
NAME: FIRST MIDDLE LAST ..
DATE OF BIRTH: J... J............. CURRENT AGE: SEX: 0 M 0 F
REASON FOR REFERRAlITRANSFER: .
ART START DATE: J J UNIQUE CTC 10#: ..
AT START OF AR1':
WEIGHT FUNCTION CLINICAL STAGE CD4 .
CURRENT S'rATUS - DATE J.. .I ..
WEIGHT FUNCTION CLINICAL STAGE CD4 ..
ORIGINAL FIRST LINE REGIMEN: .
,ST SUBSTITUTION: DATE ..: ..1 1 WHy ..
2ND SUBSTITUTION: DATE J J WHY .
SECOND LINE REGIMEN: DATE J J WHY .
CURRENTLY ON TB TREATMENT? YES NO IF YES, DATE STARTED: ..
OTHE.R RELEVANT MEDS (lnoluding.INH. CTX, Diflucan): ; ..
DRUG AL.LERGIES: .
CURRENTLY PREGNANT? 0YES 0 NO . IF YES. EDD:...... . ;;.,,\;.,~ ..n"q •...
OTHER RELEVANT CLINICAL NOTES: ~i=: -: '.' ; ..
........................................................................ , ~,::.:~:.: ;\ .
NAME, SIGNATURE AND STAMP ·0 ·· : ..
- - - - - -- - - - - - - - -;:EEDB~CK SECTI~ - - - -t~~~,7 ~.- --
Services Provided: To be filled out by the organization providing the reqlllrnTeClservice
Date:
Services Provided:
, Services provided: _. .__ ._ _ .._ . . .. _ _ _ . _.__ __ . .__ _
., Servlcos camp Ieled as requested _. Yes _ .__ . No
n FollOW-liP neoded: services: Date for touow-uo: _
Additional Comments:
Name 0' Organlzatlon/Hoalth Facility: I Contact Person/ref.rral focal per.on:
N()me'
l_~__._._-..-~~I'..._.__~_._.:.~_._.;~._.,_i._~.i~:'~:~~~:·~l__"r _._ •• ~__ ._., _:'~~'I.I..~ _::. ': ~ __.. __ ..-.- .s
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Annex 8: Cohort tracing information
Annex 7: Implementation of PMTCT and maternal syphilis screening in
Mwanza city
Cohort Recruitment -Tracing Information
114 I" neighbour on righl I
115 1t.1 neighbour on left I I
Own house 1
Type of Ihe house
Renting Ihe whole hoU8B 2
Renting a room in a house 3
116 If 2-renllnl1 the whole house or :1
·rentlng a room In • hou •••• k lIvong witn famIly 4
q1.17 olherwfse skip 10 q.1.18 Renltng a nat 5
Other( specify) 6
1.17 Owner of the house I I
118 Head of the household I I
1.f9 Description of route to the house
Cohort recriutment-Tracmg form -Ellli'li~h - tinaI version (09/10.·2008)
RB1010
228
RB2010
Annex 7: Implementation of PMTCT and maternal syphilis screening in
Mwanza city
Cohort Recruitment -Tracing Information
1.20 Description of the house induding colour of the door
1.21 Name and code of the ANC attended during I 1 1_1_1-1
pregnancy
1.22 Name and code of the MCH clinic where the mother 1 1 1_1_1_1
intends to attend for the under five clinic
1.23 Next appointment date at the under five dinic 1_1_1/1_1_1/2001_1
Int.rvl.wtr piNS' discuss with the wom,n ,bout the hom. visit" not Sffn 3t the under flv. clinic
1.24 Has the participant agreed to be visited at home
(Circle one) Yes 1
No 2
Care and treatment clinic where the participant
(Circle one) BMC 1
1.25 STRH 2
intends to attend for her own health Other (specify) 3
COh011recruitment- Tracing form -English - final version (09/10/.2008)
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Annex 9: Knowledge questions from the cross-sectional questionnaire
Annex 8: Implementation of PMTCT and maternal syphilis screening In Mwanza city
Cross-sectional questionnaire-Maternity ward (Knowledge questions only)
4" ····.·>1StOtkm'D:K~a..Qout HlVIAlDS ..
Now I ,m going ro 14k you f,w qUNrion. ,bour HIV'AIDS. rhi. i. ro h.,p u. undtra~nd wh,r prtgn,nr wom.n know ,bour rhi.
problem
4.1 15there anything a person can do to avoid getting HIV. the virus I (Circle one) Yes 1
that causes AIDS? If 2-No .kip 10q 4.3 No 2
IC/~I' 1.m.mloned for ,1/ rhlt 're menrloned) M•• _ 1I0r HA
" .. lion«!
Condom use 1 2 B
Have few or one partner(s) 1 2 8
Do you Both partners have no other partners 1 2 8
know how
people can No casual sex 1 2 8
proted No sex at all 1 2 8
themselves
4.2 from being Avoid infechons With contaminated (used) needles 1 2 B
Infected AVOidblood transfusion 1 2 8
with HIV?
8Circumcision 1 2
STD Treatment 1 2 8
Not shanng plates or cups With HIV infected people 1 2 8
Other(Specify) 1 2 8
Don't know 1 2 8
YES NO DON'T4.3 Can HIV or AIDS be caught by KNOW
4.3.1 using condom every time when haVing sex 1 2 9
4.3.2 haVing vaginal sex Without a condom 1 2 9
4.3.3 being bitten by mosquitoee 1 2 9
4.3.4 sharing a toilet with and HIV infected person 1 2 9
43,5 abstaining completely from sex 1 2 9
436 haVing anal sex 1 2 9
4.3.7 sharing a plate of food wrth an HIV infected person 1 2 9
0.8 having oral sex 1 2 9
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Annex 8: Implementation of PMTCTand maternal syphilis screening In Mwanza city
Cross-sectional questionnaire-Maternity ward (Knowledge questions only)
4.3 YES NO DON'T
(cont..d) Can HIVor AIDS be caught by KNOW
4.3.9 witchcraft 1 2 9
4.3.10 Shaking hands with an HIV person? 1 2 9
(Circle one) Yes 1
4.4. Do you think that a person who looks healthy could be infected No 2with HIV?
Don't know 9
Have you ever seen anyone who is infected by HIV?
(Circle one) Yes 1
4.5
if 2wNoQOre $tctlon E No 2
(Circle one) Yes 1
4.6 Do you know anyone who has died of AIDS No 2
NA 8
(Circle one) Yes 1
4.7 Have you ever cared an HIV patient? No 2
NA 8
5 ..;. $tctloriE: KnoWledp on·MTCTof HI\I'_ SyphIll.&.PMTCT ..of HN & Syphllit
"l am now Qoingro ilk you .om. qUNtiOn, about dl,.,,,, thi! can b. rran,milttd from rh. moth., re rh. baby during p"gnancy
and aff., deliv.ry and how th.y Cln b.lJ"v.nted"
Do you know of any mfecbons that can be transmitted from the
(Circle one) Yes 1pregnant woman 10her baby during pregnancy or after birth?
5.1 Int.rvl.w.,: If 2wNopltase ,xplain rh. qUNtion in a ,impl.'anguag. to No 2confirm that 'he rtal don 'r know, if It ~ true that ,h. do.. n't know .klp to
a5.3
(Cirel. 1.menr/oned for ,11rh,t art mentioned M.ntioned Not
m.nrioned
HIV 1 2
What InfectIOns do you
Syphilis 1 2know that can be
5.2 transmitted from the Malaria 1 2molher 10the unbom
child? Other (specify) 1 2
Other (specify ) 1 2
Don't know 1 2
Crow-sectional questtotmaire-engltsh-ftnnl rerston 112/09(2008)
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Annex 8: Implementation of PMTCT and maternal syphilis screening in Mwanza city
Cross-sectional questionnaire-Maternity ward (Knowledge questions only)
(Circle one) Yes 1
Can HIV positive woman transmit HIV to her baby?
No 25.3 " 2-No .kip to qU
Don'lknow 9
(Circle one) Yes 1
Can HIV positive woman transmit HIV to her baby before birth (in the No 25.4 womb)? NIA 8
Don't know 9
(Circle one) Yes 1
Can HIV positive woman transmit HIV to her baby dunng labour or No 25.5
delivery? NIA 8
Don't know 9
(Circle one) Yes 1
Can HIV positive woman transmit HIV to her baby dunng No 25.6
breastteedmq? N/A 8
Don't know 9
Do you (Clrcl. 1.mtnriontd for ,11th,t'ft mentioned M."tJoMd Nor NA_"tJoMd
know how By giving drugs that act against HIV to the mother dunng pregnancy 1 2 8
we can
prevent an By giVing drugs that act against HIV to the baby soon after birth 1 2 8
5.7 HIV Having a baby by caesarean section 1 2 8Infeeled
mother to Not breaslfeedlng 1 2 8
transmit Exclusive breastteedmq 1 2 8
HIVto her
1 2 8baby? Other (specify)
(Circle one) Yes 1
5.8
Can a woman Infected with syphilis transmit syphilis to her baby?
No 2" 2-No .kip to ,.cllon F
Don't know 9
(Circle one) Yes 1
Can a woman infected with syphilis transmit the infection (syphilis) No 25.9
to her baby before birth (in the womb)? N/A 8
Don't know 9
Crow-sectional qnesttommire-engltsh-ftnal version (;:;:.09.;:0081
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Annex 8: Implementation of PMTCTand maternal syphilis screening In Mwanza city
Cross-sectional questionnaire-Maternity ward (Knowledge questions only)
(Circle one) Yes 1
Can a woman mfected with syphilis transmit the infection (syphilis) No 25.10
to her baby during labour or delivery? N/A 8
Don't know 9
(Circle one) Yes 1
Can a woman mfected With syphilis transmit the infection (syphilis) No
2
5.11
to her baby during breastfeeding? N/A 8
Don't know 9
How can we
IClrel. 1-m.ntloned for all !hil! if' m.ntloned Ikntiontd Not NA
lIIOfI~ontd
prevent a By giving treatment to the mother durtng pregnancy 1 2 8
mother with By trealing the baby soon after birth 1 2 8syphilis5.12 transmitting Having a baby by caesarean section 1 2 8
this to her Not breastieedinq 1 2 8
baby?
Other (specify) 1 2 8
Cross-sectional qnestionnntre-engltsh-ftnal verston (!]:09/!008)
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